Covalent polymer-antigen conjugated particles

Abstract

To provide a process where particle size and antigen encapsulation as well as antigen release can be precisely controlled.SOLUTION: The present invention provides compositions comprising tolerizing immune modified particles (TIMPs) and methods for using and making the TIMPs. In particular, carrier polymer is covalently conjugated with antigenic peptide before particle formation, which allows for exquisite control of particle size and antigen encapsulation (e.g., for use in eliciting induction of immunological tolerance).SELECTED DRAWING: Figure 1

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Patent Application No. 62 / 387,183, filed December 23, 2015, and U.S. Provisional Patent Application No. 62 / 292,098, filed February 5, 2016, the contents of each of which are incorporated by reference in their entirety into this specification.

[0002] Description of electronically submitted text files

[0002] The contents of the text file submitted electronically herewith are incorporated by reference in their entirety into this specification: Computer-readable format copy of the sequence listing (filename: COUR-011#00US#Seqlist.txt, data record: December 23, 2015, file size 1.16 MB). [Background technology]

[0003]

[0003] Inflammatory diseases and disorders are conditions in which an abnormal or otherwise dysregulated inflammatory response contributes to the pathogenesis or severity of the disease. Examples include autoimmune diseases such as type 1 diabetes and celiac disease.

[0004]

[0004] Many of these diseases are characterized by mononuclear cell infiltration at the site of tissue injury or other damage. Examples of mononuclear cells that have been observed in these infiltrates include lymphocytes, particularly T lymphocytes, and cells of the mononuclear phagocyte system (MPS cells), such as monocytes, macrophages, dendritic cells, microglial cells, and others.

[0005] Many of the cells observed in the mononuclear cell infiltrates are suspected to play a role in these abnormal inflammatory responses. For example, in diseases such as multiple sclerosis, CD4 + T cells are known to play a central role in pathological autoimmune responses. At an earlier point in T cell activation, dendritic cells and other MPS cells express CD4 +MPS cells can also contribute to inflammation by phagocytosis, but in at least some inflammatory diseases such cells are CD4 + Whether this can be done in the absence of T cells is unclear.

[0006] Peripheral blood monocytes can be classified into one of two groups depending on the expression or absence of certain cell surface molecules. In particular, human "resident monocytes" or "mature monocytes" are classified into two groups based on the expression or absence of CD14 lo CD16 + It is understood that the mouse counterpart has a CX3CR1 phenotype. hi CCR2 - Gr1 - Another group of cells, the "inflammatory monocytes" or "immature monocytes," expresses CD14 + CD16 - It is understood that the mouse counterpart has the CX3CR1 lo CCR2 + Gr1 + ) (Geissmann F. et al., 2003 Immunity 19: 71-82).

[0007] Importantly, although the latter are understood to be "inflammatory" in the sense that they are observed to migrate from bone marrow-derived peripheral blood cells into inflamed tissues, these cells have not been shown to cause inflammation, either directly or through the action of other cells. Furthermore, the various MPS cells that may form when these cells differentiate have also not been shown to cause inflammation.

[0008]

[0008] Conventional clinical strategies for general long-term immunosuppression in disorders associated with undesired immune responses are based on long-term administration of broad-acting immunosuppressants, such as signal 1 blockers, such as cyclosporine A (CsA), FK506 (tacrolimus) and corticosteroids. Long-term use of high doses of these drugs can have toxic side effects. Moreover, even in patients who can tolerate these drugs, the requirement for lifelong immunosuppressant therapy carries significant risks of severe side effects, such as tumors, serious infections, nephrotoxicity and metabolic disorders.

[0009] Methods for inducing antigen-specific tolerance have been developed, including cell coupling of antigens or peptides. For example, in one method, peptide-induced cell-binding tolerance involved the collection, separation and processing of peripheral blood cells with disease-specific autoantigens and ethylene carbodiimide (EDCI) coupling reagents under sterile conditions, followed by reinfusion into the donor / patient. This process is costly, needs to be performed under conditions closely monitored by highly specialized physicians, and is limited to a few facilities that can perform the procedure. The use of red blood cells as a donor cell type expands the potential sources for deriving allogeneic donors, thus dramatically increasing the supply of source cells and potentially extending the delivery of this therapy to any setting certified for transfusion. These approaches have significant limitations regarding the supply of source cells and require tissue type matching to minimize immune responses against the donor cells. Furthermore, localized treatment of cells to couple autoantigens with EDCI presents significant quality control issues. Furthermore, these approaches also require at least some knowledge of the pathological antigen to which immune tolerance is sought.

[0010]

[0010] Antigen-specific tolerance is generally not ideal because the specific antigens / epitopes in human diseases are generally unknown. Furthermore, antigens can vary between subjects. Therefore, for an antigen-specific approach to be effective, it is necessary to determine which antigens each individual patient recognizes, or to couple a library of possible peptides to the particles before administration.

[0011]

[0011] Recently, peptide-coupled particles have been described that eliminate the requirement for source cell supply and avoid the previous requirement for tumor tissue typing. See WO2010 / 085509; US2012 / 0076831; and US2016 / 0166664, the contents of which are incorporated herein by reference in their entirety. Nevertheless, the use of antigens coupled to the outside of the particle poses significant chemical, manufacturing and control problems, as it is associated with an increase in anaphylaxis.

[0012]

[0012] If the antigen is encapsulated within the particle, these adverse events are avoided. See WO2013 / 192532; US2015 / 0209293; WO2015 / 023796; US2015 / 0190485; and US2015 / 0283218, the contents of which are incorporated herein by reference in their entirety. Furthermore, size and charge can be varied to enhance tolerance to specific antigens. However, a problem with antigen encapsulation within nanoparticles is the ability to control antigen release in addition to antigen loading. Currently, the amount of antigen entering each particle cannot be precisely controlled. Similarly, the amount of antigen released is not tightly controlled, resulting in the possibility of a burst release effect under certain conditions where a slower controlled release is desired. The present invention provides a process that allows precise control of particle size and antigen encapsulation as well as antigen release. Summary of the Invention [Problem to be solved by the invention]

[0013]

[0013] The present disclosure relates to tolerizing immune modifying particles (TIMPs) with encapsulated antigens covalently attached to their internal surface. Covalent coupling to the internal particle surface allows for delicate control of particle size and antigen encapsulation efficiency while simultaneously reducing the risk of antigen burst effect and avoiding undesirable side effects associated with surface-bound peptides. [Means for solving the problem]

[0014]

[0014] The present disclosure provides a composition comprising one or more antigens covalently bound to carrier particles having a negative zeta potential, wherein the one or more antigens are encapsulated within the particles.

[0015]

[0015] The present disclosure provides a composition comprising one or more antigens encapsulated within a polymeric carrier particle, wherein the one or more antigens are covalently bound to a polymer that constitutes the polymeric carrier particle.

[0016]

[0016] In some embodiments, the composition further comprises a non-conjugated carrier polymer. In some embodiments, the composition further comprises a pharma- ceutically acceptable carrier.

[0017]

[0017] In some embodiments, the present invention provides compositions (e.g., for inducing antigen-specific tolerance) comprising carrier particles (e.g., PLG particles) covalently bound to one or more antigenic peptides, wherein the one or more antigenic peptides are encapsulated in the carrier particles. In certain embodiments, the carrier particles are poly(lactide-co-glycolide) (PLG) particles. In other embodiments, the carrier particles are PLURONIC® stabilized polypropylene sulfide particles.

[0018]

[0018] In some embodiments, the present invention provides a composition comprising an antigen coupled to a carrier particle having a negative zeta potential. In some embodiments, the zeta potential of the particle is less than about -100mV. In some embodiments, the zeta potential of the particle is between about -100mV and about -15mV. In some embodiments, the zeta potential of the particle is between about -100mV and about -75mV. In some embodiments, the zeta potential of the particle is between about -50mV and about -20mV. In some embodiments, the particle is a copolymer having a molar ratio of about 50:50, 80:20 to about 100:0. In some embodiments, the ratio of the copolymers may be, but is not limited to, polystyrene:poly(vinyl carboxylate) / 80:20, polystyrene:poly(vinyl carboxylate) / 90:10, poly(vinyl carboxylate):polystyrene / 80:20, poly(vinyl carboxylate):polystyrene / 90:10, polylactic acid:polyglycolic acid / 80:20, or polylactic acid:polyglycolic acid / 90:10, or polylactic acid:polyglycolic acid / 50:50. In yet other embodiments, the particles are polystyrene particles, carboxylated polystyrene particles, PLURONIC® stabilized polypropylene sulfide particles, or poly(lactic-co-glycolic acid) particles. In some embodiments, the particles are poly(lactic-co-glycolic acid) particles.

[0019]

[0019] In some embodiments, the particles have an average diameter between about 0.1 μm and about 10 μm. In some embodiments, the particles have an average diameter between 0.2 μm and about 2 μm. In some embodiments, the particles have an average diameter between about 0.3 μm and about 5 μm. In some embodiments, the particles have an average diameter between about 0.5 μm and about 3 μm. In some embodiments, the particles have an average diameter between about 0.5 μm and about 1 μm. In some embodiments, the particles have an average diameter of about 0.5 μm.

[0020] In further embodiments, the one or more antigens comprise at least a portion of an autoimmune antigen, an allergen, an antigen expressed on a tissue to be transplanted into the subject, an enzyme for enzyme replacement therapy, or an allergen. In some embodiments, the antigen is myelin basic protein, acetylcholine receptor, endogenous antigen, myelin oligodendrocyte glycoprotein, pancreatic beta cell antigen, insulin, proinsulin, islet specific glucose-6-phosphatase catalytic subunit related protein (IGRP), glutamic acid decarboxylase (GAD), collagen type 11, human cartilage gp39, fp130-RAPS, proteolipid protein, fibrillarin, small nucleolar protein, thyroid stimulating factor receptor, histones, glycoprotein gp70, pyruvate dehydrogenase dehydrolipoamide acetyltransferase (PCD-E2), hair follicle antigen, aquaporin 4, desmoglein 1, desmoglein 3, nicotinic acetylcholine receptor, A-gliadin, and human tropomyosin isoform 5, bahiagrass pollen (BaGP), peach allergen Pru p3, alpha s1-cane milk allergen, Apig1 cereria allergen, Bere1 Brazil nut allergen, B-lactoglobulin milk allergen, bovine serum albumin, Cor a 1.04 Hazelnut allergen, ovalbumin egg allergen, Advate, antihemophilic factor, Kogenate, Eloctate, recombinant factor VIII Fc fusion protein, Refacto, Novo VIIa, recombinant factor VII, eptacog alfa, Helixate, Monanin, coagulation factor IX, Wilate, ceredase, alglucerase, cerezyme, imiglucerase, elerso, taliglucerase alfa, fabrazyme, agalsidase beta, aldrazyme, -I-iduronidase, myozyme, acid glucosidase, elaprase, iduronate-2-sulfatase, naglazyme arylsulfatase B, or N-acetylgalactosamine-4-sulfatase, myozyme and at least a portion of a protein therapy used in enzyme or coagulation factor replacement, such as erythromycin, alglucerase, imiglucerase, taliglucerase, agalsidase beta, 1-iduronidase, acid glucosidase, iduronate-2-sulfatase, N-acetylgalactosamine-4-sulfatase, antihemophilic factor, factor VII, eptacoglucerase alfa, factor IX, miglustat, lomiplastim, epotetin alfa, protein C, laronidase, lumizyme, or factor VIII.

[0021] In further embodiments, the one or more antigens include an autoimmune antigen, an antigen expressed on a tissue to be transplanted into a subject, an enzyme for enzyme replacement therapy, or an allergen. In non-limiting embodiments, the antigen is, for example, myelin basic protein, acetylcholine receptor, endogenous antigen, myelin oligodendrocyte glycoprotein, pancreatic beta cell antigen, insulin, glutamic acid decarboxylase (GAD), collagen type 11, human cartilage gp39, fp130-RAPS, proteolipid protein, fibrillarin, small nucleolar protein, thyroid stimulating factor receptor, histone, glycoprotein gp70, pyruvate dehydrogenase dehydrolipoamide acetyltransferase (PCD-E2), hair follicle antigen, aquaporin 4, desmoglein 1, desmoglein 3, nicotinic acetylcholine receptor, A-gliadin, and human tropomyosin isoform 5, bahiagrass pollen (BaGP), peach allergen Pru p3, alpha s1-caine milk allergen, Apig1 cereria allergen, Bere1 Brazil nut allergen, B-lactoglobulin milk allergen, bovine serum albumin, Cor a 1.04 hazelnut allergen, insulin, proinsulin, islet specific glucose-6-phosphatase catalytic subunit related protein (IGRP), ovalbumin egg allergen, myozyme, alglucerase, imiglucerase, thaliglycerase, agalsidase beta, 1-iduronidase, acid glucosidase, iduronate-2-sulfatase, N-acetylgalactosamine-4-sulfatase, antihemophilic factor, factor VII, eptacog alfa, factor IX, miglustat, lomiplastim, epotetin alfa, protein C, laronidase, lumizyme, or factor VIII.

[0022] In a further embodiment, the particles are covalently coupled to one or more antigens comprising one or more epitopes, hi a further embodiment, the epitopes are associated with allergy, an autoimmune disease, an enzyme used in enzyme replacement therapy, a lysosomal storage disease, or an inflammatory disease or disorder. In one embodiment, the epitope is associated with type 1 diabetes, multiple sclerosis, systemic lupus, neuromyelitis optica, idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura, membranous nephropathy, bullous pemphigoid, pemphigus vulgaris, myasthenia gravis, mucopolysaccharidosis storage disease, gangliosidosis, hypoalkaline phosphatasia, cholesterol ester storage disease, hyperuricemia, growth hormone deficiency, renal anemia, Gaucher disease, Fabry disease, Furler disease, Hunter disease, Maroteaux-Lamy disease, hemophilia A, hemophilia B, von Willebrand disease, venous thrombosis, purpura fulminans, mucopolysaccharidosis VI, Pompe disease, celiac disease, or inflammatory bowel disease, including Crohn's disease or colitis, e.g., ulcerative colitis. In a further embodiment, the epitope is found within a protein therapy used in enzyme or coagulation factor replacement, such as myozyme, alglucerase, imiglucerase, taliglucerase, agalsidase beta, 1-iduronidase, acid glucosidase, iduronate-2-sulfatase, N-acetylgalactosamine-4-sulfatase, antihemophilic factor, factor VII, eptacog alfa, factor IX, miglustat, lomiplastim, epotetin alfa, protein C, laronidase, lumizyme, factor VIII. In a further embodiment, the epitope is an epitope listed in Table 2 or Table 3. In one embodiment, the particle is coupled to an antigen that contains only one epitope associated with one disease and / or disorder. In a further embodiment, the antigen contains more than one epitope associated with the same disease and / or disorder. In a further embodiment, the antigen comprises more than one epitope associated with different diseases and / or disorders.

[0023]

[0023] In some embodiments, one or more antigens are covalently coupled to the particle by a conjugate molecule. In some embodiments, one or more antigens are directly covalently attached to the carrier particle. In some embodiments, one or more antigens are covalently coupled to the particle by a linker. In some embodiments, the conjugate molecule comprises a carbodiimide compound. In some embodiments, the conjugate molecule comprises 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC). In some embodiments, linkers may include various bifunctional protein coupling agents such as, but not limited to, N-succinimidyl-3-(2-pyridyldithio)propionic acid (SPDP), succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate, iminothiolane (IT), imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde, paraformaldehyde), bis-azido compounds (such as bis(p-azidobenzoyl)hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as toluene 2,6-diisocyanate), and bifunctional derivatives of bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene), biotinylation, and streptavidin conjugation. Particular coupling agents include N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP) and N-succinimidyl-4-(2-pyridylthio)pentanoate (SPP), which provide disulfide bonds.

[0024] In some embodiments, the one or more antigens are encapsulated in particles having a negative surface zeta potential. In some embodiments, the particles are biodegradable.

[0025]

[0025] In some embodiments, the present invention provides a method for inducing antigen-specific tolerance in a subject, comprising administering to the subject an effective amount of a composition comprising one or more antigens covalently coupled to carrier particles having a negative zeta potential, wherein the one or more antigens are encapsulated within the particles, and wherein the particles and antigens induce tolerance to the antigens in the subject.

[0026]

[0026] In some embodiments, the present invention provides a method for inducing antigen-specific tolerance in a subject, the method comprising administering to the subject an effective amount of a composition comprising one or more antigens covalently bound to carrier particles having a negative zeta potential, wherein the one or more antigens are encapsulated in the particles.

[0027] In some embodiments, the administration is performed to treat or prevent a disease or condition. In some embodiments, the administration is performed before or after the onset of a disease or condition caused by the antigen. In some embodiments, the disease or condition is selected from the group consisting of autoimmune diseases, inflammatory diseases, allergies, transplant rejection, lysosomal storage diseases, enzyme deficiencies, inflammatory responses, and hyperimmune responses. In some embodiments, the disease or condition is selected from the group consisting of multiple sclerosis, type 1 diabetes, asthma, food allergies, environmental allergies, inflammatory bowel diseases including celiac disease, Crohn's disease, or ulcerative colitis, mucopolysaccharide storage disorders, gangliosidosis, hypoalkaline phosphatasia, cholesterol ester storage disease, hyperuricemia, growth hormone deficiency, renal anemia, hemophilia, hemophilia A, hemophilia B, von Willebrand disease, Gaucher disease, Fabry disease, Fuller's disease, Pompe disease, Hunter disease, Maroteaux-Lamy disease, and conditions caused by the antigen in the subject to reduce hyperresponsiveness to the antigen. In some embodiments, the composition minimizes or eliminates burst release of the antigen in the subject following administration, hi some embodiments, the method further comprises repeating the administration of the composition in the subject.

[0028] In a further embodiment, administration of the particles results in activation-induced death of effector T cells.

[0029] In a further embodiment, administration of the particles results in anergy of effector T cells.

[0030] In a further embodiment, administration of the particles results in apoptosis of effector T cells.

[0031] In a further embodiment, administration of the particles results in the conversion of effector T cells into regulatory T cells.

[0032]

[0032] In a further embodiment, administration of the particles results in conversion of effector T cells into regulatory T cells that express FOXP3.

[0033]

[0033] In a further embodiment, administration of the particles results in conversion of effector T cells to regulatory T cells that do not express FOXP3.

[0034] In a further embodiment, administration of the particles results in the induction and expansion of both antigen-specific and non-specific regulatory T cells. In a further embodiment, administration of the particles results in the isolation of effector T cells in the lymph nodes and spleen, inhibiting their ability to migrate to peripheral sites and cause inflammation.

[0035] In a further embodiment, administration of the particles results in downregulation of T cell dependent antibody production.

[0036]

[0036] In certain embodiments, the present invention provides a method for treating celiac disease in a subject, comprising administering to the subject an effective amount of a composition comprising an antigen covalently coupled to a carrier particle having a negative zeta potential. In certain embodiments, the antigen is gliaden or a gliaden epitope. In some embodiments, the antigen is one or more antigens selected from the group consisting of SEQ ID NOs: 1295-1724, 1726-1766, and 4986-5140. In some embodiments, the antigen is gliaden and the antigen-bound particles have a post-synthesis average size of about 600-1500 nanometers and a post-synthesis average charge of about -30 to about -80 mV. In some embodiments, the particles have a post-synthesis average size of about 600-1200 nanometers and a post-synthesis average charge of about -40 to about -70 mV. In certain embodiments, the particles have an average post-synthesis size of about 600 μm and an average post-synthesis charge of about −50 mV. In further embodiments, the particles are polystyrene particles, carboxylated polystyrene particles, PLURONIC® stabilized polypropylene sulfide particles, or poly(lactic-co-glycolic acid) particles.

[0037]

[0037] In some embodiments, the present invention provides a method for treating diabetes in a subject, comprising administering to the subject an effective amount of a composition comprising an antigen covalently coupled to a carrier particle having a negative zeta potential, wherein the antigen is encapsulated in the particle. In some embodiments, the diabetes is type I diabetes. In some embodiments, the diabetes is type II diabetes.

[0038]

[0038] In some embodiments, the antigen is insulin, proinsulin, islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP), or an epitope derived from insulin, proinsulin, or IGRP. In some embodiments, the antigen is one or more antigens selected from the group consisting of SEQ ID NOs: 1767-1840, 1842-1962, 1964-2027, 2029-2073, 2075-2113, 2115-2197, 2199-2248, 2250-2259, 2261-2420, 2422-2486, and 2489-2505. In some embodiments, the antigen is insulin, and the antigen-bound particles have a post-synthesis average size of about 300-800 nanometers and a post-synthesis average charge of about -30 to about -70 mV. In some embodiments, the particles have a post-synthesis average size of about 350-600 nanometers and a post-synthesis average charge of about -40 to about -60 mV. In some embodiments, the particles have a post-synthesis average size of about 500 nanometers and a post-synthesis average charge of about -50 mV. In some embodiments, the antigen is proinsulin and the antigen-bound particles have a post-synthesis average size of about 300-800 nanometers and a post-synthesis average charge of about -30 to about -70 mV. In certain embodiments, the particles have a post-synthesis average size of about 400-600 nanometers and a post-synthesis average charge of about -40 to about -60 mV. In some embodiments, the particles have a post-synthesis average size of about 570 nanometers and a post-synthesis average charge of about -45 mV. In some embodiments, the antigen is IGRP and the antigen-bound particles have a post-synthesis average size of about 300-800 nanometers and a post-synthesis average charge of about -30 to about -70 mV. In some embodiments, the particles have an average post-synthesis size of about 400 to 700 nanometers and an average post-synthesis charge of about -40 to about -60 mV. In some embodiments, the particles have an average post-synthesis size of about 600 nanometers and an average post-synthesis charge of about -40 mV. In certain embodiments, the particles are polystyrene particles, carboxylated polystyrene particles, PLURONIC® stabilized polypropylene sulfide particles, or poly(lactic-co-glycolic acid) particles.

[0039] In some embodiments, the present invention provides a method of treating a subject undergoing enzyme replacement therapy, comprising administering to the subject an effective amount of a composition comprising one or more antigens covalently coupled to a carrier particle having a negative zeta electron, wherein the one or more antigens are encapsulated in the particle. In some embodiments, the subject is undergoing enzyme replacement therapy for the treatment of a disease selected from the group consisting of hemophilia, hemophilia A, hemophilia B, von Willebrand disease, mucopolysaccharide storage disease, gangliosidosis, hypoalkaline phosphatasia, cholesterol ester storage disease, hyperuricemia, growth hormone deficiency, renal anemia, Gaucher disease, Fabry disease, Fuller disease, Pompe disease, Hunter disease, and Maroteaux-Lamy disease. In some embodiments, the antigen-binding particles comprise one or more enzymes selected from the group consisting of Advate, antihemophilic factor, Kogenate, Eloctate, recombinant Factor VIII Fc fusion protein, Refacto, Novo VIIa, recombinant Factor VII, eptacog alfa, helixate, monanin, coagulation factor IX, wilate, ceredase, alglucerase, cerezyme, imiglucerase, elerso, taliglucerase alfa, fabrazyme, agalsidase beta, aldrazyme, -I-iduronidase, myozyme, acid glucosidase, elaprase, iduronate-2-sulfatase, naglazyme arylsulfatase B, and N-acetylgalactosamine-4-sulfatase. In some embodiments, the particles are polystyrene particles, carboxylated polystyrene particles, PLURONIC stabilized polypropylene sulfide particles, or poly(lactic-co-glycolic acid) particles. In certain embodiments, the particles are copolymers having a molar ratio of about 80:20 to about 100:0. In certain embodiments, the particles are polystyrene particles, carboxylated polystyrene particles, PLURONIC stabilized polypropylene sulfide particles, or poly(lactic-co-glycolic acid) particles. In other embodiments, the particles are poly(lactic-co-glycolic acid) particles and have a copolymer ratio of polylactic acid:polyglycolic acid of about 50:50.

[0040] In a further embodiment, administration of the particles of the invention prevents the accumulation of neutrophils and other granulocytes in a subject. In a further embodiment, the particles of the invention are administered to a subject with cancer.

[0041]

[0041] In one embodiment, administration of the particles of the invention increases regeneration of damaged tissue. In a further embodiment, the particles increase regeneration of epithelial cells. In a further embodiment, the particles increase remyelination of neurons. In another embodiment, the subject has an autoimmune disease. In yet another embodiment, the subject has inflammatory bowel disease, including ulcerative colitis and / or Crohn's disease. In yet another embodiment, the subject has multiple sclerosis.

[0042]

[0042] In one embodiment, administration of the particles of the present invention to a subject minimizes or eliminates burst release of said antigen in said subject following administration.

[0043] In some embodiments, the composition is administered intravenously. In some embodiments, the composition is administered subcutaneously, orally, intramuscularly, lymphatically, portally, or by aerosol. In one embodiment, administration of the negatively charged particles induces antigen-specific tolerance in a subject. In one embodiment, the particles that induce antigen-specific tolerance include one or more epitopes associated with allergy, autoimmune disease, and / or inflammatory disease. In one embodiment, the epitopes are selected from those listed in Table 2 or Table 3. In one embodiment, the negatively charged particles are polystyrene, diamond, PLURONIC® stabilized polypropylene sulfide, or poly(lactic-co-glycolic acid) particles. In one embodiment, the particles are carboxylated. In one embodiment, the particles have a zeta potential of less than about -100 mV. In some embodiments, the particles have a zeta potential of between about -100 mV and about -15 mV. In some embodiments, the particles have a zeta potential between about -100 mV and about -75 mV. In some embodiments, the particles have a zeta potential between about -50 mV and about -20 mV. In one embodiment, the particles have an average diameter of about 0.1 μm to about 10 μm, e.g., about 0.2 μm to about 2 μm, or about 0.3 μm to about 5 μm, or 0.5 μm to about 3 μm, or about 0.5 μm to about 1 μm.

[0044] In one embodiment, the subject has an autoimmune disease. In one embodiment, the autoimmune disease is multiple sclerosis, scleroderma, diabetes mellitus type I, rheumatoid arthritis, thyroiditis, systemic lupus erythematosus, Raynaud's syndrome, Sjogren's syndrome, autoimmune uveitis, autoimmune myocarditis, inflammatory bowel disease, amyotrophic lateral sclerosis (ALS), systemic lupus, neuromyelitis optica, idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura, membranous nephropathy, bullous pemphigoid, pemphigus vulgaris, myasthenia gravis, celiac disease, ulcerative colitis, or Crohn's disease. In one embodiment, the particle comprises a full-length polypeptide or a fragment thereof. In one embodiment, the particle comprises one or more myelin basic protein epitopes. In one embodiment, the myelin basic protein epitopes are derived from SEQ ID NO: 4975 or SEQ ID NO: 4976. In one embodiment, the particle comprises one or more myelin oligodendrocyte glycoprotein epitopes. In one embodiment, the myelin oligodendrocyte glycoprotein epitopes are derived from SEQ ID NO: 1 or SEQ ID NO: 4978. In one embodiment, the particle contains one or more insulin epitopes. In one embodiment, the one or more insulin epitopes are derived from SEQ ID NO: 4981. In one embodiment, the particle comprises one or more glutamic acid decarboxylase epitopes. In one embodiment, the glutamic acid decarboxylase epitopes are derived from SEQ ID NO: 4982. In one embodiment, the particle comprises one or more proteolipid protein epitopes. In one embodiment, the proteolipid protein epitopes are derived from SEQ ID NO: 4977. In one embodiment, the particle comprises one or more gliaden epitopes. In one embodiment, the gliaden epitopes are derived from SEQ ID NO: 4983-4985.

[0045]

[0045] In one embodiment, the present invention provides a method for inducing regulatory T cells, comprising treating the T cells with an effective amount of a composition comprising one or more antigens covalently coupled to carrier particles having a negative zeta potential, wherein the one or more antigens are encapsulated within the particles and have a particle size greater than 80 nm.

[0046]

[0046] In some embodiments, the present invention further provides a process for preparing a tolerizing immune-modifying particle (TIMP) having a negative zeta potential, comprising: a) covalently linking one or more carrier polymers to one or more antigens to form a carrier polymer-antigen conjugate; and b) combining the carrier polymer-antigen conjugate with an unconjugated carrier polymer in a predetermined mixing ratio in solution under conditions effective to form a TIMP, wherein a TIMP having a negative zeta potential is formed and the one or more antigens are encapsulated in the TIMP.

[0047]

[0047] In some embodiments, the present invention further provides a process for the preparation of a tolerizing immunomodifying particle (TIMP) having a negative zeta potential, comprising: a) covalently linking one or more carrier polymers with one or more antigens to form a carrier polymer-antigen conjugate; and b) contacting the carrier polymer-antigen conjugate with a solution under conditions effective to form a TIMP, whereby a TIMP having a negative zeta potential is formed and the one or more antigens are encapsulated in the TIMP. In some embodiments, the contacting of the carrier polymer-antigen conjugate with the solution is performed in the presence of unconjugated carrier polymer at a predetermined mixing ratio.

[0048] In some embodiments, the particles produced by the process have a zeta potential of less than about -100 mV. In some embodiments, the particles have a zeta potential of between about -100 mV and about -15 mV. In some embodiments, the particles have a zeta potential of between about -100 mV and about -75 mV. In some embodiments, the particles have a zeta potential of between about -50 mV and about -20 mV.

[0049]

[0049] In some embodiments, the particles produced by the process have an average diameter of about 0.1 μm to about 10 μm, for example, about 0.2 μm to about 2 μm, or about 0.3 μm to about 5 μm, or about 0.5 μm to about 3 μm, or about 0.5 μm to about 1 μm.

[0050] In some embodiments, the particles produced by the process comprise polystyrene particles, carboxylated polystyrene particles, PLURONIC® stabilized polypropylene sulfide particles, or poly(lactic-co-glycolic acid) particles. In some embodiments, the particles comprise poly(lactic-co-glycolic acid) particles.

[0051] In some embodiments, the one or more antigens of the process are covalently coupled to the one or more carrier polymers by a conjugate molecule. In some embodiments, the one or more antigens are covalently coupled to the one or more carrier polymers by a linker. In some embodiments, the conjugate molecule comprises a carbodiimide compound. In some embodiments, the conjugate molecule comprises 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC).

[0052] In some embodiments, the one or more carrier polymers are formed by copolymerization. In some embodiments, the solution is a buffer solution. In some embodiments, the solution has a basic pH. In some embodiments, the solution includes sodium bicarbonate, potassium bicarbonate, lithium bicarbonate, potassium dihydrogen phosphate, sodium dihydrogen phosphate, or lithium dihydrogen phosphate.

[0053] In some embodiments, the TIMP does not contain other bioactive agents (i.e., drugs, immunomodulators, cytokines). In some embodiments, the TIMP is biodegradable. In some embodiments, the process further comprises formulating the TIMP in a pharma- ceutically acceptable carrier. [Brief description of the drawings]

[0054] [Figure 1] FIG. 1 shows the synthesis of PLG-fluorescent dye and PLG-antigen conjugates using EDC / NHS as coupling reagents. [Figure 2A]

[0055] Figure 1: Synthesis and characterization of PLG-peptide conjugates and nanoparticle formation. 1H-NMR spectra of (i) PLG, (ii) OVA323-339, and (iii) PLG-OVA323-339 measured in DMSO-d6 (calibrated at 2.5 ppm). [Figure 2B] Figure 1 shows the synthesis and characterization of PLG-peptide conjugates and nanoparticle formation. The coupling efficiency of OVA323-339, PLP139-151, and PLP178-191 to PLG was calculated by comparing the integrated value of the overlapping methyl proton peaks of leucine and isoleucine at 1.4 ppm in OVA323-339 (d, d') with the integrated value of the methylene proton peak at 5.3 ppm in PLG (b). [Figure 2C] 1 is a schematic representation of a polymer-conjugated nanoparticle. [Diagram 3]

[0056] Figure 1. Size- and time-dependent cellular interactions of PLG nanoparticles. 80 nm and 400 nm PLG nanoparticles were fluorescently labeled with 1 wt% PLG-Cy5.5 conjugate and incubated with bone marrow derived dendritic cells (BMDCs) or bone marrow derived macrophages (BMMOs) at 37°C for up to 4 h. Blue: DAPI; Red: PLG-Cy5.5 nanoparticles. [Figure 4A]

[0057] Figure 1 shows BMDC surface marker characterization after treatment with PLG-OVA323-339 particles with various antigen loadings. MHCII marker expression after treatment with 400 nm particles. [Figure 4B] Figure 1 shows BMDC surface marker characterization after treatment with PLG-OVA323-339 particles with various antigen loadings. CD80 marker expression after treatment with 400 nm particles. [Figure 4C] Figure 1 shows BMDC surface marker characterization after treatment with PLG-OVA323-339 particles with various antigen loadings. CD86 marker expression after treatment with 400 nm particles. [Figure 4D]Figure 1 shows BMDC surface marker characterization following treatment with PLG-OVA323-339 particles with various antigen loadings. MHCII marker expression following treatment with 80 nm particles. [Figure 4E] Figure 1: BMDC surface marker characterization after treatment with PLG-OVA323-339 particles with various antigen loadings. CD80 marker expression after treatment with 80 nm particles. [Figure 4F] Figure 1 shows BMDC surface marker characterization after treatment with PLG-OVA323-339 particles with various antigen loadings. CD86 marker expression after treatment with 80 nm particles. [Diagram 5]

[0058] Figure 1 shows antigen-specific induction of regulatory T cells by PLG-OVA323-339 particles delivered to antigen-presenting cells (APCs). The difference in induction between BMDCs and BMMO cells was significant at p<0.0001. [Figure 6]

[0059] 1 shows size- and antigen-loading-dependent CD25 activation and induction of regulatory T cells by PLG-OVA323-339 particles. * indicates significance at p<0.05. [Figure 7A]

[0060] FIG. 1 shows induction of regulatory T cells as indicated by CD25 activation as a function of PLG-OVA323-339 particle dose. [Figure 7B] FIG. 1 shows induction of regulatory T cells as indicated by foxp3 expression as a function of PLG-OVA323-339 particle dose. [Figure 8A]

[0061] Figure 1 shows the size and concentration dependent biodistribution of PLG particles. Mice were injected intravenously (IV) or subcutaneously (SC) with 1.25 mg of 400 nm or 80 nm PLG-Cy5.5 nanoparticle formulations. Cells from liver, kidney, heart, lung, spleen and inguinal lymph nodes were isolated. Data were analyzed by flow cytometry 24 hours after injection. [Figure 8B]Figure 1 shows size and concentration dependent biodistribution of PLG particles. The ratio of cells that were CD45+ to cells that were CD45- was determined for liver, spleen and lung. [Figure 8C] Figure 1 shows the size and concentration dependent biodistribution of PLG particles. Mice were IV injected with 1.25 mg of PLG-Cy5.5 nanoparticle formulations of various particle sizes. Data were analyzed by flow cytometry 24 hours after injection. The percentage of Cy5.5+ cells found in the liver, spleen and lungs was determined for a given particle size. [Figure 8D] Figure 1 shows size- and concentration-dependent biodistribution of PLG particles. The percentage of CD45+ or CD45- cells that were Cy5.5+ was determined for a given particle size. [Figure 8E] Figure 14. Size and concentration dependent biodistribution of PLG particles. The percentage of CD45+ or CD45- cells that were Cy5.5+ was determined for a particle size of 400 nm PLG-Cy5.5. [Figure 9]

[0062] Figure 1 shows flow cytometry analysis of blood from healthy mice (n=3) injected intravenously with 1.25 mg of 400 nm or 80 nm PLG-Cy5.5 nanoparticle formulation. Two hours after injection, blood was collected and analyzed. Expression of CD11b, CD11c, Gr-1 and Ly6c markers was used to identify the type of leukocytes. Cy5.5 fluorescence was used to determine that the cells had PLG-Cy5.5 nanoparticles. [Figure 10A]

[0063] Figure 1 shows that PLG particles induce regulatory T cells ex vivo and induce tolerance in experimental autoimmune encephalitis (EAE). BMDCs, splenic dendritic cells or liver dendritic cells were treated with 0.1 μg / mL OVA alone or 0.1 μg / mL PLG-OVA nanoparticle formulations (PLG antigen loading of 0.01-10 μg / mg) for 12-24 h. Flow cytometry was used to measure CD25 activation and foxp3 expression on T cells as an indication of regulatory T cell induction. * indicates significance at p<0.05. [Figure 10B]Figure 1 shows that PLG particles induce regulatory T cells ex vivo and induce tolerance in experimental autoimmune encephalitis (EAE). Mice were intravenously injected with 1.25 mg of PLG-Cy5.5 nanoparticle formulation. Twenty-four hours after injection, CD25 activation and foxp3 expression of T cells were measured using flow cytometry as an indication of regulatory T cell induction. * indicates significance at p<0.05. [Figure 10C] Figure 1 shows that PLG particles induce regulatory T cells ex vivo and induce tolerance in experimental autoimmune encephalitis (EAE). Peptides administered to animals were covalently coupled to particles with diameters of 200-1200 nm. Mice were treated with PLP139-151-PLG (N=5) or PBS buffer on day -7 relative to the time of immunization (day 0). Disease peaks were typically observed around days 12 to 14, and mice were scored for clinical disease. PBS buffer alone did not prevent disease induction. However, PLG particles covalently coupled with PLP139-151 or derived from PLGA covalently linked to antigen resulted in a clinical score of 0 (no disease) at all times except for low clinical scores below 1 shown between days 20 and 30. * indicates significance at p<0.05. [Figure 10D] FIG. 1 shows that PLG particles induce regulatory T cells ex vivo and induce tolerance in experimental autoimmune encephalitis (EAE). Treatment of mice with the nanoparticle formulation resulted in significantly abolished clinical disease scores as measured by cumulative disease scores from days 0 to 30 post-immunization. * indicates significance at p<0.05. [Figure 11A]

[0064] Synthesis and characterization of PLG-peptide conjugates and nanoparticle formation. (1H-NMR spectra of (i) PLG, (ii) OVA323-339, and (iii) PLG-OVA323-339 measured in DMSO-d6 (calibrated at 2.5 ppm). [Figure 11B]Figure 1 shows the synthesis and characterization of PLG-peptide conjugates and nanoparticle formation. (The coupling efficiency of OVA323-339 to PLG was calculated by comparing the integrated values ​​of the overlapping methyl proton peaks of leucine and isoleucine at 1.4 ppm in OVA (d, d') with the integrated value of the methylene proton peak at 5.3 ppm in PLG (b). [Figure 11C] Figure 1. Synthesis and characterization of PLG-peptide conjugates and nanoparticle formation. Schematic representation of antigen-conjugated nanoparticles. [Figure 11D] Figure 1: Synthesis and characterization of PLG-peptide conjugates and nanoparticle formation. PLG, PLG(OVA), PLG-OVA, and acPLG-OVA were incubated with FITC-labeled anti-OVA323-339 IgG to identify the presence of peptides on the surface of the particles. Results are geometric mean fluorescence intensity. [Figure 11E] Synthesis and characterization of PLG-peptide conjugates and nanoparticle formation. Release profiles of PLG(OVA323-339) and acPLG-OVA323-339. p<0.05. [Figure 12A]

[0065] Figure 12: In vitro regulatory T cell induction is dependent on nanoparticle size and Ag loading. Bone marrow-derived dendritic cells were treated with 300 μg / mL of 400 nm (FIG. 12B and FIG. 12D) and 80 nm (FIG. 12C and FIG. 12E) acPLG-OVA323-339 particles for 3 h. Excess acPLG-OVA323-339 particles were then washed from the wells before adding naive CD4+ OT-II T cells and 2 ng / mL TGF-β. Cells were co-cultured for 4 days before flow cytometry analysis. Representative gating strategy for regulatory T cell induction. Single, live CD4+ cells were examined for CD25 and foxp3 expression. [Figure 12B]The effect of antigen loading on CD25 was measured. Although both particle formulations were able to similarly increase CD25 expression, only the 400 nm acPGL-OVA323-339 particles were able to efficiently induce CD4+CD25+Foxp3+ regulatory T cells. [Figure 12C] The effect of antigen loading on CD25 was measured. Although both particle formulations were able to similarly increase CD25 expression, only the 400 nm acPGL-OVA323-339 particles were able to efficiently induce CD4+CD25+Foxp3+ regulatory T cells. [Figure 12D] Foxp3 expression in T cells was measured. Although both particle formulations were able to increase CD25 expression similarly, only the 400 nm acPGL-OVA32 particles were able to efficiently induce CD4+CD25+Foxp3+ regulatory T cells. [Figure 12E] Foxp3 expression in T cells was measured. Although both particle formulations were able to increase CD25 expression similarly, only the 400 nm acPGL-OVA323-339 particles were able to efficiently induce CD4+CD25+Foxp3+ regulatory T cells. [Figure 13A]

[0066] Figure 1 shows that regulatory T cell induction is dependent on nanoparticle concentration. Bone marrow-derived dendritic cells were treated with various concentrations of 400 nm PLG-OVA nanoparticle (8 μg / mg loading) formulations for 3 h. Excess acPLG-OVA323-339 particles were then washed from the cell surface before addition of OT-II T cells and 2 ng / mL TGF-β1. After co-culturing the cells for 4 days, CD25 activation of T cells was measured using flow cytometry. [Figure 13B]Figure 1 shows that regulatory T cell induction is dependent on nanoparticle concentration. Bone marrow-derived dendritic cells were treated with various concentrations of 400 nm PLG-OVA nanoparticle (8 μg / mg loading) formulations for 3 h. Excess acPLG-OVA323-339 particles were then washed from the cell surface before addition of OT-II T cells and 2 ng / mL TGF-β1. After co-culturing the cells for 4 days, Foxp3 expression in T cells was measured using flow cytometry. [Figure 14A]

[0067] Figure 1 shows that acPLG(Ag) nanoparticles prophylactically induce tolerance in R-EAE. Clinical scores for SJL / J mice treated with PBS (control), PLG(PLP139-151) 2.5 mg (1.4 μg / mg PLP) or acPLG-PLP139-151 1.25 mg (8 μg / mg PLP139-151) and immunized with PLP139-151 / CFA to induce R-EAE 7 days later. Treatment of mice with the nanoparticle formulation resulted in significantly abolished clinical disease scores compared to PBS. [Figure 14B] Figure 1: acPLG(Ag) nanoparticles prophylactically induce tolerance in R-EAE. Corresponding cumulative clinical scores for mice (n=3-7) treated with tolerogenic particles. [Figure 15A]

[0068] Figure 1 shows that acPLG(Ag) particles induce protective tolerance against R-EAE induced with a cocktail of autoantigens. Clinical scores of SJL / J mice treated with 1.25 mg of pcPLG-OVA323-339 (8 μg / mg OVA323-339), pcPLG-PLP139-151 (8 μg / mg PLP139-151), pcPLG-PLP178-191 (8 μg / mg PLP178-191), or pcPLG-PLP139-151,178-191 (8 μg / mg PLP139-151 and 8 μg / mg PLP178-191) and immunized with PLP139-151 and PLP178-191 in CFA 7 days after induction of R-EAE. Schematic representation of antigen-polymer conjugate nanoparticles delivering multiple Ags. [Figure 15B]Figure 1 shows that acPLG(Ag) particles induce protective tolerance against R-EAE induced with a cocktail of autoantigens. Clinical scores of SJL / J mice treated with 1.25 mg of pcPLG-OVA323-339 (8 μg / mg OVA323-339), pcPLG-PLP139-151 (8 μg / mg PLP139-151), pcPLG-PLP178-191 (8 μg / mg PLP178-191), or pcPLG-PLP139-151,178-191 (8 μg / mg PLP139-151 and 8 μg / mg PLP178-191) and immunized with PLP139-151 and PLP178-191 in CFA 7 days after induction of R-EAE. Treatment of mice with acPLG nanoparticles formulated with both pathogenic epitopes resulted in significantly abrogated mean clinical disease scores compared to mice treated with only a single or irrelevant epitope. [Figure 15C] Figure 1 shows that acPLG(Ag) particles induce protective tolerance against R-EAE induced with a cocktail of autoantigens. Clinical scores of SJL / J mice treated with 1.25 mg of pcPLG-OVA323-339 (8 μg / mg OVA323-339), pcPLG-PLP139-151 (8 μg / mg PLP139-151), pcPLG-PLP178-191 (8 μg / mg PLP178-191), or pcPLG-PLP139-151,178-191 (8 μg / mg PLP139-151 and 8 μg / mg PLP178-191) and immunized with PLP139-151 and PLP178-191 in CFA 7 days after induction of R-EAE. Corresponding cumulative clinical scores for mice treated with particles (n=3-7). [Figure 16]

[0069] FIG. 1 shows BCA assay raw data for determination of protein content per mg of PLGA-OVA conjugate. [Figure 17]

[0070] The percentage of CD25+Foxp3+ cells among CD4+ T cells is shown. [Figure 18]

[0071] FIG. 1 shows the percentage of CD25+Foxp3+ cells among CD4+ T cells. [Figure 19]

[0072] Figure 1: Synthesis and characterization of PLGA-PLP139-151 conjugates. 1H-NMR spectra of (i) PLGA, (ii) PLP139-151, and (iii) PLGA-PLP139-151 measured in DMSO-d6 (calibrated at 2.5 ppm). [Figure 20]

[0073] Figure 1: Synthesis and characterization of PLGA-PLP178-191 conjugates. 1H-NMR spectra of (i) PLGA, (ii) PLP178-191, and (iii) PLGA-PLP178-191 measured in DMSO-d6 (calibrated at 2.5 ppm). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0055]

[0074] The inventors have found that tolerizing immune-modifying particles (TIMPs) in which encapsulated antigens are covalently linked to the inner surface of the particle allow for delicate control of particle size and antigen encapsulation and mitigation of antigen burst effect, while still avoiding the undesirable side effects associated with surface-bound peptides. The process for producing such TIMPs includes covalently coupling one or more antigens to one or more carrier polymers to form a carrier polymer-antigen conjugate, followed by combining the carrier polymer-antigen conjugate with a non-conjugated carrier polymer in a predetermined mixture ratio in solution under conditions effective to form a TIMP, in which one or more antigens are encapsulated in the TIMP. These TIMPs can induce tolerance to autoimmune diseases and reduce immune responses. Thus, these particles may be useful in the treatment of any disease or condition characterized by an excessive inflammatory immune response, such as autoimmune diseases or allergies. These TIMPs can minimize or eliminate burst release of one or more antigens from the particle. Minimizing or eliminating burst release of antigen is desirable, for example, to better control the amount of antigen released during treatment, to avoid toxic levels of antigen, and / or to avoid ineffective antigen delivery.

[0056]

[0075] As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

[0057]

[0076] It is understood that the aspects and embodiments of the invention described herein include the aspects and embodiments "comprising," "consisting," and "consisting essentially of."

[0058]

[0077] In some embodiments, a reference herein to "about" a value or parameter includes (and describes) a variation relative to the value or parameter itself. For example, a description that refers to "about X" includes the description of "X."

[0059]

[0078] As used herein, "particle" refers to any non-tissue derived composition of matter. It may be a sphere or spherical entity, a bead, or a liposome. The terms "particle", "immunomodifying particle", "carrier particle", and "bead" may be used interchangeably depending on the context. Furthermore, the term "particle" may be used to encompass beads and spheres.

[0060]

[0079] As used herein, "negatively charged particles" refer to particles that have been modified to have a net surface charge that is less than zero.

[0061]

[0080] "Carboxylated particles" or "carboxylated beads" or "carboxylated spheres" include any particle that has been modified to contain carboxyl groups on its surface. In some embodiments, the addition of carboxyl groups enhances phagocyte / monocyte uptake of the particle from the circulation, for example, by interaction with scavenger receptors such as MARCO. Carboxylation of particles can be achieved using any compound that adds carboxyl groups, such as, but not limited to, poly(ethylene-maleic anhydride) (PEMA).

[0062]

[0081] As used herein, "carrier particle" refers to a particle that is covalently coupled to an antigen prior to forming a tolerizing immune modifying particle (TIMP). Also, as used herein, "carrier particle" or "carrier polymer" refers to a polymer that can be covalently coupled to an antigen to form a tolerizing immune modifying particle (TIMP). The particle may be a polymer, which may be, but is not limited to, polystyrene, carboxylated polystyrene, diamond, PLURONIC® stabilized polypropylene sulfide, or poly(lactic-co-glycolic acid).

[0063]

[0082] "Unconjugated carrier polymer" or "unconjugated carrier particle" refers to a carrier polymer or carrier particle that does not contain an antigen covalently attached thereto.

[0064]

[0083] As used herein, "loading amount" refers to the amount of antigen per amount of carrier polymer. Loading amount can be expressed as micrograms (μg) of antigen per milligram (mg) of carrier polymer.

[0065]

[0084] As used herein, "antigenic moiety" refers to any moiety, e.g., peptide, that is recognized by the host's immune system. Examples of antigenic moieties include, but are not limited to, autoantigens, enzymes, and / or bacterial or viral proteins, peptides, drugs, or components. Without being bound by theory, carboxylated beads that have nothing attached to them are not considered "antigenic moieties" for purposes of the present invention, although the carboxylated beads themselves may be recognized by the immune system.

[0066]

[0085] As used herein, "bare bead" or "bare particle" or "bare sphere" refers to a bead, particle or sphere that is not carboxylated.

[0067]

[0086] As used herein, "proinflammatory mediator" or "proinflammatory polypeptide" refers to a polypeptide or fragment thereof that induces, maintains, or prolongs inflammation in a subject. Examples of proinflammatory mediators include, but are not limited to, cytokines and chemokines.

[0068]

[0087] As used herein, the term "inflammatory monocyte" refers to any myeloid cell that expresses any combination of CD14 / CD26 and CCR2.

[0069]

[0088] As used herein, the term "inhibitory neutrophils" refers to neutrophils and / or monocyte-derived suppressor cells.

[0070]

[0089] As used herein, the term "Th cells" or "helper T cells" refers to cells that are + Refers to cells. CD4 +T cells assist other white blood cells in immunological processes, such as the maturation of B cells into plasma cells and memory B cells, and the activation of cytotoxic T cells and macrophages. T cells become activated when they are presented with peptide antigens by MHC class II molecules expressed on the surface of antigen-presenting cells (APCs).

[0071]

[0090] The term "Th1 cells" as used herein refers to a subset of Th cells that produce proinflammatory mediators. Th1 cells secrete cytokines to facilitate immune responses and play a role in host defense against pathogens, in part by mediating the recruitment of neutrophils and macrophages to infected tissues. Th1 cells secrete cytokines including IFN-gamma, IL2, IL-10, and TNF alpha / beta to orchestrate defense against intracellular pathogens such as viruses and some bacteria.

[0072]

[0091] The term "Th2 cells" as used herein refers to a subset of Th cells that mediate the activation and maintenance of antibody-mediated immune responses against extracellular parasites, bacteria, allergens, and toxins. Th2 cells mediate these functions by producing a variety of cytokines, such as IL-4, IL-5, IL-6, IL-9, IL-13, and IL-17E (IL-25), which are responsible for antibody production, eosinophil activation, and inhibition of some macrophage functions, thus providing a phagocytosis-independent protective response.

[0073]

[0092] The term "Th17 cells" as used herein refers to a subset of Th cells. Th17 cells play a role in host defense against pathogens by secreting cytokines to facilitate immune responses and mediate the recruitment of neutrophils and macrophages to infected tissues. TH17 cells secrete cytokines such as IL17, IL21, IL22, IL24, IL26 and TNF alpha to coordinate defense against extracellular pathogens, including fungi and bacteria.

[0074]

[0093] As used herein with reference to an antigen, "coupled," "linked," or "crosslinked" refers to the antigen being covalently bound to or covalently attached to the carrier particle and encapsulated within the particle.

[0075]

[0094] The term "IMP" as used herein refers to an immune-modifying particle that is not coupled to an antigen. The term "TIMP" as used herein refers to a tolerizing immune-modifying particle that is coupled to an antigen. In certain embodiments, the term "IMP" as used herein refers to an immune-modifying particle that does not contain an antigen. The term "TIMP" as used herein refers to a tolerizing immune-modifying particle that contains an antigen.

[0076]

[0095] The term "bioactive agent" refers to an agent other than those used to construct the particle (i.e., polymer, linker) and the antigen contained therein. Examples of bioactive agents include drugs, immunomodulators, and cytokines.

[0077]

[0096] The particles may have any particle shape or conformation. However, in some embodiments, it is preferred to use particles that are unlikely to aggregate in vivo. Exemplary particles within these embodiments are those having a spherical shape.

[0078]

[0097] One aspect of the invention relates to compositions comprising immunomodifying particles having a negative zeta potential coupled to one or more antigens encapsulated within the particles.

[0079]

[0098] Yet another aspect of the invention relates to a process for the preparation of tolerizing immunomodifying particles (TIMPs) with negative zeta potential, comprising: a) covalently linking one or more carrier polymers with one or more antigens to form a carrier polymer-antigen conjugate; and b) combining the carrier polymer-antigen conjugate with a non-conjugated carrier polymer in a predetermined mixture ratio in solution under conditions effective to form a TIMP, whereby a TIMP with negative zeta potential is formed. In some embodiments of the invention, the carrier polymer is formed by copolymerization. The microstructure of the particle may depend on the method of copolymerization.

[0080]

[0099] In some embodiments, the present disclosure relates to a process for the preparation of a tolerizing immunomodifying particle (TIMP) having a negative zeta potential, comprising: a) covalently linking one or more carrier polymers with one or more antigens to form a carrier polymer-antigen conjugate; and b) contacting the carrier polymer-antigen conjugate with a solution under conditions effective to form a TIMP, whereby a TIMP having a negative zeta potential is formed and the one or more antigens are encapsulated in the TIMP. In some embodiments, contacting the carrier polymer-antigen conjugate with the solution is performed in the presence of a predetermined mixture ratio of unconjugated carrier polymer.

[0081]

[0100] In some embodiments, the antigenic peptide molecule is coupled to a carrier polymer (e.g., PLG) by a conjugate molecule and / or a linker group. In some embodiments, the coupling of the antigenic peptide and / or apoptosis signaling molecule to the carrier polymer (e.g., PLG) comprises one or more covalent interactions. In some embodiments, the antigenic peptide is encapsulated within a carrier particle having a negative zeta potential.

[0082]

[0101] In one embodiment, the solution contacting the carrier polymer-antigen conjugate and the unconjugated carrier polymer may have a basic pH. Suitable basic pH for the basic solution includes 7.1, 7.5, 8.0, 8.5, 9.5, 10.0, 10.5, 11.0, 11.5, 12.0, 12.5, 13.0, and 13.5. The solution may also be composed of any suitable base and its conjugates. In some embodiments of the present invention, the solution may include, but is not limited to, sodium bicarbonate, potassium bicarbonate, lithium bicarbonate, potassium dihydrogen phosphate, sodium dihydrogen phosphate, or lithium dihydrogen phosphate and their conjugates.

[0083]

[0102] In one embodiment of the present invention, the tolerizing immunomodifying particles contain copolymers. These copolymers may have varying molar ratios. Suitable copolymer ratios for the tolerizing immunomodifying particles of the present invention may be 25:75, 30:70, 35:65, 40:60, 45:55, 50:50, 55:45, 60:40, 65:35, 70:30, 75:25, 80:20, 81:19, 82:18, 83:17, 84:16, 85:15, 86:14, 87:13, 88:12, 89:11, 90:10, 91:9, 92:8, 93:7, 94:6, 95:5, 96:4, 97:3, 98:2, 99:1, or 100:0. In other embodiments, the copolymer may be a periodic, statistical, linear, branched (including star, brush, or comb copolymers) copolymer. In some embodiments, the copolymer ratio may be, but is not limited to, polystyrene:poly(vinyl carboxylate) / 80:20, polystyrene:poly(vinyl carboxylate) / 90:10, poly(vinyl carboxylate):polystyrene / 80:20, poly(vinyl carboxylate):polystyrene / 90:10, polylactic acid:polyglycolic acid / 50:50, polylactic acid:polyglycolic acid / 80:20, or polylactic acid:polyglycolic acid / 90:10.

[0084]

[0103] In one embodiment, the particles of the present invention are prepared by adding the composition comprising carrier particles to a solution of non-conjugated carrier polymer.In some embodiments, the carrier particles are contacted with the solution in the presence of non-conjugated carrier polymer in a predetermined mixing ratio.In some embodiments, the non-conjugated carrier polymer is PLG (poly(lactide-co-glycolic acid)).

[0085]

[0104] In one embodiment, the particles of the present invention are made by adding a composition comprising a polymer to a solution of biocompatible polymers. Examples of biocompatible polymers include poly(ethylene-maleic anhydride) (PEMA) and polymer scaffolds based on citric acid. Further examples of biocompatible polymers include poly(alpha-esters), polyurethanes, poly(ester amides), poly(orthoesters), polyanhydrides, poly(anhydride-co-imides), crosslinked polyanhydrides, poly(propylene fumarate), pseudopoly(amino acids), poly(alkyl cyanoacrylates), polyphosphazenes, polyphosphoesters, poly(amino acids), polysaccharides, poly(ethylene glycols) (Nair et al., Progress in Polymer Science, 32(2007), 762-798, incorporated herein by reference). The solution of biocompatible polymers may contain the same or different polymers and may be mixed in different ratios to provide different effects.

[0086]

[0105] In one embodiment, the particles of the present invention are made by adding a composition containing a polymer (e.g., PLGA) to a solution of poly(ethylene-maleic anhydride) (PEMA). The concentration of PEMA in the solution can be between about 0.1% and about 10%. In one embodiment, the concentration of PEMA in the solution is between about 0.2% and about 5%. In another embodiment, the concentration of PEMA in the solution is between about 0.1% and 4%. In another embodiment, the concentration of PEMA in the solution is between about 0.1% and 2%. In another embodiment, the concentration of PEMA in the solution is between about 0.5% and 1%. In one embodiment, the percentage of PEMA in solution is 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, or 10%. In one embodiment, the percentage of PEMA in solution is about 0.5%. In another embodiment, the percentage of PEMA in solution is about 1.0%. Other compounds that can be used include, but are not limited to, poly(ethylene-alt-maleic anhydride), poly(isobutylene-co-maleic acid), poly(methyl vinyl ether-alt-maleic acid), poly(methyl vinyl ether-alt-maleic acid monoethyl ester), poly(methyl vinyl ether-alt-maleic anhydride), poly(methyl vinyl ether-alt-maleic anhydride) crosslinked with 1,9-decadiene powder, and / or poly(styrene-alt-maleic acid) sodium salt.

[0087]

[0106] In one embodiment, the particle is a liposome. In a further embodiment, the particle is a liposome composed of the following lipid molar ratios: phosphatidylcholine:phosphatidylglycerol:cholesterol -30:30:40. In a further embodiment, the particle is encapsulated within the liposome.

[0088]

[0107] Although each particle need not be uniform in size, the particles should generally be of sufficient size to be sequestered in the spleen or liver and induce phagocytosis or uptake via receptor or non-receptor mediated mechanisms by antigen presenting cells such as endothelial cells or other MPS cells. Preferably, the particles are microscale or nanoscale in size to enhance solubility, avoid potential complications caused by aggregation in vivo, and facilitate pinocytosis. Particle size may be a factor for uptake from the interstitial space to areas of lymphocyte maturation. Particles having a diameter of about 0.1 μm to about 10 μm can induce phagocytosis. Thus, in one embodiment, the particles have a diameter within these limits. In another embodiment, the particles have an average diameter of about 0.3 μm to about 5 μm. In yet another embodiment, the particles have an average diameter of about 0.5 μm to about 3 μm. In another embodiment, the particles have an average diameter of about 0.2 μm to about 2 μm. In further embodiments, the particles have an average size of about 0.1 μm, or about 0.2 μm, or about 0.3 μm, or about 0.4 μm, or about 0.5 μm, or about 1.0 μm, or about 1.5 μm, or about 2.0 μm, or about 2.5 μm, or about 3.0 μm, or about 3.5 μm, or about 4.0 μm, or about 4.5 μm, or about 5.0 μm. In certain embodiments, the particles have an average size of about 0.5 μm. In some embodiments, the total weight of the particles is less than about 10,000 kDa, less than about 5,000 kDa, or less than about 1,000 kDa, 500 kDa, 400 kDa, 300 kDa, 200 kDa, 100 kDa, 50 kDa, 20 kDa, 10 kDa. The particles in the composition do not need to be of uniform diameter. For example, a pharmaceutical formulation may contain a plurality of particles, some of which are about 0.5 μm, while others are about 1.0 μm. Any mixture of particle sizes within these given ranges is useful.

[0089]

[0108] The particles of the present invention may have a particular zeta potential. In certain embodiments, the zeta potential is negative. In one embodiment, the zeta potential is less than about -100 mV. In one embodiment, the zeta potential is less than about -50 mV. In certain embodiments, the particles have a zeta potential between -100 mV and 0 mV. In further embodiments, the particles have a zeta potential between -75 mV and 0 mV. In further embodiments, the particles have a zeta potential between -60 mV and 0 mV. In further embodiments, the particles have a zeta potential between -50 mV and 0 mV. In further embodiments, the particles have a zeta potential between -40 mV and 0 mV. In further embodiments, the particles have a zeta potential between -30 mV and 0 mV. In further embodiments, the particles have a zeta potential between -20 mV and +0 mV. In further embodiments, the particles have a zeta potential between -10 mV and -0 mV. In a further embodiment, the particles have a zeta potential between -100 mV and -50 mV. In another particular embodiment, the particles have a zeta potential between -75 mV and -50 mV. In a particular embodiment, the particles have a zeta potential between -50 mV and -40 mV.

[0090]

[0109] In some embodiments, the charge of the carrier (e.g., positive, negative, neutral) is selected to provide application-specific benefits (e.g., physiological compatibility, beneficial surface-peptide interactions, etc.). In some embodiments, the carrier has a net neutral or negative charge (e.g., to reduce non-specific binding to cell surfaces, which generally carry a net negative charge). In certain embodiments, the carrier polymer can be covalently conjugated, directly or indirectly, to an antigen (also referred to herein as an antigen-specific peptide, antigenic peptide, autoantigen, induced antigen, or tolerizing antigen) to which tolerance is desired. In some embodiments, the carrier polymer-antigen conjugate is mixed with a non-conjugated carrier polymer in a predetermined mixing ratio. In some embodiments, the predetermined mixing ratio may be 5:95, 10:90, 15:85, 20:80, 25:75, 30:70, 35:65, 40:60, 45:55, 50:50, 55:45, 60:40, 65:35, 70:30, 75:25, 80:20, 85:15, 90:10, or 95:5. In some embodiments, the predetermined mixing ratio is 50:50. In some examples, the carrier has multiple binding sites (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10...20...50...100 or more) to have multiple copies of an antigen-specific peptide or multiple different peptides (e.g., to increase the likelihood of a tolerance response) encapsulated within the carrier particle. In some embodiments, the carrier encapsulates a single type of antigenic peptide. In some embodiments, the carrier encapsulates a plurality of different antigenic peptides.

[0091]

[0110] In some embodiments, the antigen loading is about 0.10, 0.20, 0.30, 0.40, 0.50, 0.60, 0.70, 0.80, 0.90, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 μg of antigen per mg of carrier polymer and all values ​​therebetween. In some embodiments, the antigen loading is about 0.10 to about 0.50 μg of antigen per mg of carrier polymer. In some embodiments, the antigen loading is about 0.50 to about 2 μg of antigen per mg of carrier polymer. In some embodiments, the antigen loading is about 2 to about 4 μg of antigen per mg of carrier polymer. In some embodiments, the antigen loading is about 4 to about 8 μg of antigen per mg of carrier polymer. In some embodiments, the antigen loading is about 8 to about 16 μg antigen per mg of carrier polymer. In some embodiments, the antigen loading is about 16 to about 20 μg antigen per mg of carrier polymer. In some embodiments, the antigen loading is about 20 to about 30 μg antigen per mg of carrier polymer. In some embodiments, the antigen loading is about 30 to about 40 μg antigen per mg of carrier polymer. In some embodiments, the antigen loading is about 40 to about 50 μg antigen per mg of carrier polymer. In some embodiments, the antigen loading is about 50 to about 60 μg antigen per mg of carrier polymer. In some embodiments, the antigen loading is about 60 to about 70 μg antigen per mg of carrier polymer. In some embodiments, the antigen loading is about 70 μg or more antigen per mg of carrier polymer.

[0092]

[0111] The size and charge of the particles are important for tolerance induction. Although particles vary in size and charge based on the antigen encapsulated therein (see Tables 1 and 5 for examples of specific particles), generally, the particles of the present invention are effective in inducing tolerance when they are between about 100 nanometers and about 1500 nanometers and have a charge of 0 to about -100 mV, and are most effective in inducing tolerance when they are between 400-800 microns and have a charge of between about -25 mV and -70 mV. As used herein, the terms "post-synthesis size" and "post-synthesis charge" refer to the size and charge of the particles before lyophilization. The terms "post-lyophilization size" and "post-lyophilization charge" refer to the size and charge of the particles after lyophilization. Table 1 shows the size and zeta potential of representative nanoparticle formulations. Particles of various sizes were prepared by double emulsion and nanoprecipitation methods. The loading amount (μg antigen (Ag) / mg PLG) was precisely controlled by combining PLG-Ag conjugates with unconjugated PLG in a defined mixing ratio. Tables 1 and 5 show the size and zeta potential of representative nanoparticle formulations.

[0093] [Table 1]

[0094]

[0112] In some embodiments, the particles are non-metallic. In these embodiments, the particles can be formed from polymers. In preferred embodiments, the particles are biodegradable in the individual. In this embodiment, the particles can be provided in the individual over multiple doses without accumulation of the particles in the individual. Examples of suitable particles include polystyrene particles, PLGA particles, PLURONIC® stabilized polypropylene sulfide particles, and diamond particles. In some embodiments, suitable particles include particles prepared from the following general classes of polymers: poly(alpha-esters), polyurethanes, poly(ester amides), poly(orthoesters), polyanhydrides, poly(anhydride-co-imides), crosslinked polyanhydrides, poly(propylene fumarates), pseudopoly(amino acids), poly(alkyl cyanoacrylates), polyphosphazenes, polyphosphoesters, poly(amino acids), and polysaccharides.

[0095]

[0113] Preferably, the particle surface is composed of a material that minimizes non-specific or undesirable biological interactions. Interaction of the particle surface with the interstitium may be a factor that plays a role in lymphatic uptake. The particle surface can be coated with a material that prevents or reduces non-specific interactions. Steric stabilization by coating the particle with a hydrophilic layer such as poly(ethylene glycol) (PEG) and its copolymers such as PLURONIC® (including copolymers of poly(ethylene glycol)-bl-poly(propylene glycol)-bl-poly(ethylene glycol)) can reduce non-specific interactions with interstitial proteins, as shown by improved lymphatic uptake after subcutaneous injection. All these facts point to the significance of the particle's physical properties with respect to lymphatic uptake. Biodegradable polymers can be used to make all or part of the polymer and / or particle and / or layer. Biodegradable polymers can undergo degradation, for example, as a result of functional groups reacting with water in solution. The term "degradation" as used herein refers to becoming soluble by a decrease in molecular weight or by conversion of hydrophobic groups to hydrophilic groups. Polymers with ester groups, such as polylactide and polyglycolide, generally undergo spontaneous hydrolysis.

[0096]

[0114] The particles of the present invention may also contain additional components. For example, the carrier may have a contrast agent incorporated or conjugated to the carrier. An example of the carrier nanosphere with contrast agent that is currently commercially available is the Kodak X-site nanosphere inorganic quantum confined luminescent nanocrystal, known as quantum dot (QD), which has emerged as an ideal donor in FRET applications: due to its high quantum yield and tunable size-dependent Stokes shift, different sizes can emit from blue to infrared when excited by a single ultraviolet wavelength (Bruchez et al., Science, 1998, 281, 2013;Niemeyer, C. M Angew. Chem. Int. Ed. 2003, 42, 5796;Waggoner, A. Methods Enzymol. 1995, 246, 362;Brus, LEJ Chem. Phys. 1993, 79, 5566). Quantum dots, such as hybrid organic / inorganic quantum dots based on a class of polymers known as dendrimers, can be used in biological labeling, imaging, and optical biosensing systems (Lemon et al., J. Am. Chem. Soc. 2000, 122, 12886). Unlike traditional synthesis of inorganic quantum dots, the synthesis of these hybrid quantum dot nanoparticles does not require high temperatures or highly toxic, unstable reagents (Etienne et al., Appl. Phys. Lett. 87, 181913, 2005).

[0097]

[0115] The particles of the present invention can be covalently linked to imaging agents such as cyanine fluorescent dyes. In some embodiments, the cyanines include open-chain cyanines, hemicyanines, and / or closed-chain cyanines. In some embodiments, the cyanine fluorescent dyes include Cy2, Cy3, Cy3B, Cy3.5, Cy5, Cy5.5, and Cy7. In some embodiments, the particles are covalently linked to Cy5.5 for in vivo imaging.

[0098]

[0116] Particles can be formed from a variety of materials. Particles are preferably composed of materials suitable for biological use. For example, particles may be composed of glass, silica, polyesters of hydroxycarboxylic acids, polyanhydrides of dicarboxylic acids, or copolymers of hydroxycarboxylic acids and dicarboxylic acids. More generally, carrier particles may be composed of polyesters of linear or branched chain, substituted or unsubstituted, saturated or unsaturated, linear or crosslinked alkanyl, haloalkyl, thioalkyl, aminoalkyl, aryl, aralkyl, alkenyl, aralkenyl, heteroaryl, or alkoxy hydroxy acids, or polyanhydrides of linear or branched chain, substituted or unsubstituted, saturated or unsaturated, linear or crosslinked alkanyl, haloalkyl, thioalkyl, aminoalkyl, aryl, aralkyl, alkenyl, aralkenyl, heteroaryl, or alkoxy dicarboxylic acids. Additionally, the carrier particles may be or be composed of quantum dots, such as quantum dot polystyrene particles (Joumaa et al., (2006) Langmuir 22: 1810-6). Carrier particles comprising a mixture of ester and anhydride linkages (e.g., copolymers of glycolic acid and sebacic acid) may also be used. For example, the carrier particles may comprise materials including polyglycolic acid polymers (PGA), polylactic acid polymers (PLA), polysebacic acid polymers (PSA), poly(lactic acid-co-glycolic acid) copolymers (PLGA or PLG; the terms are interchangeable), [rho]poly(lactic acid-co-sebacic acid) copolymers (PLSA), poly(glycolic acid-co-sebacic acid) copolymers (PGSA), polypropylene sulfide polymers, poly(caprolactone), chitosan, and the like. Other biocompatible, biodegradable polymers useful in the present invention include polymers or copolymers of caprolactones, carbonates, amides, amino acids, orthoesters, acetals, cyanoacrylates, and degradable urethanes, and copolymers thereof with linear or branched, substituted or unsubstituted alkanyl, haloalkyl, thioalkyl, aminoalkyl, alkenyl, or aromatic hydroxy- or di-carboxylic acids.Additionally, biologically important amino acids with reactive side groups, such as lysine, arginine, aspartic acid, glutamic acid, serine, threonine, tyrosine and cysteine, or their enantiomers, can be included in copolymers with any of the above materials to provide reactive groups for conjugation to antigenic peptides and proteins or conjugation moieties. Suitable biodegradable materials for the present invention include diamond, PLA, PGA, polypropylene sulfide, and PLGA polymers. Biocompatible but non-biodegradable materials can also be used in the carrier particles of the present invention. For example, non-biodegradable polymers of acrylate, ethylene-vinyl acetate, acyl-substituted cellulose acetate, non-degradable urethane, styrene, vinyl chloride, vinyl fluoride, vinyl imidazole, chlorosulfonated olefins, ethylene oxide, vinyl alcohol, TEFLON® (DuPont, Wilmington, Del.), and nylon can be used.

[0099] Preparation of the Composition

[0117] The particles of the present invention can be manufactured by any means generally known in the art. Exemplary methods for manufacturing particles include, but are not limited to, microemulsion polymerization, interfacial polymerization, precipitation polymerization, emulsion evaporation, emulsion diffusion, solvent displacement, and salting out (Astete and Sabliov, J. Biomater. Sci. Polymer Edn., 17:247-289(2006)). Manipulation of the manufacturing process for PLGA particles can control particle properties (e.g., size, size distribution, zeta potential, morphology, hydrophobicity / hydrophilicity, polypeptide entrapment, etc.). The size of the particles is influenced by several factors, including, but not limited to, the concentration of PLGA, the solvent used in the manufacture of the particles, the nature of the organic phase, the surfactant used in the manufacture, the viscosity of the continuous and discontinuous phases, the nature of the solvent used, the temperature of the water used, sonication, evaporation rate, additives, shear stress, sterilization, and the nature of any encapsulated antigen or polypeptide.

[0100]

[0118] Particle size is affected by the polymer concentration; higher polymer concentrations result in larger particle sizes. For example, increasing the PLGA concentration from 1% to 4% (w / v) can increase the average particle size from about 205 nm to about 290 nm when using propylene carbonate solvent. Alternatively, in ethyl acetate and 5% Pluronic F-127, increasing the PLGA concentration from 1% to 5% (w / v) increases the average particle size from 120 nm to 230 nm.

[0101]

[0119] The viscosity of the continuous and discontinuous phases is also an important parameter that influences the diffusion process, which is a key step in the formation of smaller particles. The size of the particles increases with increasing viscosity of the dispersed phase, while the size of the particles decreases with a more viscous continuous phase. In general, the smaller the ratio of organic solvent to aqueous solvent phase, the smaller the particle size.

[0102]

[0120] The speed and agitation of the homogenizer also affect particle size; generally, higher speed and agitation cause a reduction in particle size, but there is a point where further increases in speed and agitation no longer reduce particle size. There is a favorable effect of size reduction when the emulsion is homogenized using a high pressure homogenizer compared to high agitation alone. For example, at a ratio of 20% phase in 5% PVA, the average particle size using agitation is 288 nm, and the average particle size using homogenization (high pressure of 300 bar) is 231 nm.

[0103]

[0121] A significant size reduction of the particles can be achieved by varying the temperature of the added water to improve the diffusion of the solvent. The average particle size decreases with increasing water temperature.

[0104]

[0122] The nature of the polypeptide encapsulated in the particle also affects particle size. In general, encapsulation of hydrophobic polypeptides results in the formation of smaller particles compared to encapsulation of more hydrophilic polypeptides. In the double emulsion process, the entrapment of more hydrophilic polypeptides is improved by using high molecular weight PLGA and a high molecular weight first surfactant that causes higher internal phase viscosity. The interaction between the solvent, polymer, and polypeptide affects the efficiency of incorporating the polypeptide into the particle.

[0105]

[0123] The PLGA molecular weight affects the final average particle size. Generally, the higher the molecular weight, the larger the average particle size. For example, as the composition and molecular weight of the PLGA change (e.g., 12 to 48 kDa for 50:50 PLGA; 12 to 98 kDa for 75:25 PLGA), the average particle size changes (approximately 102 nm to 154 nm; approximately 132 nm to 152 nm, respectively). Even if the particles are of the same molecular weight, their composition can affect the average particle size; for example, particles with a 50:50 ratio generally form smaller particles than those with a 75:25 ratio. The end groups on the polymer also affect the particle size. For example, particles prepared with ester end groups form particles with an average size of 740 nm (PI=0.394) compared to an average size of 240 nm (PI=0.225) for acid PLGA end groups.

[0106]

[0124] The solvent used can also affect particle size; solvents that decrease the surface tension of the solution also decrease the particle size.

[0107]

[0125] The organic solvent is removed by evaporation under reduced pressure to avoid damage to the polymer and polypeptide and to facilitate the reduction of the final particle size.The evaporation of the organic solvent under reduced pressure is more effective in forming smaller particles.For example, the evaporation under reduced pressure produces an average particle size that is about 30% smaller than that produced under normal evaporation speed.

[0108]

[0126] The amplitude of the sonication wavelength also influences the particle characteristics. The amplitude of the wavelength should be above 20% for 600 to 800 s of sonication to form a stable miniemulsion where the droplet size does not change further. However, the main drawback of sonication is the lack of monodispersity of the emulsions formed.

[0109]

[0127] Organic phases that can be used in the production of the particles of the present invention include, but are not limited to, methylene chloride, ethyl acetate, methyl ethyl ketone, propylene carbonate, and benzyl alcohol. Continuous phases that can be used include, but are not limited to, the surfactant poloxamer 188.

[0110]

[0128] A variety of surfactants can be used in the preparation of the particles of the present invention. The surfactants can be anionic, cationic, or nonionic. Surfactants in the poloxamer and poloxamine families are commonly used in particle synthesis. Surfactants that can be used include, but are not limited to, PEG, Tween-80, gelatin, dextran, Pluronic L-63, PVA, methylcellulose, lecithin, DMAB, PEMA, sodium deoxycholate, poly(acrylic acid), hyaluronic acid, and other negatively charged natural or synthetic small molecules or polymers. Additionally, biodegradable and biocompatible surfactants include, but are not limited to, Vitamin E TPGS (D-α-tocopheryl polyethylene glycol 1000 succinate). In certain embodiments, two surfactants are required (e.g., in the double emulsion evaporation method). These two surfactants may include a hydrophobic surfactant for the first emulsion and a hydrophobic surfactant for the second emulsion.

[0111]

[0129] Another manufacturing technique involves nanoprecipitation. For example, the polymer is soluble in an organic solvent, but the organic solvent is miscible with an aqueous phase. Since the aqueous phase is a non-solvent for the polymer, when the organic phase (polymer-containing solution) and the aqueous phase are mixed, the polymer can precipitate and form particles.

[0112]

[0130] Solvents that can be used in the production of the particles of the present invention include, but are not limited to, ethyl acetate, acetone, tetrahydrofuran (THF), chloroform, and the member of the chlorinate family, methylene chloride. The selection of the organic solvent requires two selection criteria: the polymer must be soluble in the solvent, and the solvent must be completely immiscible with the aqueous phase.

[0113]

[0131] Salts that can be used in producing the particles of the present invention include, but are not limited to, magnesium chloride hexahydrate, magnesium acetate tetrahydrate.

[0114]

[0132] Common salting out agents include, but are not limited to, electrolytes (eg, sodium chloride, magnesium acetate, magnesium chloride) or non-electrolytes (eg, sucrose).

[0115]

[0133] The stability and size of the particles of the present invention can be improved by adding compounds, including but not limited to fatty acids or short carbon chains. The addition of lauric acid with longer carbon chains is associated with improved particle properties. Furthermore, the addition of hydrophobic additives can improve particle size, polypeptide incorporation into particles, and release profile. The preparation of particles can be stabilized by lyophilization. The addition of cryoprotectants such as trehalose can reduce particle aggregation during lyophilization.

[0116]

[0134] Suitable beads currently commercially available include polystyrene beads, such as FluoSpheres (Molecular Probes, Eugene, Oreg.).

[0117]

[0135] In some embodiments, the present invention provides a system comprising: (a) a delivery scaffold configured for delivery of a chemical and / or biological agent to a subject; and (b) antigen-bound poly(lactide-co-glycolide) particles for induction of antigen-specific tolerance. In some embodiments, at least a portion of the delivery scaffold is microporous. In some embodiments, antigen-bound poly(lactide-co-glycolide) particles are encapsulated within the scaffold. In some embodiments, the chemical and / or biological agent is selected from the group consisting of proteins, peptides, small molecules, nucleic acids, cells, and particles. In some embodiments, the chemical and / or biological agent comprises cells, and the cells comprise pancreatic islet cells.

[0118]

[0136] Physical properties are also relevant to the usefulness of the nanoparticles after uptake and retention in areas with immature lymphocytes. These include mechanical properties such as rigidity or elasticity. Some embodiments are based on an elastic core, e.g., a poly(propylene sulfide) (PPS) core with a coating layer, e.g., a hydrophilic coating layer, as in the PPS-PEG system, recently developed and characterized for systemic (not targeted or immune) delivery, as in PEG. Elastic cores are in contrast to substantially rigid cores, as in polystyrene or metal nanoparticle systems. The term elastic refers to certain resilient materials that are different from natural or synthetic rubbers, and elastic is a term well known to those skilled in the polymer industry. For example, crosslinked PPS can be used to form a hydrophobic elastic core. PPS is a polymer that degrades under oxidative conditions to polysulfoxide and eventually polysulfone, transitioning from a hydrophobic rubber to a hydrophilic water-soluble polymer. Other sulfide polymers may be adapted for use, where the term sulfide polymer refers to a polymer with sulfur in the backbone of the polymer unit (mer). Other elastic polymers that can be used are polyesters that have a glass transition temperature under hydration conditions that is less than about 37°C. Hydrophobic cores can be advantageously used with hydrophilic coating layers because the hydrophobic core and coating layer tend not to mix and the coating layer tends to expand sterically away from the core. Core refers to a particle that has a layer thereon. Layer refers to a material that coats at least a portion of the core. The layer may be adsorbed or covalently bonded. The particle or core may be solid or hollow. Elastic hydrophobic cores are advantageous over rigid hydrophobic cores, such as crystalline or glass (as in the case of polystyrene) cores, in that a higher loading of hydrophobic drug can be loaded by particles with elastic hydrophobic cores.

[0119]

[0137] Another physical property is the hydrophilicity of the surface. A hydrophilic material may have a solubility in water of at least 1 gram per liter if it is not crosslinked. Steric stabilization of particles with hydrophilic polymers can improve uptake from the interstitium by reducing non-specific interactions; however, the increased stealth of the particles can also reduce internalization by phagocytes in areas with immature lymphocytes. The challenge of balancing these competing characteristics has been met, and the present application demonstrates the creation of nanoparticles for effective lymphatic delivery to DCs and other APCs in lymph nodes. Some embodiments include a hydrophilic component, e.g., a layer of hydrophilic material. Examples of suitable hydrophilic materials are one or more of polyalkylene oxides, polyethylene oxides, polysaccharides, polyacrylic acids, and polyethers. The molecular weight of the polymers in the layer can be adjusted to provide a useful degree of steric hindrance in vivo, for example, from about 1,000 to about 100,000 or even more; one of ordinary skill in the art will readily recognize that all ranges and values ​​within the explicitly stated ranges are contemplated, for example, between 10,000 and 50,000.

[0120]

[0138] The nanoparticles may contain functional groups for further reaction. Functional groups for further reaction include electrophiles or nucleophiles; these are convenient for reacting with other molecules. Examples of nucleophiles are primary amines, thiols, and hydroxyls. Examples of electrophiles are succinimidyl esters, aldehydes, isocyanates, and maleimides.

[0121]

[0139] Antigenic peptides and proteins can be conjugated to carrier polymers using a variety of means well known in the art. These methods include any standard chemistry that allows a sufficient number of antigenic peptides and proteins to be conjugated to the carrier polymer in an orientation that allows the antigenic peptide or protein to interact with its cognate T-cell receptor without destroying or significantly limiting the biological activity of the antigenic peptides and proteins. In general, methods that conjugate the C-terminal region of the antigenic peptide or protein, or the C-terminal region of an antigenic peptide or protein fusion protein, to the workforce are preferred. Of course, the exact chemistry will depend on the nature of the workforce material, the presence or absence of a C-terminal fusion to the antigenic peptide or protein, and / or the presence or absence of a conjugated moiety.

[0122]

[0140] Functional groups can be placed on the carrier polymer as needed for availability. One location can be on the core polymer or on a polymer that is a layer on the core or otherwise tethered to the particle, as a side group or terminal. For example, examples are included herein that describe PEG stabilizing nanoparticles that can be easily functionalized for specific cell targeting or protein and peptide drug delivery.

[0123] Conjugation Procedure

[0141] The present disclosure provides a conjugate of a carrier particle (e.g., a carrier polymer). A polymer is typically a chemical species that contains multiple repeat units linked together. A polymer may contain more than one different repeat unit. The repeat unit is typically derived from the polymerization of a monomer. A copolymer specifically refers to a polymer that contains two or more structurally different repeat units. The different repeat units of a polymer may be in a random order in the polymer chain, or the same repeat unit may be grouped into consecutive blocks in the polymer. When there are two or more consecutive blocks of repeat units in a polymer, the polymer is a block copolymer. In certain embodiments, the polymer is a graft copolymer. The term "polymer" as used herein refers to a chemical species that contains more than about 10 repeat units.

[0124]

[0142] Suitable carrier particles (e.g., carrier polymers) for conjugation contain functional groups for reaction. The carrier particles (e.g., carrier polymers) described herein can be chemically modified by reaction to introduce desired terminal functional groups. Terminal functional groups include, in particular, carboxyl, hydroxyl, thiol, amine, azide, alkyne, alkene, ketone, phenol, halide, imidazole, guanidinium, carboxylate, or phosphate groups. These functional groups can be introduced to the ends of the carrier particles (e.g., carrier polymers) herein using well-known chemical methods.

[0125]

[0143] The functional groups can be used to further conjugate the carrier particle (e.g., carrier polymer) to other chemical species, such as other polymers, other oligomers, peptides, proteins, small molecules, carbohydrates, antibodies, nucleic acids, and / or aptamers.

[0126]

[0144] In certain embodiments, the carrier particles (e.g., carrier polymers) contain carboxyl groups that can be conjugated to amino-containing conjugate partners using carbodiimide crosslinking chemistry. Carbodiimide reagents are used as coupling reagents for the reaction of carboxylic acids to amide or ester formation. Examples of carbodiimide reagents include EDCI (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, or EDC, or ECDI), DCC (N,N'-dicyclohexylcarbodiimide), and DIC (N,N'-diisopropylcarbodiimide). In addition to coupling reagents, activating reagents can be used to facilitate the reaction. Examples of activating reagents include hydroxysuccinimide. The reaction of a carbodiimide-activated carboxylic acid on the carrier particle (e.g., carrier polymer) with an amino-containing conjugate partner can produce an amide bond that connects the carrier polymer and the conjugate partner.

[0127]

[0145] In certain embodiments, the carrier particle (e.g., carrier polymer) and the conjugate partner (e.g., antigen) are coupled using a multifunctional coupling reagent (e.g., a bifunctional coupling reagent). The choice of multifunctional coupling reagent depends on the functional groups present on the carrier particle (e.g., carrier polymer) and the conjugate partner (e.g., antigen).

[0128]

[0146] The groups of the multifunctional coupling reagent may independently comprise carboxyl-reactive groups, carbonyl-reactive groups, amine-reactive groups, thiol-reactive groups, or photoreactive groups, but are not the same (e.g., orthogonal). Examples of carboxyl-reactive groups include hydrazine derivatives and amines. Examples of carbonyl-reactive groups include aldehyde- and ketone-reactive groups, such as hydrazine derivatives and amines. Examples of amine-reactive groups include active esters, such as NHS or sulfo-NHS, isothiocyanates, isocyanates, acyl azides, sulfonyl chlorides, aldehydes, glyoxals, epoxides, oxiranes, carbonates, aryl halides, imidoesters, anhydrides, and the like. Examples of thiol reactive groups include non-polymerizable Michael acceptors, haloacetyl groups (such as iodoacetyl), aromatic groups capable of undergoing nucleophilic displacement, such as alkyl halides, maleimides, aziridines, acryloyl groups, vinyl sulfones, benzoquinones, fluorobenzene groups (such as tetra- and pentafluorobenzene groups), and disulfide groups, such as pyridyl disulfide groups and thiols activated with Ellman's reagent. Examples of photoreactive groups include aryl azides and halogenated aryl azides. Further examples of each of these types of groups will be apparent to those skilled in the art. Further examples and information regarding reaction conditions and methods for exchanging one type of reactive group for another are provided in Hermanson, Bioconjugate Techniques, Academic Press, San Diego, 1996, which is incorporated herein by reference.

[0129] Alternative conjugation procedures

[0147] Conjugates such as ethylene carbodiimide (EDCI), hexamethylene diisocyanate, propylene glycol diglycidyl ether containing two epoxy residues, and epichlorohydrin can be used for immobilization of peptides or proteins to carrier polymers. Without being bound by theory, EDCI is believed to perform two main functions for the induction of tolerance: (a) chemically coupling proteins / peptides to carrier polymers via catalysis of peptide bond formation between free amino and free carboxyl groups; and (b) inducing carriers to mimic apoptotic cell death such that they are picked up by host antigen-presenting cells (which may include endothelial cells) in the spleen and induce tolerance. It is this presentation to host T cells in a non-immunogenic manner that results in the direct induction of anergy in self-reactive cells. In addition, EDCI serves as a potent stimulant for the induction of specific regulatory T cells.

[0130]

[0148] In one series of embodiments, the antigen peptides and proteins are bound to the carrier polymer by covalent chemical bonds. For example, a reactive group or moiety near the C-terminus of the antigen (e.g., the C-terminal carboxyl group, or a hydroxyl, thiol, or amine group derived from an amino acid side chain) can be directly conjugated to a reactive group or moiety of the carrier polymer (e.g., a hydroxyl or carboxyl group of a PLA or PGA polymer, a terminal amine or carboxyl group of a dendrimer, or a hydroxyl, carboxyl, or phosphate group of a phospholipid) by direct chemical reaction. Alternatively, there may be conjugation moieties that link the antigen peptides and proteins together with the carrier polymer by covalently conjugating both of them.

[0131]

[0149] The reactive carboxyl groups of the carrier polymer can be linked to free amines (e.g., from Lys residues) on antigenic peptides or proteins by reacting them with, for example, 1-ethyl-3-[3,9-dimethylaminopropyl]carbodiimide hydrochloride (EDC) or N-hydroxysuccinimide ester (NHS). Similarly, the same chemistry can be used to conjugate free amines on the surface of the carrier polymer with free carboxyls (e.g., from the C-terminus or from Asp or Glu residues) on antigenic peptides or proteins. Alternatively, free amine groups on the carrier polymer can be covalently attached to antigenic peptides and proteins, or antigenic peptide or protein fusion proteins, using sulfo-SIAB chemistry, essentially as described by Arano et al. (1991) Chem.2:71-6.

[0132]

[0150] Conjugation of the nucleic acid moiety to the platform moiety can be performed in a variety of ways, typically by including one or more crosslinkers and functional groups on the nucleic acid moiety and the platform molecule. The linking group is added to the platform using standard synthetic chemistry techniques. The linking group can be added to the nucleic acid moiety using standard synthetic techniques. The practitioner has several choices for the antigens used in the combination of the present invention. The induced antigen present in the combination contributes to the specificity of the tolerogenic response induced. The induced antigen may or may not be the same as the target antigen present in or placed in the subject to be treated, which is the target for which tolerance is sought for an undesired immunological response.

[0133] Biological and Chemical Antigens

[0151] The inducing antigen of the present invention may be a polypeptide, polynucleotide, carbohydrate, glycolipid, or other molecule isolated from a biological source, or it may be a chemically synthesized small molecule, polymer, or derivative of biological material, provided that it has the ability to induce tolerance according to the present description when combined with a mucosal binding component.

[0134]

[0152] In some embodiments, the invention provides a carrier polymer covalently coupled to one or more peptides, polypeptides, and / or proteins. In some embodiments, carriers such as those described herein (e.g., PLG carriers) are effective in inducing antigen-specific tolerance and / or preventing the onset of immune-related disease (such as EAE in mouse models) and / or reducing the severity of pre-existing immune-related disease. In some embodiments, the compositions and methods of the invention enable T cells to initiate early events associated with T cell activation, but the T cells are unable to acquire effector function. For example, administration of the compositions of the invention can result in T cells with a pseudo-activated phenotype, such as CD69 and / or CD44 upregulation, but not exhibiting effector function, such as that indicated by a lack of IFN-γ or IL-17 synthesis. In some embodiments ... + / Foxp3 + The present invention provides a method for producing T cells having a pseudo-activated phenotype without converting them to a regulatory phenotype, such as one having a pseudo-activated phenotype.

[0135]

[0153] In some embodiments, the carrier includes one or more biological or chemical agents attached to, adsorbed onto, encapsulated within, and / or contained within the carrier. In some embodiments, the chemical or biological agents are encapsulated within particles and / or contained within the particles. The present invention is not limited by the nature of the chemical or biological agents. Such agents include, but are not limited to, proteins, nucleic acid molecules, small molecule drugs, lipids, carbohydrates, cells, cellular components, and the like. In some embodiments, two or more (e.g., 3, 4, 5, etc.) different chemical or biological agents are included on or within the carrier. In some embodiments, the agent is configured for a specific release rate. In some embodiments, multiple different agents are configured for different release rates. For example, a first agent may release over a period of hours, while a second agent releases over a longer period of time (e.g., days, weeks, months, etc.). In some embodiments, the carrier or a portion thereof is configured for delayed release of the biological or chemical agent. In some embodiments, the delayed release provides for release of a biologically active amount of agent over a period of at least 30 days (e.g., 40 days, 50 days, 60 days, 70 days, 80 days, 90 days, 100 days, 180 days, etc.). In some embodiments, the carrier or a portion thereof is configured to be sufficiently porous to allow ingrowth of cells into the pores. The size of the pores can be selected for the particular cell type of interest and / or the amount of ingrowth desired. In some embodiments, the particles contain an antigen of interest without other non-peptide active agents, such as drugs or immunomodulatory agents. Furthermore, in some embodiments, the particles of the present invention do not contain immunostimulatory or immunosuppressive peptides in addition to the antigen of interest. Furthermore, in some embodiments, the particles do not contain other proteins or peptides (e.g., co-stimulatory molecules, MHC molecules, immunostimulatory or immunosuppressive peptides) on the surface or encapsulated within the particle.

[0136]

[0154] The encapsulation of antigens, biological agents, and / or chemical agents in the particles of the present invention has surprisingly been found to induce immune tolerance and has several advantages. First, the encapsulated particles have a slower cytokine response. Second, when multiple antigens, biological agents, and / or chemical agents are used, encapsulation eliminates the competition between these various molecules that may occur when the agent is bound to the surface of the particle. Third, encapsulation allows more antigens, biological agents, and / or chemical agents to be incorporated into the particle. Fourth, encapsulation allows easier use of complex protein antigens or organ homogenates (e.g., pancreatic homogenates for type 1 diabetes or peanut extracts in peanut allergy). Finally, instead of conjugation to the surface of the particle, the encapsulation of antigens, biological agents, and / or chemical agents within the particle maintains a net negative charge on the surface of the particle. The encapsulation of antigens, biological agents, and / or chemical agents in the particles of the present invention can be carried out by any method known in the art. In one embodiment, the polypeptide antigen is encapsulated in the particles by a double emulsion process, hi a further embodiment, the polypeptide antigen is water soluble.

[0137]

[0155] In another embodiment, the polypeptide antigen is encapsulated in the particle by the single emulsion process. In a further embodiment, the polypeptide antigen is more hydrophobic. Sometimes, the double emulsion process leads to the formation of large particles, which can lead to leakage of hydrophilic active ingredients and low entrapment efficiency. Coalescence and Ostwald ripening are two mechanisms that can destabilize double emulsion droplets, while diffusion of hydrophilic active ingredients through the organic phase is the main mechanism responsible for low levels of entrapped active ingredients. In some embodiments, it can be beneficial to reduce the size of the nanoparticles. One strategy to achieve this is to apply a second strong shear rate. The leakage effect can be mitigated by using high polymer concentration and high polymer molecular weight, which is achieved by increasing the viscosity of the internal aqueous phase and increasing the surfactant molecular weight.

[0138]

[0156] In certain embodiments, the present invention provides a carrier having cells or other biological or chemical agents thereon. When cells are used, the carrier is not limited to a particular cell type. In some embodiments, the carrier has pancreatic islet cells thereon. In some embodiments, the microporous carrier further has ECM proteins and / or exendin-4 thereon. The carrier is not limited to a particular type. In some embodiments, the carrier has regions of varying porosity (e.g., varying pore size, pore depth, and / or pore density). In some embodiments, the carrier has drugs, DNA, RNA, extracellular matrix proteins, exendin-4, etc. thereon. In certain embodiments, the present invention provides a method for implanting such carriers with pancreatic islet cells. In certain embodiments of the present invention, the inducing antigen is a single isolated or recombinantly produced molecule. To treat conditions where the target antigen has been seeded in various locations in the host, it is generally necessary that the inducing antigen is identical to or immunologically related to the target antigen. Examples of such antigens are many polynucleotide antigens, and some carbohydrate antigens (such as blood group antigens).

[0139]

[0157] Any suitable antigen may be useful within the scope of the present invention. In some embodiments, the induced antigen contributes to the specificity of the induced tolerogenic response. The induced antigen may or may not be the same as the target antigen, which is the antigen present in or introduced into the subject to be treated, that is the target of the undesired immunological response and against which tolerance is sought.

[0140]

[0158] If the target antigen is preferentially expressed on a particular organ, cell, or tissue type, the practitioner again has the option of using an inducing antigen that is identical to or immunologically related to the target antigen. However, there is also the further option of using an antigen that is a third party to the target. This is an antigen that may not be immunologically related to the target antigen, but is preferentially expressed in the tissue in which the target antigen is expressed. The working theory for the effectiveness of third party suppression is that suppression is an active cell-mediated process that downregulates the effector arm of the immune response in target cells. Suppressor cells are specifically stimulated by the inducing antigen at mucosal surfaces and are present in tissue sites where the third party antigen is preferentially expressed. Then, by interaction or cytokine-mediated mechanisms, the localized suppressor cells downregulate nearby effector cells (or inducers of effector cells), regardless of whether they are reactive or not. If the effector cells are specific for a target different from the inducing antigen, the result is a third party effect. For further elaboration of the third party response and a list of tolerogenic peptides that have this effect, the reader is referred to International Patent Application Publication WO 93 / 16724. An implication of the third-party theory is that it is not necessary for the skilled artisan to identify or isolate the particular target antigen to which tolerance is desired in order to practice the invention: the practitioner need only obtain at least one molecule that is preferentially expressed at the target site for use as an inducing antigen.

[0141]

[0159] In certain embodiments of the present invention, the induced antigen is not in the same form as that expressed in the individual to be treated, but is a fragment or derivative thereof. The induced antigen of the present invention includes peptides based on molecules of appropriate specificity, but are adapted by fragmentation, residue substitution, labeling, conjugation, and / or fusion with peptides having other functional properties. Adaptation can be performed for any desired purpose, including, but not limited to, the elimination of any undesirable properties, such as toxicity or immunogenicity; or the enhancement of any desired properties, such as mucosal binding, mucosal penetration, or stimulation of the tolerogenic arm of the immune response. As used herein, terms such as insulin peptides, collagen peptides, and myelin basic protein peptides refer not only to intact subunits but also to allotypes and synthetic variants, fragments, fusion peptides, conjugates, and other derivatives that contain regions that are homologous to at least 10, preferably 20 contiguous amino acids of the respective molecules that they are analogs of (preferably 70% identical, more preferably 80% identical, and even more preferably 90% identical at the amino acid level), and in which the homologous regions of the derivatives share with their respective parent molecules the ability to induce tolerance to a target antigen.

[0142]

[0160] It is recognized that the tolerogenic region of an inducing antigen is often different from the immunodominant epitope for stimulating an antibody response. A tolerogenic region is generally a region that can be presented in a specific cell interaction involving T cells. A tolerogenic region is present upon presentation of an intact antigen and can induce tolerance. Some antigens contain secret tolerogenic regions in that processing and presentation of the native antigen does not normally induce tolerance. A detailed description of secret antigens and their identification can be found in International Patent Application Publication WO94 / 27634.

[0143]

[0161] In certain embodiments of the invention, two, three, or more induced antigens are used. It is desirable to implement these embodiments when there are multiple target antigens, or to provide multiple third parties for targeting. For example, both insulin and glucagon can be mixed with the mucosal binding component in the treatment of diabetes. It is also desirable to provide an antigen cocktail that encompasses several possible alternative targets. For example, a cocktail of histocompatibility antigen fragments can be used to tolerize a subject in anticipation of a future transplant with an allograft of unknown phenotype. Allovariant regions of human leukocyte antigens are known in the art, see, for example, Immunogenetics 29:231, 1989. In another example, a mixture of allergens can serve as an induced antigen for the treatment of atopy.

[0144]

[0162] Depending on the nature of the molecule, the induced antigens can be prepared by several techniques known in the art. Polynucleotide, polypeptide, and carbohydrate antigens can be isolated from the cells of the species to be treated in which they are enriched. Short peptides are conveniently prepared by amino acid synthesis. Longer proteins of known sequence can be prepared by synthesizing the coding sequence from a natural source or vector, or by PCR amplification of the coding sequence followed by expression of the coding sequence in a suitable bacterial or eukaryotic host cell.

[0145]

[0163] In certain embodiments of the invention, the combination comprises a complex mixture of antigens obtained from cells or tissues, one or more of which play a role in deriving the antigen. The antigen may be in the form of whole cells, intact or treated with fixatives such as formaldehyde, glutaraldehyde, or alcohol. The antigen may be in the form of a cell lysate, produced by detergent lysis or mechanical disruption of cells or tissues, followed by clarification. The antigen may also be obtained by subcellular fractionation, in particular enrichment of cell membranes, by techniques such as differential centrifugation, optionally followed by detergent lysis and dialysis. Other separation techniques are also suitable, such as affinity or ion exchange chromatography of solubilized membrane proteins.

[0146]

[0164] In one embodiment, the antigenic peptide or protein is an autoantigen, an alloantigen or a transplantation antigen. In yet another particular embodiment, the autoantigen is selected from the group consisting of myelin basic protein, collagen or fragments thereof, DNA, nuclear and nucleolar proteins, mitochondrial proteins and pancreatic beta cell proteins.

[0147]

[0165] The present invention provides for the induction of tolerance to self-antigens for the treatment of autoimmune diseases by administering the antigen to which tolerance is desired. For example, autoantibodies against myelin basic protein (MBP) are observed in patients with multiple sclerosis, and thus MBP antigenic peptides or proteins can be used in the present invention to be delivered using the compositions of the present invention to treat and prevent multiple sclerosis.

[0148]

[0166] As another non-limiting example, an individual who is a candidate for transplantation from a fraternal twin may suffer from rejection of the transplanted cells, tissues or organs because the transplanted antigens are foreign to the recipient. Prior tolerance of the recipient individual to the intended graft negates or reduces subsequent rejection. Reduction or elimination of chronic anti-rejection therapy can be achieved by the practice of the present invention. In another example, many autoimmune diseases are characterized by a cellular immune response against endogenous or self-antigens. Tolerance of the immune system to endogenous antigens is desirable to control the disease.

[0149]

[0167] In a further example, sensitization of an individual to industrial pollutants or chemicals, such as those that may be encountered on the job, presents a risk of an immune response. Pre-tolerization of the individual's immune system to the chemicals, particularly in the form of chemicals that have reacted with the individual's endogenous proteins, is desirable to prevent the subsequent occupational development of an immune response.

[0150]

[0168] The allergen is another antigen to which a tolerant immune response is also desired. In one embodiment, the antigen is gliaden. In a further embodiment, the antigen is A-gliaden.

[0151]

[0169] Of note, even in diseases where pathogenic autoantigens are unknown, third-party suppression can be induced using antigens that are anatomically close.For example, autoantibodies against collagen are observed in rheumatoid arthritis, and therefore, collagen-encoding genes can be used as antigen-expressing gene modules to treat rheumatoid arthritis (see, for example, Choy (2000) Curr Opin Investig Drugs 1: 58-62).Furthermore, tolerance to beta cell autoantigens can be used to prevent the development of type 1 diabetes (see, for example, Bach and Chatenoud (2001) Ann Rev Immunol 19: 131-161).

[0152]

[0170] As another example, autoantibodies against myelin oligodendrocyte glycoprotein (MOG) are observed in autoimmune encephalomyelitis and many other CNS diseases, as well as multiple sclerosis (see, e.g., Iglesias et al. (2001) Glia 36:22-34). Thus, use of MOG antigen-expressing constructs in the present invention can treat multiple sclerosis and related autoimmune disorders of the central nervous system.

[0153]

[0171] Further examples of candidate autoantigens for use in the treatment of autoimmune diseases include pancreatic beta cell antigen, insulin and GAD for treating insulin-dependent diabetes mellitus; collagen type 11, human cartilage gp39 (HCgp39) and gp130-RAPS for use in rheumatoid arthritis; myelin basic protein (MBP), proteolipid protein (PLP) and myelin oligodendrocyte glycoprotein (MOG, see above) for treating multiple sclerosis; fibrillarin and nucleolar fragments for treating scleroderma. thyroid stimulating factor receptor (TSH-R) for use in the treatment of Graves' disease; nuclear antigens, histones, glycoprotein gp70 and ribosomal proteins for use in the treatment of systemic lupus erythematosus; pyruvate dehydrogenase dehydrolipoamide acetyltransferase (PCD-E2) for use in the treatment of primary biliary cirrhosis; hair follicle antigens for use in alopecia areata; and human tropomyosin isoform 5 (hTM5) for use in the treatment of ulcerative colitis.

[0154]

[0172] In one embodiment, the particles of the invention are covalently coupled to an antigen comprising one or more epitopes associated with allergy, autoimmune disease and / or inflammatory disease or disorder. The antigen may comprise one or more copies of the epitope. In one embodiment, the antigen comprises a single epitope associated with one disease or disorder. In a further embodiment, the antigen comprises more than one epitope associated with the same disease or disorder. In a further embodiment, the antigen comprises more than one epitope associated with different diseases or disorders. In a further embodiment, the antigen comprises one or more epitopes associated with one or more allergies. In a further embodiment, the antigen comprises one or more epitopes associated with multiple sclerosis, type 1 diabetes, celiac disease, and / or inflammatory bowel disease, including Crohn's disease or ulcerative colitis. In one embodiment, the epitope is derived from myelin basic protein (e.g., SEQ ID NOs: 4975 and 4976), proteolipid protein (e.g., SEQ ID NO: 4977), myelin oligodendrocyte glycoprotein (e.g., SEQ ID NOs: 1 and 4978), aquaporin (e.g., SEQ ID NO: 4979), myelin associated glycoprotein (e.g., SEQ ID NO: 4980), insulin (e.g., SEQ ID NO: 4981), glutamic acid decarboxylase (e.g., SEQ ID NO: 4982), gliadin (e.g., SEQ ID NOs: 4983-4985 or SEQ ID NOs: 5136-5140), the alpha 3 chain of type IV collagen (e.g., SEQ ID NO: 5017), or a fragment, homolog, or isoform thereof. In a further embodiment, the epitope is derived from gluten, such as from gliadin and / or glutenin. In one embodiment, the epitope is from an insulin homolog, such as those described in U.S. Patent No. 8,476,228, which is incorporated by reference in its entirety for all purposes. In one embodiment, the gliaden epitope is SEQ ID NO: 13, 14, 16, 320, or 321 in U.S. Patent Application No. 20110293644, which is incorporated by reference in its entirety for all purposes.

[0155]

[0173] Further non-limiting examples of epitopes associated with various autoimmune and / or inflammatory diseases or disorders contemplated by the present invention are set forth in Tables 2 and 3.

[0156] [Table 2]

[0157]

[0174] Not all epitopes are linear epitopes; epitopes may be discontinuous conformational epitopes. Several discontinuous epitopes are known that are associated with autoimmune or inflammatory diseases and / or disorders. Non-limiting examples of discontinuous epitopes are listed in Table 3.

[0158] [Table 3-1]

[0159] [Table 3-2]

[0160] [Table 3-3]

[0161]

[0175] Combinations of antigens and / or epitopes can be tested for their ability to promote tolerance by using isolated cells or by conducting experiments in animal models.

[0162]

[0176] In some embodiments, the tolerance-inducing compositions of the invention contain an immunomodulatory agent, such as rapamycin or tacrolimus.

[0163]

[0177] In some embodiments, the tolerance-inducing compositions of the invention contain an immunomodulatory agent, such as a Janus kinase antagonist and / or a Janus kinase agonist.

[0164]

[0178] In some embodiments, the tolerance-inducing compositions of the invention contain an immunomodulatory agent, such as a cytokine and / or an antibody to a cytokine.

[0165]

[0179] In some embodiments, the tolerance-inducing compositions of the present invention contain growth factors capable of promoting the regulation of T cells. Such factors may include insulin, transforming growth factor beta, serum albumin, and any other factors known to support immune cell regulation.

[0166]

[0180] In some embodiments, the tolerance-inducing compositions of the invention contain an antibody capable of promoting tolerance induction.

[0167]

[0181] In some embodiments, the tolerance-inducing composition of the present invention contains an apoptosis signaling molecule (e.g., in addition to an antigenic peptide or other antigenic molecule). In some embodiments, the apoptosis signaling molecule is coupled to and / or binds to the surface of the carrier. In some embodiments, the apoptosis signaling molecule allows the carrier to be recognized as an apoptotic body by the host's antigen-presenting cells, such as cells of the host's retinal endothelial system; this allows the presentation of the bound peptide epitope in a tolerance-inducing manner. Without being bound by theory, it is speculated that this prevents the upregulation of molecules involved in immune cell stimulation, such as MHC class I / II and costimulatory molecules. These apoptosis signaling molecules may also serve as phagocyte markers. For example, apoptosis signaling molecules suitable for the present invention are described in U.S. Patent Application Publication No. 20050113297, the entirety of which is incorporated herein by reference. Molecules suitable for the present invention include molecules that target phagocytes, including macrophages, dendritic cells, monocytes, granulocytes, and neutrophils.

[0168]

[0182] In some embodiments, molecules suitable as apoptosis signaling molecules act to enhance the tolerance of the bound peptide. In addition, carriers bound to apoptosis signaling molecules can be bound by C1q in apoptotic cell recognition (Paidassi et al. (2008) J. Immunol. 180:2329-2338; incorporated herein by reference in its entirety). For example, molecules that may be useful as apoptosis signaling molecules include phosphatidylserine, annexin-1, annexin-5, milk fat globule-EGF-factor 8 (MFG-E8), or the family of thrombospondins (e.g., thrombospondin-1 (TSP-1)). Various molecules suitable for use as apoptosis signaling molecules with the present invention are discussed, for example, in U.S. Patent Application Publication No. 2012 / 0076831, incorporated herein by reference in its entirety.

[0169]

[0183] In some embodiments, the apoptosis signaling molecule can be conjugated to the antigen-specific peptide. In some examples, the apoptosis signaling molecule and the antigen-specific peptide are conjugated by creating a fusion protein. For example, a fusion protein may comprise at least one antigen-specific peptide (or a fragment or variant thereof) coupled to at least one apoptosis signaling molecule (or a fragment or variant thereof). For creating a fusion protein, the terms "fusion protein", "fusion peptide", "fusion polypeptide", and "chimeric peptide" are used interchangeably. Suitable fragments of antigen-specific peptides include any fragment of a full-length peptide that retains the function of generating the desired antigen-specific tolerance function of the present invention. Fusion proteins can be created by various means understood in the art (e.g., gene fusion, chemical conjugation, etc.). The two proteins can be fused directly or via an amino acid linker. Polypeptides forming a fusion protein are typically linked C-terminus to N-terminus, but they can also be linked C-terminus to C-terminus, N-terminus to N-terminus, or N-terminus to C-terminus. The polypeptides of the fusion protein may be in any order. A peptide linker sequence may be used to separate the first and second polypeptide components by a distance sufficient to ensure that each polypeptide folds into its secondary and tertiary structure. Amino acid sequences that may be usefully used as linkers include those disclosed in Maratea et al., Gene 40:39-46 (1985); Murphy et al., Proc. Natl. Acad. Sci. USA 83:8258-8262 (1986); U.S. Patent Nos. 4,935,233 and 4,751,180, which are incorporated herein by reference in their entirety. Linker sequences may generally be from 1 to about 50 amino acids in length. In some embodiments, for example, when the first and second polypeptides have non-essential N-terminal amino acid regions that can be used to separate functional domains and prevent steric hindrance, linker sequences are not required and / or are not used.

[0170]

[0184] A surrogate for tolerogenic activity is the ability of intact antigens or fragments to stimulate the production of appropriate cytokines at the target site. The immunomodulatory cytokine released by suppressor T cells at the target site is thought to be TGF-β (Miller et al., Proc. Natl. Acad. Sci. USA 89:421, 1992). Other factors that may be produced during tolerance are the cytokines IL4 and IL-10, and the mediator PGE. In contrast, lymphocytes in tissues undergoing active immune destruction secrete cytokines such as IL-1, IL-2, IL-6, and γ-IFN. Thus, the efficiency of a candidate inducing antigen can be evaluated by measuring its ability to stimulate the appropriate type of cytokine.

[0171]

[0185] With this in mind, rapid screening tests for tolerogenic epitopes of inducing antigens, effective mucosal binding components, effective combinations, or effective modes and schedules of mucosal administration can be performed using syngeneic animals as donors for in vitro cell assays. Animals are treated at the mucosal surface with the test composition and, at one time, challenged with parenteral administration of the target antigen in complete Freund's adjuvant. Spleen cells are isolated and cultured in vitro in the presence of the target antigen at a concentration of about 50 μg / mL. The target antigen can be replaced with a candidate protein or subfragment to map the location of the tolerogenic epitope. Cytokine secretion into the medium can be quantified by standard immunoassays.

[0172]

[0186] The ability of cells to suppress the activity of other cells can be determined using cells isolated from animals immunized with the target antigen or by generating cell lines that respond to the target antigen (Ben-Nun et al., Eur. J. Immunol. 11:195, 1981, incorporated herein by reference in its entirety). In one variation of this experiment, suppressor cell populations are mildly irradiated (approximately 1000 to 1250 rad) to prevent proliferation, and the suppressors are co-cultured with responder cells, after which tritiated thymidine incorporation (or MTT) is used to quantitate the proliferative activity of the responder cells. In another variation, suppressor and responder cell populations are cultured in upper and lower levels of a dual-chamber transwell culture system (Coster, Cambridge Mass.), separated by a polycarbonate membrane, allowing populations to be co-incubated within 1 mm of each other (WO93 / 16724). This approach does not require irradiation of the suppressor cell population, since the proliferative activity of the responder cells can be measured separately.

[0173]

[0187] In embodiments of the invention where the target antigen is already present in the individual, it is not necessary to isolate the antigen or premix it with the mucosal-binding component. For example, the antigen may be expressed in an individual in a certain manner as a result of a pathological condition (such as inflammatory bowel disease or celiac disease) or through the digestion of a food allergen. Testing is performed by providing the mucosal-binding component in one or more doses or formulations and determining its ability to promote tolerization to the antigen in situ.

[0174]

[0188] The efficacy and mode of administration of the composition for the treatment of a particular disease can also be detailed in the corresponding animal disease model. The ability of the treatment to reduce or delay the symptoms of the disease is monitored at the level of circulating biochemical and immunological characteristics of the disease, immunohistology of affected tissues, and overall clinical characteristics appropriate for the model used. Non-limiting examples of animal models that can be used for testing are included in the following section.

[0175]

[0189] The present invention contemplates modulating tolerance by modulating a TH1 response, a TH2 response, a TH17 response, or a combination of these responses. Modulating a TH1 response includes, for example, altering the expression of interferon-gamma. Modulating a TH2 response includes, for example, altering the expression of any combination of IL-4, IL-5, IL-10, and IL-13. Typically, an increase (decrease) in a TH2 response includes an increase (decrease) in the expression of at least one of IL-4, IL-5, IL-10, or IL-13; more typically, an increase (decrease) in a TH2 response includes an increase (decrease) in the expression of at least two of IL-4, IL-5, IL-10, or IL-13, and most typically, an increase (decrease) in a TH2 response includes an increase (decrease) in the expression of at least three of IL-4, IL-5, IL-10, or IL-13, but ideally, an increase (decrease) in a TH2 response includes an increase (decrease) in the expression of all of IL-4, IL-5, IL-10, and IL-13. Modulation of TH17 includes, for example, altering the expression of TGF-beta, IL-6, IL-21 and IL23, and the effective levels of IL-17, IL-21 and IL-22.

[0176]

[0190] Other suitable methods for assessing the effectiveness of the compositions and methods of the invention will be understood in the art, for example, as discussed in U.S. Patent Application No. 2012 / 0076831, which is incorporated herein by reference in its entirety.

[0177]

[0191] Certain embodiments of the present invention relate to priming immune tolerance in individuals not previously tolerized by therapeutic intervention. These embodiments generally include multiple administrations of a combination of antigen and mucosal binding component. Typically, at least three administrations, frequently at least four administrations, and sometimes at least six administrations, are administered during priming to achieve long-lasting results, although the subject may show signs of tolerance early in the course of treatment. Most frequently, each dose is given as a bolus administration, although sustained release formulations that allow mucosal release are also suitable. When multiple administrations are administered, the time between administrations is generally between 1 day and 3 weeks, typically between about 3 days and 2 weeks. Generally, the same antigen and mucosal binding component are present in the same concentration, and administrations are given to the same mucosal surface, although changes in any of these variables during the course of treatment can be accommodated.

[0178]

[0192] Other embodiments of the invention relate to the strengthening or extension of the persistence of previously established immune tolerance. These embodiments generally involve one administration or a short course of treatment at a time when established tolerance is diminished or at risk of diminishing. Strengthening is generally performed one month to one year after priming or a previous strengthening, and typically two to six months after. The invention also includes embodiments involving regular maintenance of tolerance with a schedule of administration occurring twice weekly, weekly, biweekly, or on any other regular schedule.

[0179]

[0193] The particles of the present invention can be provided at any dose effective to suppress an inflammatory immune response in a subject in need thereof or to treat a bacterial or viral infection in a subject in need thereof. In certain embodiments, the particles of the present invention can be provided at any dose effective to suppress an inflammatory immune response in a subject in need thereof or to treat a bacterial or viral infection in a subject in need thereof. 2 About 10 20 In a further embodiment, about 10 particles are provided to the individual. 3 About 10 15 In a further embodiment, between about 10 6 About 10 12 In a further embodiment, between about 10 8 About 1010 In a preferred embodiment, the preferred dose is 0.1% of particles / ml. Thus, for 0.5 μm beads, the preferred dose is approximately 4×10 9 beads, for 0.05 μm beads the preferred dose is about 4×10 12 beads, for 3 μm beads the preferred dose is 2x10 7 beads. In some embodiments, the particle dose is about 25 mg / mL to about 50 mg / mL. In some embodiments, the particle dose is about 50 mg / mL to about 100 mg / mL. In some embodiments, the particle dose is about 100 mg / mL to about 150 mg / mL. In some embodiments, the particle dose is about 150 mg / mL to about 200 mg / mL. In some embodiments, the particle dose is about 200 mg / mL to about 250 mg / mL. In some embodiments, the particle dose is about 250 mg / mL to about 300 mg / mL. In some embodiments, the particle dose is about 300 mg / mL or more. However, any dose that is effective to treat the particular condition being treated is encompassed by the present invention.

[0180]

[0194] The present invention is useful for the treatment of immune-related disorders such as autoimmune diseases, graft rejection, enzyme deficiencies and allergic reactions. The substitution of synthetic biocompatible particulate systems to induce immune tolerance can provide easy manufacture, wide availability of therapeutic agents, increase heterogeneity between samples, increase the number of potential treatment sites and dramatically reduce the possibility of allergic responses to carrier cells.

[0181]

[0195] As used herein, the term "immune response" includes T cell-mediated and / or B cell-mediated immune responses. Exemplary immune responses include T cell responses, such as cytokine production and cell-mediated cytotoxicity. Additionally, the term immune response includes immune responses that are indirectly mediated by T cell activation, such as antibody production (humoral response) and activation of cytokine-responsive cells, such as macrophages. Immune cells involved in an immune response include B cells and T cells (CD4 + , CD8+ antigen presenting cells (e.g., professional antigen presenting cells such as dendritic cells, macrophages, B lymphocytes, Langerhans cells, and non-professional antigen presenting cells such as keratinocytes, endothelial cells, astrocytes, fibroblasts, oligodendrocytes); natural killer cells; myeloid cells such as macrophages, eosinophils, mast cells, basophils, and granulocytes. In some embodiments, the modified particles of the invention are effective in reducing inflammatory cell trafficking to sites of inflammation.

[0182]

[0196] As used herein, the terms "anergy", "tolerance" or "antigen-specific tolerance" refer to the insensitivity of T cells to T cell receptor-mediated stimulation. Such insensitivity is generally antigen-specific and persists after exposure to antigenic peptides has ceased. For example, anergy in T cells is characterized by the lack of cytokine production, e.g., IL-2. T cell anergy occurs when T cells are exposed to an antigen and receive a first signal (T cell receptor or CD3-mediated signal) in the absence of a second signal (costimulatory signal). Under these conditions, re-exposure of the cells to the same antigen (even if the re-exposure occurs in the presence of a costimulatory molecule) results in failure to produce cytokines and subsequently failure to proliferate. Thus, failure to produce cytokines prevents proliferation. However, anergic T cells can proliferate when cultured with a cytokine (e.g., IL-2). For example, T cell anergy can also be observed by the lack of IL-2 production by T lymphocytes when measured by ELISA or by a proliferation assay using an indicator cell line. Alternatively, reporter gene constructs can be used, for example, anergic T cells are unable to initiate DL-2 gene transcription induced by a heterologous promoter under the control of the 5'IL-2 gene enhancer or by multimers of API sequences that can be found within the enhancer (Kang et al., 1992 Science. 257:1134).

[0183]

[0197] The term "immune tolerance" as used herein refers to a method implemented in a proportion of treated subjects compared to untreated subjects, which refers to a) a reduction in the level of specific immune response (believed to be at least partially mediated by antigen-specific effector T lymphocytes, B lymphocytes, antibodies, or equivalents); b) a delay in the initiation or progression of a specific immune response; or c) a reduction in the risk of initiating or progressing a specific immune response. "Specific" immune tolerance occurs when immune tolerance is preferentially induced to a certain antigen compared to other antigens. "Non-specific" immune tolerance occurs when immune tolerance is induced indiscriminately to an antigen that induces an inflammatory immune response. "Pseudo-specific" immune tolerance occurs when immune tolerance is induced semi-indiscriminately to an antigen that leads to a pathological immune response, but not to other antigens that induce a protective immune response.

[0184]

[0198] Tolerance to self-antigens and autoimmune diseases is achieved by various mechanisms including negative selection of self-reactive T cells in the thymus and peripheral tolerance to these self-reactive T cells that escape thymic deletion and are found in the periphery. Examples of mechanisms that provide peripheral T cell tolerance include "ignoring" self-antigens, anergy or non-responsiveness to self-antigens, cytokine immune deviation, and activation-induced cell death of self-reactive T cells. In addition, regulatory T cells have been shown to be involved in mediating peripheral tolerance. See, for example, Walker et al. (2002) Nat. Rev. Immunol. 2:11-19; Shevach et al. (2001) Immunol. Rev. 182:58-67. In some situations, peripheral tolerance to self-antigens is lost (or destroyed), resulting in an autoimmune response. For example, in animal models of EAE, activation of antigen-presenting cells (APCs) via TLR innate immune receptors has been shown to break self-tolerance and lead to the induction of EAE (Waldner et al. (2004) J. Clin. Invest. 113:990-997).

[0185]

[0199] Thus, in some embodiments, the invention provides methods for increasing antigen presentation while suppressing or decreasing TLR7 / 8, TLR9, and / or TLR7 / 8 / 9 dependent cellular stimulation. As described herein, administration of certain modified particles results in antigen presentation by DCs or APCs while suppressing TLR7 / 8, TLR9, and / or TLR7 / 8 / 9 dependent cellular responses associated with immunostimulatory polynucleotides. Such suppression may include a reduction in the levels of one or more TLR-associated cytokines.

[0186]

[0200] As discussed above, the present invention provides novel compounds that have biological properties useful for the treatment of Mac-1 and LFA-1 mediated disorders.

[0187] Pharmaceutical Compositions

[0201] Thus, in another aspect of the present invention, pharmaceutical compositions are provided that include tolerizing immune-modifying particles and, optionally, a pharma- ceutically acceptable carrier. In certain embodiments, these compositions optionally further include one or more additional therapeutic agents. Alternatively, the modified particles of the present invention can be administered to a patient in need thereof along with administration of one or more other therapeutic agents. For example, the additional therapeutic agent for co-administration with the compounds of the present invention or inclusion in a pharmaceutical composition can be an approved anti-inflammatory agent, or it can be any one of several drugs approved by the U.S. Food and Drug Administration that will eventually obtain approval for the treatment of any disorder characterized by an uncontrolled inflammatory immune response or bacterial or viral infection. It will also be understood that certain modified particles of the present invention can be present for treatment in free form or, where appropriate, as a pharma- ceutical acceptable derivative thereof.

[0188]

[0202] The pharmaceutical composition of the present invention, as used herein, further comprises a pharma- ceutically acceptable carrier, including any and all solvents, diluents, or other liquid media, dispersing or suspending aids, surfactants, isotonicity agents, thickening or emulsifying agents, preservatives, solid binders, lubricants, etc., suitable for the particular dosage form desired. Remington's Pharmaceutical Sciences, 6th Edition, EW Martin (Mack Publishing Co., Easton, Pa., 1980) discloses various carriers used in formulating pharmaceutical compositions and known techniques for their preparation. Except insofar as any conventional carrier medium is incompatible with the compounds of the present invention, such as by producing undesirable biological effects or otherwise interacting in a deleterious manner with any other component of the pharmaceutical composition, its use is contemplated within the scope of the present invention. Some examples of materials which can serve as pharma- ceutically acceptable carriers include, but are not limited to, sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening agents, flavoring agents, and perfuming agents, preservatives, and antioxidants may be present in the composition, according to the judgment of the formulator.

[0189]

[0203] Liquid dosage forms for oral administration include, but are not limited to, pharma- ceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.In addition to the active compound, liquid dosage forms may contain, for example, water or other solvents, solubilizers and inert diluents commonly used in the art, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (especially cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil and sesame oil), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycol and fatty acid esters of sorbitan, and mixtures thereof.In addition to inert diluents, oral compositions may contain adjuvants, such as wetting agents, emulsifying and suspending agents, sweeteners, flavoring agents and perfumes.

[0190]

[0204] The particles of the invention can be administered orally, intranasally, intravenously, intramuscularly, intraocularly, transdermally, intraperitoneally, or subcutaneously, hi one embodiment, the particles of the invention are administered intravenously.

[0191] Administration

[0205] The effective amount and method of administration of the present invention for modulation of immune response may vary based on the individual, the condition being treated, and other factors that will be apparent to one of skill in the art. Factors to consider include the route of administration and the number of doses administered. Such factors are known in the art, and it is within the skill of the artisan to make such determinations without undue experimentation. A suitable dose range is one that provides the desired modulation of immunity. A useful dose range of the carrier, given the amount of carrier delivered, may be, for example, from about any of the following: 0.5 to 10 mg / kg, 1 to 9 mg / kg, 2 to 8 mg / kg, 3 to 7 mg / kg, 4 to 6 mg / kg, 5 mg / kg, 1 to 10 mg / kg, 5 to 10 mg / kg. Alternatively, the dose may be administered based on particle number. For example, a useful dose of the carrier, given the amount of carrier delivered, may be, for example, from about 10 mg / kg per dose. 6 , 107 , 10 8 , 10 9 , 10 10 The amount of the drug administered to each patient may be as small as 100 or more particles. The absolute amount given to each patient depends on pharmacological properties such as bioavailability, clearance rate and route of administration. Details of pharmacologic acceptable carriers, diluents and excipients and methods for preparing pharmaceutical compositions and formulations are provided in Remington's Pharmaceutical Sciences, 18th Edition, 1990, Mack Publishing Co., Easton, Pa., USA, which is incorporated herein by reference in its entirety.

[0192]

[0206] The effective amount of a particular carrier formulation and its method of administration may vary based on the individual patient, the type of desired outcome and / or disorder, the stage of the disease, and other factors apparent to one of skill in the art. Routes of administration useful in a particular application will be apparent to one of skill in the art. Routes of administration include, but are not limited to, topical, dermal, transdermal, transmucosal, epidermal, parenteral, gastrointestinal, and pulmonary, including nasopharyngeal and transbronchial and transalveolar. A suitable dose range is one that provides sufficient IRP-containing composition to achieve a tissue concentration of about 1-50 μM, as measured by blood levels. The absolute amount given to each patient will depend on pharmacological properties such as bioavailability, clearance rate, and route of administration.

[0193]

[0207] The present invention provides suitable carrier formulations for topical application, including, but not limited to, physiologically acceptable implants, ointments, creams, rinses and gels. Exemplary routes of dermal administration are those that are at least invasive, such as transdermal transmission, epidermal administration and subcutaneous injection.

[0194]

[0208] Transdermal administration is achieved by application of creams, rinses, gels, etc., in which the carrier can penetrate the skin and enter the bloodstream. Suitable compositions for transdermal administration include, but are not limited to, pharma- ceutically acceptable suspensions, oils, creams, and ointments, which are applied directly to the skin or incorporated into a protective carrier, such as a transdermal device (a so-called "patch"). Examples of suitable creams, ointments, etc. can be found, for example, in the Physician's Desk Reference. Transdermal permeation can also be achieved by iontophoresis, for example, using commercially available patches that deliver their products continuously through unbroken skin over a period of several days or more. The use of this method allows controlled permeation of pharmaceutical compositions at relatively high concentrations, allows injection of combination drugs, and allows simultaneous use of absorption enhancers.

[0195]

[0209] Parenteral routes of administration include, but are not limited to, direct injection, such as electrical (iontophoretic) injection or direct injection into a central venous line, intravenous, intramuscular, intraperitoneal, intradermal, or subcutaneous injection. Suitable carrier formulations for parenteral administration are generally formulated in USP water or water for injection, and may further include pH buffers, salt bulking agents, preservatives, and other pharmaceutically acceptable excipients. Immunomodulatory polynucleotides for parenteral injection can be formulated in pharmaceutically acceptable sterile isotonic solutions, such as saline and phosphate buffered saline for injection.

[0196]

[0210] Alimentary tract administration routes include, but are not limited to, ingestion and rectal routes, and may include, for example, the use of a pharma- ceutically acceptable powder, pill or liquid for ingestion and a suppository for rectal administration.

[0197]

[0211] Nasopharyngeal and pulmonary administration is achieved by inhalation and includes delivery routes such as intranasal, transbronchial and transalveolar routes. The present invention includes formulations of carriers suitable for administration by inhalation, including, but not limited to, liquid suspensions for forming aerosols and powder forms for dry powder inhalation delivery systems. Devices suitable for administration by inhalation of carrier formulations include, but are not limited to, atomizers, vaporizers, nebulizers, and dry powder inhalation delivery devices.

[0198]

[0212] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions, can be formulated according to known techniques using suitable dispersing or wetting agents and suspending agents.Sterile injectable preparations can also be sterile injectable solutions, suspensions or emulsions in non-toxic parenterally acceptable diluents or solvents, for example, as a solution in 1,3-butanediol.Acceptable vehicles and solvents that can be used are water, Ringer's solution, USP and isotonic sodium chloride solution.In addition, sterile fixed oils are conventionally used as solvents or suspending media.For this purpose, any brand of fixed oil can be used, such as synthetic mono- or diglycerides.In addition, fatty acids, such as oleic acid, are used in the preparation of injectables.

[0199]

[0213] Injectable preparations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water, or other sterile injectable medium prior to use.

[0200]

[0214] In order to prolong the effect of a drug, it is often desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This can be accomplished by using a liquid suspension or crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends on its rate of dissolution, which in turn may depend on crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer and the nature of the particular polymer used, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissues.

[0201]

[0215] In some embodiments, the synthetic biodegradable particles of the present invention provide ease of manufacture, broad availability of therapeutic agents, and increased treatment sites. Experiments conducted during the development of embodiments of the present invention have demonstrated the incorporation of peptides (e.g., PLP) into these particles. 139 ~ 151 Conjugation of peptides (peptides) to such particles has been shown to be useful in preventing disease onset and in inducing immune tolerance (e.g., SJL / J PLP in multiple sclerosis). 139 ~ 151It has been shown to be effective for immunization with IL-10 and / or TGF-β in a CFA-induced R-EAE mouse model. The peptide-conjugated carriers of the present invention offer many advantages over other tolerance-inducing structures. In some embodiments, the particles are biodegradable and therefore do not persist in the body for long periods of time. The time for complete degradation can be controlled. In some embodiments, the particles are functionalized to facilitate internalization without cell activation (e.g., phosphatidylserine loaded into PLG microspheres). In some embodiments, the particles contain targeting ligands for specific cell populations. In some embodiments, anti-inflammatory cytokines such as IL-10 and TGF-β are contained on or within the particles to limit activation of the cell type internalizing the particle and facilitate induction of tolerance by energy and / or depletion as well as activation of regulatory T cells. The composition of the particles was found to affect the length of time the particles persist in the body, with tolerance requiring rapid particle uptake and clearance / degradation. Because ratios of lactide:glycolide greater than 50:50 slow down the rate of degradation, the particles of the present invention have a lactide:glycolide ratio of about 50:50 or less, hi one embodiment, the particles of the present invention have a D,L-lactide:glycolide ratio of about 50:50.

[0202]

[0216] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the modified particles are mixed with at least one inert pharma- ceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and / or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) humectants such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents.

[0203]

[0217] Solid compositions of similar type can also be used as fillers in soft and hard filled gelatin capsules using excipients such as lactose or milk sugar and high molecular weight polyethylene glycols. Solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical formulation industry. They can optionally contain opacifying agents and can be of a composition that they release the active ingredient only, or preferentially, in a certain part of the intestinal tract, optionally in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of similar type can also be used as fillers in soft and hard filled gelatin capsules using excipients such as lactose or milk sugar and high molecular weight polyethylene glycols.

[0204]

[0218] The modified particles may also be in microencapsulated form with one or more excipients as described above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings, release-controlling coatings, and other coatings well known in the pharmaceutical formulation industry. In such solid dosage forms, the active compound can be mixed with at least one inert diluent, such as sucrose, lactose, and starch. Such dosage forms can also contain, as in normal practice, additional substances other than the inert diluent, such as tableting lubricants and other tableting aids, such as magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets, and pills, the dosage forms can also contain buffering agents. They can optionally contain opacifying agents, and they can be of a composition that releases only, or preferentially, the modified particles in a certain part of the intestinal tract, optionally in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.

[0205]

[0219] The present invention encompasses pharma- ceutically acceptable topical formulations of the modified particles of the present invention. As used herein, the term "pharma- ceutically acceptable topical formulation" refers to any formulation that is pharma- ceutically acceptable for intradermal administration of the modified microparticles of the present invention by application of the formulation to the epidermis. In certain embodiments of the present invention, the topical formulation comprises a carrier system. Pharmaceutically effective carriers include, but are not limited to, solvents (e.g., alcohols, polyalcohols, water), creams, lotions, ointments, oils, plasters, liposomes, powders, emulsions, microemulsions, and buffered solutions (e.g., hypotonic or buffered saline) or any other carriers known in the art for topical administration of pharmaceuticals. A more complete listing of carriers known in the art is provided by standard reference texts in the art, such as Remington's Pharmaceutical Sciences, 16th Edition, 1980 and 17th Edition, 1985, both published by Mack Publishing Company, Easton, Pa., the disclosures of which are incorporated herein by reference in their entireties. In certain other embodiments, the topical formulations of the present invention may include excipients. Any pharma- ceutically acceptable excipient known in the art can be used to prepare the pharma-ceutically acceptable topical formulation of the present invention. Examples of excipients that can be included in the topical formulation of the present invention include, but are not limited to, preservatives, antioxidants, moisturizers, emollients, buffers, solubilizers, other penetrants, skin protectants, surfactants, and propellants, and / or additional therapeutic agents used in combination with modified particles. Suitable preservatives include, but are not limited to, alcohols, quaternary amines, organic acids, parabens, and phenols. Suitable antioxidants include, but are not limited to, ascorbic acid and its esters, sodium bisulfite, butylated hydroxytoluene, butylated hydroxyanisole, tocopherol, and chelating agents such as EDTA and citric acid. Suitable moisturizers include, but are not limited to, glycerin, sorbitol, polyethylene glycol, urea, and propylene glycol.Suitable buffering agents for use with the present invention include, but are not limited to, citric acid, hydrochloric acid, and lactic acid buffer.Suitable solubilizing agents include, but are not limited to, quaternary ammonium chloride, cyclodextrin, benzyl benzoate, lecithin, and polysorbate.Suitable skin protectants that can be used in the topical formulation of the present invention include, but are not limited to, vitamin E oil, allantoin, dimethicone, glycerin, petrolatum, and zinc oxide.

[0206]

[0220] In certain embodiments, the pharma- ceutically acceptable topical formulation of the present invention comprises at least the modified particles of the present invention and a permeation enhancer. The choice of topical formulation depends on several factors, such as the condition to be treated, the physicochemical characteristics of the compound of the present invention and other excipients present, their stability in the formulation, available manufacturing equipment, and cost constraints. As used herein, the term "permeation enhancer" refers to an agent that can transport pharma- ceutical active compounds through the stratum corneum and into the epidermis or dermis, preferably with little or no systemic absorption. Various compounds have been evaluated for their effectiveness in enhancing the permeation rate of drugs through the skin. See, for example, Percutaneous Penetration Enhancers, Maibach HI and Smith HE (eds.), CRC Press, Inc., Boca Raton, Fla. (1995), which reviews the use and testing of various dermal penetration enhancers, and Buyuktimkin et al., Chemical Means of Transdermal Drug Permeation Enhancement in Transdermal and Topical Drug Delivery Systems, Gosh TK, Pfister WR, Yum SI (eds.), Interpharm Press Inc., Buffalo Grove, Ill. (1997). In certain exemplary embodiments, penetrating agents for use with the present invention include, but are not limited to, triglycerides (e.g., soybean oil), aloe compositions (e.g., aloe vera gel), ethyl alcohol, isopropyl alcohol, octotriphenyl polyethylene glycol, oleic acid, polyethylene glycol 400, propylene glycol, N-decyl methyl sulfoxide, fatty acid esters (e.g., isopropyl myristate, methyl laurate, glycerol monooleate, and propylene glycol monooleate), and N-methylpyrrolidone.

[0207]

[0221] In certain embodiments, the composition may be in the form of an ointment, paste, cream, lotion, gel, powder, solution, spray, inhalant or patch. In certain exemplary embodiments, the formulation of the composition according to the invention is a cream which may further contain saturated or unsaturated fatty acids, such as stearic acid, palmitic acid, oleic acid, palmito-oleic acid, cetyl or oleyl alcohol, with stearic acid being particularly preferred. The cream of the present invention may also contain a non-ionic surfactant, for example, polyoxy-40-stearic acid. In certain embodiments, the active ingredient is mixed under sterile conditions with a pharma- ceutically acceptable carrier and any necessary preservatives or buffers that may be required. Ophthalmic formulations, ear drops, and eye drops are also contemplated as being within the scope of the present invention. Additionally, the present invention contemplates the use of transdermal patches, which have the added advantage of providing a controlled delivery of a compound to the body. Such dosage forms are made by dissolving or dispersing the compound in a suitable medium. As discussed above, penetration enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.

[0208]

[0222] The modified particles can be administered by aerosol. This can be accomplished by preparing an aqueous aerosol, liposomal preparation, or solid particles containing the modified particles. Non-aqueous (e.g., fluorocarbon propellant) suspensions can be used.

[0209]

[0223] Usually, aqueous aerosol is made by formulating aqueous solution or suspension of drug with conventional pharmaceutically acceptable carrier and stabilizer.Carrier and stabilizer vary with the requirements of a particular compound, but typically include non-ionic surfactant (Tween, PLURONIC®, or polyethylene glycol), harmless protein such as serum albumin, sorbitan ester, oleic acid, lecithin, amino acid such as glycine, buffer, salt, sugar or sugar alcohol.Aerosol is generally prepared from isotonic solution.

[0210]

[0224] It is also understood that the modified particles and pharmaceutical compositions of the present invention can be formulated and used in combination therapy, i.e., the compounds and pharmaceutical compositions can be formulated together with one or more other desired therapeutic agents or medical procedures, or administered simultaneously, before, or after.The specific combination of therapies (therapeutic agents or procedures) to be used in a combination regimen takes into account the compatibility of the desired therapeutic agents and / or procedures, as well as the desired therapeutic effect to be achieved.It is also understood that the therapies used can achieve the desired effect on the same disorder (e.g., the compound of the present invention can be administered together with another anti-inflammatory agent), or they can achieve different effects (e.g., control of any adverse effects).

[0211]

[0225] In certain embodiments, the pharmaceutical composition containing the modified particles of the present invention further comprises one or more additional therapeutically active ingredients (e.g., anti-inflammatory and / or palliative agents). For the purposes of the present invention, the term "palliative" refers to treatments that focus on relieving symptoms of a disease and / or side effects of a therapeutic regimen, but are not curative. For example, palliative treatments include analgesics, antiemetics, and antinausea medications.

[0212]

[0226] The present invention provides a method of modulating an immune response in an individual, preferably a mammal, more preferably a human, comprising administering to the individual a modified particle as described herein. Methods of immunomodulation provided by the present invention include, but are not limited to, those that suppress and / or inhibit innate or adaptive immune responses, such as immune responses stimulated by immunostimulatory polypeptides or viral or bacterial components.

[0213]

[0227] The modified particles are administered in an amount sufficient to modulate an immune response. As described herein, modulation of the immune response may be humoral and / or cellular, and is measured using standard techniques in the art and described herein.

[0214]

[0228] In some embodiments, the compositions described herein are administered in conjunction with (e.g., simultaneously with, prior to, or after) an implant (e.g., device) and / or graft (e.g., tissue, cell, organ) to mediate, neutralize, modulate, and / or reduce the immune response associated therewith.

[0215] Indications

[0229] In certain embodiments, the individual suffers from a disorder associated with undesired immune activation, such as an allergic disease or condition, allergy, and asthma. An individual with an allergic disease or asthma is an individual with a recognizable symptom of an allergic disease or asthma present. For example, tolerance can be induced in such individuals by particles complexed with certain foods (e.g., peanut proteins, etc.), injected substances (e.g., bee venom proteins, etc.), or inhaled substances (e.g., ragweed pollen proteins, pet dander proteins, etc.) that provoke an allergic reaction.

[0216]

[0230] In certain embodiments, the individual suffers from a disorder associated with unwanted immune activation, such as autoimmune and inflammatory diseases. An individual with an autoimmune or inflammatory disease is an individual with recognizable symptoms of an autoimmune or inflammatory disease present. For example, tolerance can be induced in such individuals by particles complexed with the relevant autoantigen that induces the particular autoimmune disease.

[0217]

[0231] In certain embodiments, the individual suffers from a disorder associated with enzyme replacement therapy. For example, tolerance in such individuals, e.g., tolerance to human factor VIII in patients with hemophilia due to a genetic deficiency in the ability to make factor VIII, can be induced by particles covalently coupled with an enzyme that the patient with the genetic deficiency cannot produce, so that the patient does not make a neutralizing antibody response to the recombinantly produced enzyme administered to treat that particular deficiency. Another example may include enzyme replacement for conditions such as mucopolysaccharide storage disease, gangliosidosis, hypoalkaline phosphatasia, cholesterol ester storage disease, hyperuricemia, growth hormone deficiency, renal anemia, or with lysosomal storage disorders including Fabry disease, Gaucher disease, Fuller disease, Hunter disease, Maroteaux-Lamy disease, Niemann-Pick disease, Tay-Sachs disease, and Pompe disease.

[0218]

[0232] In certain embodiments, the individual suffers from a robust or otherwise harmful immune response to a drug administered for the treatment of a disease that actually or potentially impairs the patient's health or treatment. Furthermore, the novel compounds provided by the present invention can be provided to individuals who do not show an immune response to the drug, but may do so in the future. In certain embodiments, the individual is undergoing enzyme replacement therapy. In certain embodiments, the therapeutic agent includes, but is not limited to, peptide or protein-based drugs, DNA vaccines, siRNA, splice site switching oligomers, and RNA-based nanoparticles. In some embodiments, therapeutic agents include, but are not limited to, Advate, antihemophilic factor, Kogenate, Eloctate, recombinant factor VIII Fc fusion protein, Refacto, Novo VIIa, recombinant factor VII, eptacog alfa, helixate, monanin, coagulation factor IX, wilate, ceredase, alglucerase, cerezyme, imiglucerase, elerso, taliglucerase alfa, fabrazyme, agalsidase beta, aldrazyme, -I-iduronidase, myozyme, acid glucosidase, elaprase, iduronate-2-sulfatase, naglazyme arylsphatase B, and N-acetylgalactosamine-4-sulfatase. In some embodiments, the individual is administered a therapeutic agent administered to treat a disease such as, but not limited to, hemophilia, hemophilia A, hemophilia B, von Willebrand disease, Gaucher disease, Fabry disease, Fuller disease, Pompe disease, Hunter disease, mucopolysaccharide storage disease, gangliosidosis, hypoalkaline phosphatasia, cholesterol ester storage disease, hyperuricemia, growth hormone deficiency, renal anemia, and Maroteaux-Lamy disease.

[0219]

[0233] In certain embodiments, the individual suffers from a rare autoimmune condition, including, but not limited to, idiopathic thrombocytopenic purpura, membranous nephropathy, bullous pemphigoid, pemphigus vulgaris, and myasthenia gravis.

[0220]

[0234] In certain embodiments, the individual suffers from a disorder associated with the disease therapy. In the case of recombinant antibodies, tolerance is induced, for example, to humanized antibodies used in a therapeutic context that prevents patients from making neutralizing antibodies to the antibody therapeutic, e.g., tolerance to humanized immune subset depleting antibodies or anti-cytokine antibodies used as treatments for autoimmune diseases.

[0221]

[0235] Autoimmune diseases can be divided into two broad categories: organ-specific and systemic. Autoimmune diseases include, but are not limited to, rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), diabetes mellitus type I, diabetes mellitus type II, multiple sclerosis (MS), immune-mediated infertility such as premature menopause, scleroderma, Sjogren's disease, vitiligo, alopecia (baldness), polyendocrine deficiency, Graves' disease, hypothyroidism, polymyositis, inflammatory bowel disease including pemphigus vulgaris, pemphigus foliaceus, Crohn's disease and ulcerative colitis, autoimmune hepatitis such as that associated with hepatitis B virus (HBV) and hepatitis C virus (HCV), hypopituitarism, graft-versus-host disease (GvHD), myocarditis, Addison's disease, autoimmune skin diseases, uveitis, pernicious anemia, celiac disease, hypoparathyroidism, neuromyelitis optica, membranous nephropathy, bullous pemphigoid, pemphigus vulgaris, and myasthenia gravis.

[0222]

[0236] Autoimmune diseases include, but are not limited to, Hashimoto's thyroiditis, autoimmune polyglandular syndromes type I and II, paraneoplastic pemphigus, bullous pemphigoid, dermatitis herpetiformis, linear IgA disease, epidermolysis bullosa acquisita, erythema nodosum, pemphigoid of pregnancy, cicatricial pemphigoid, essential mixed cryoglobulinemia, chronic bullous disease of children, hemolytic anemia, thrombocytopenic purpura, Goodpasture's syndrome, autoimmune neutropenia, myasthenia gravis, Eaton-Lambert myasthenic syndrome, stiff man syndrome, acute disseminated encephalomyelitis, Guillain-Barre syndrome, chronic inflammatory demyelinating polyradiculopathy, multifocal motor neuropathy with conduction block, Also included are chronic neuropathy with monoclonal gammopathy, opsoclonus-myoclonus syndrome, cerebellar degeneration, encephalomyelitis, retinopathy, primary sclerosing cholangitis, sclerosing cholangitis, gluten-sensitive enteropathy, ankylosing spondylitis, reactive arthritis, polymyositis / dermatomyositis, mixed connective tissue disease, Behçet's syndrome, psoriasis, polyarteritis nodosa, allergic vasculitis and granulomatosis (Churg-Strauss disease), polyangiitis overlap syndrome, hypersensitivity vasculitis, Wegener's granulomatosis, temporal arteritis, Takayasu's arteritis, Kawasaki disease, isolated central nervous system vasculitis, thromboangiitis obliterans, sarcoidosis, glomerulonephritis, and cryosis. These conditions are well known in the medical arts and are described, for example, in Harrison's Principles of Internal Medicine, 14th ed., Fauci AS et al. (eds.), New York: McGraw-Hill, 1998.

[0223]

[0237] Animal models for the study of autoimmune diseases are known in the art. For example, animal models believed to be most similar to human autoimmune diseases include animal strains that spontaneously develop a high incidence of the particular disease. Examples of such models include, but are not limited to, the non-obese diabetic (NOD) mouse, which develops a disease similar to type 1 diabetes, as well as the New Zealand hybrid, MRL-Fas lprand animals prone to lupus-like diseases such as BXSB mice. Animal models in which autoimmune disease is induced include, but are not limited to, experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis, collagen-induced arthritis (CIA), a model for rheumatoid arthritis, desmoglein 3 transgenic T cell mice that can be used as an experimental model for pemphigus vulgaris, and experimental autoimmune uveitis (EAU), a model for uveitis. Animal models for autoimmune disease have also been created by genetic engineering, such as IL-2 / IL-10 knockout mice for inflammatory bowel disease, Fas or Fas ligand knockout for SLE, and IL-I receptor antagonist knockout for rheumatoid arthritis.

[0224]

[0238] In certain embodiments, the individual is suffering from a bacterial or viral infection. An individual with a bacterial or viral infection is an individual who has recognizable symptoms of a bacterial or viral infection present.

[0225]

[0239] A non-limiting list of viral infections that can be treated using the modified particles of the present invention includes herpes virus infection, hepatitis virus infection, West Nile virus infection, flavivirus infection, influenza virus infection, rhinovirus infection, papilloma virus infection, paramyxovirus infection, parainfluenza virus infection, and retrovirus infection. Preferred viruses are those that infect the central nervous system of a subject. Most preferred viruses are those that cause hemorrhagic fever, encephalitis, or meningitis.

[0226]

[0240] A non-limiting list of bacterial infections that can be treated using the modified particles of the present invention includes Staphylococcus infections, Streptococcus infections, Mycobacterium infections, Bacillus infections, Salmonella infections, Vibrio infections, Spirochete infections, and Neisseria infections. Preferred are bacteria that infect the central nervous system of a subject. Most preferred are bacteria that cause encephalitis or meningitis.

[0227]

[0241] In some embodiments, the invention relates to the use of the compositions of the invention before the onset of disease. In other embodiments, the invention relates to the use of the compositions of the invention to inhibit ongoing disease. In some embodiments, the invention relates to the amelioration of disease in a subject. Ameliorating disease in a subject is meant to include treating, preventing, or suppressing disease in a subject.

[0228]

[0242] In some embodiments, the present invention relates to the prevention of disease relapse. For example, an unwanted immune response may occur at one region of the peptide (such as an antigenic determinant). Disease relapse associated with an unwanted immune response may occur by being attacked by an immune response at a different region of the peptide. Because the immune-modified particles of the present invention do not contain bound peptides or antigenic moieties, the particles are effective against multiple epitopes. T cell responses in some immune response disorders, including MS and other ThI / 17-mediated autoimmune diseases, may be dynamic and evolve during the course of relapsing-remitting and / or chronic progressive disease. The dynamic nature of the T cell repertoire has relevance to the treatment of certain diseases, since targets may change as the disease progresses. Previously, pre-existing knowledge of patterns of response was necessary to predict disease progression. The present invention provides compositions that can prevent the effects of dynamically changing diseases, which is a function of "epitope spreading". A known model for relapse is the immune response to proteolipid protein (PLP) as a model for multiple sclerosis (MS). The initial immune response is directed against PLP 139 ~ 151 Subsequent disease initiation may result from a recurrent immune response to PLP[pi]s-iβi.

[0229]

[0243] Other embodiments of the present invention relate to transplantation, which refers to the transfer of tissue samples or grafts from a donor individual to a recipient individual and is often performed on human recipients who require the tissue to restore the physiological function provided by the tissue. Transplanted tissues include (but are not limited to) whole organs such as kidneys, livers, hearts, and lungs; organ components such as skin grafts and corneas of the eye; and cell suspensions such as bone marrow cells and cultures of cells selected and expanded from bone marrow or circulating blood, and whole blood transfusions.

[0230]

[0244] A significant potential complication of any transplantation occurs as a result of antigenic differences between the host-recipient and the transplanted tissue. Depending on the nature and extent of the differences, there may be a risk of immunological attack of the graft by the host, or of the host by the graft, or both. The degree of risk is determined by tracking the response pattern in a population of similarly treated subjects with similar phenotypes and correlating with various possible contributing factors according to well-accepted clinical procedures. The immunological attack may be the result of an originally existing immunological response (such as preformed antibodies) or one that is initiated around the time of transplantation (such as the generation of Th cells). Antibodies, Th cells, or Tc cells may engage with each other and with various effector molecules and cells in any combination. However, the antigens involved in the immune response are generally not known, thus presenting difficulties in designing antigen-specific therapies or inducing antigen-specific tolerance.

[0231]

[0245] Certain embodiments of the present invention relate to reducing the risk of host-versus-graft disease, which results in the rejection of tissue grafts by the recipient. Treatment can be performed to prevent or reduce the effects of hyperacute, acute, or chronic rejection responses. Treatment is preferentially initiated well before transplantation so that tolerance is in place when the graft is introduced, but if this is not possible, treatment can be initiated at the same time as transplantation or after transplantation. Regardless of the starting time, treatment is generally continued at regular intervals for at least the first month after transplantation. If sufficient adaptation of the graft occurs, follow-up doses are not necessary, but may be resumed if there is evidence of graft rejection or inflammation. Of course, the tolerization procedure of the present invention can be combined with other forms of immunosuppression to achieve even lower levels of risk.

[0232]

[0246] Certain embodiments of the invention relate to reducing or otherwise ameliorating an inflammatory response induced in response to surgery. In one embodiment of the invention, the immunomodifying particles are administered prior to surgery. In a further embodiment of the invention, the immunomodifying particles are administered simultaneously with or during surgery. In a further embodiment of the invention, the immunomodifying particles are administered after surgery.

[0233]

[0247] The particles of the invention may also be used to treat abscesses or empyema to reduce the inflammatory response produced in a subject following exposure to an infectious agent such as a bacterium or parasite. In one embodiment of the invention, the immunomodifying particles are administered in conjunction with anti-bacterial and / or anti-parasitic treatments known in the art.

[0234]

[0248] The particles of the invention may also be used to reduce or otherwise ameliorate inflammatory responses induced in response to physical trauma or injury, such as, but not limited to, exercise injury, wounds, spinal cord injury, brain injury, and / or soft tissue injury. In one embodiment of the invention, the immunomodifying particles are administered after a subject has experienced trauma or injury.

[0235]

[0249] The particles of the present invention can also be used to reduce the inflammatory response associated with the development and / or growth of cancer cells.Cancers that can be treated include, but are not limited to, central nervous system cancer, basal cell carcinoma, cancerous brain tumors, Burkitt's lymphoma, lymphoma, cervical cancer, ovarian cancer, testicular cancer, liver cancer, non-small cell and small cell lung cancer, melanoma, bladder cancer, breast cancer, colon and rectal cancer, endometrial cancer, kidney (renal cell) cancer, leukemia, non-Hodgkin's lymphoma, pancreatic cancer, prostate cancer, melanoma, and thyroid cancer.In one embodiment, subcutaneous injection of the particles of the present invention prevents the accumulation of inhibitory neutrophils, thereby reducing inflammation in cancer patients.

[0236]

[0250] The particles of the invention are also useful for regeneration of damaged tissue. In one embodiment, administration of the particles to a patient increases regeneration of damaged epithelial cells in the digestive tract. In a further embodiment, the patient suffers from colitis, Crohn's disease, or inflammatory bowel disease. In another embodiment, administration of the particles of the invention to a patient increases remyelination of neurons. In a further embodiment, the patient suffers from multiple sclerosis.

[0237] Scaffolds, Matrices, and Delivery Systems

[0251] In some embodiments, the compositions of the invention (e.g., PLG carrier polymers covalently coupled to antigenic molecules) are useful with one or more scaffolds, matrices, and / or delivery systems (see, e.g., U.S. Patent Application Publication No. 2009 / 0238879; U.S. Patent No. 7,846,466; U.S. Patent No. 7,427,602; U.S. Patent No. 7,029,697; U.S. Patent No. 6,890,556; U.S. Patent No. 6,797,738; U.S. Patent No. 6,281,256, which are incorporated herein by reference in their entireties). In some embodiments, the particles (e.g., antigen-bound PLG particles) are bound to, adsorbed onto, embedded within, conjugated to, etc., a scaffold, matrix, and / or delivery system (e.g., for delivery of chemical / biological materials, cells, tissues, and / or organs to a subject). In some embodiments, scaffolds, matrices, and / or delivery systems (e.g., for delivery of chemical / biological materials, cells, tissues, and / or organs to a subject) comprise and / or are made from materials described herein (e.g., PLG conjugated to one or more antigenic peptides).

[0238]

[0252] In some embodiments, a microporous scaffold is provided (e.g., for implanting biological material (e.g., cells, tissues, etc.) in a subject). In some embodiments, a microporous scaffold is provided having an agent (e.g., extracellular matrix protein, exendin-4) and biological material (e.g., pancreatic islet cells) therein. In some embodiments, the scaffold is used in the treatment of disease (e.g., type 1 diabetes) and related methods (e.g., diagnostic methods, research methods, drug screening). In some embodiments, the scaffold is provided with a carrier conjugated to an antigen described herein on and / or in the scaffold. In some embodiments, the scaffold is produced from a material conjugated to an antigen (e.g., PLG conjugated to an antigen).

[0239]

[0253] In some embodiments, the scaffold and / or delivery system comprises one or more layers and / or has one or more chemical and / or biological entities / agents (e.g., particles conjugated to proteins, peptides, small molecules, cells, tissues, etc.). See, for example, US Patent Application Publication No. 2009 / 0238879, which is incorporated herein by reference in its entirety. In some embodiments, antigen-binding particles are co-administered with the scaffold delivery system to elicit induction of immune tolerance to the scaffold and associated materials. In some embodiments, a microporous scaffold is administered to a subject with particles described herein on or in the scaffold. In some embodiments, the antigen-binding particles are coupled to the scaffold delivery system. In some embodiments, the scaffold delivery system comprises antigen-binding particles.

[0240]

[0254] Various modifications, variations, and alterations of the described features and embodiments will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although specific embodiments have been described, it should be understood that the claimed invention is not unduly limited to such specific embodiments. Indeed, various modifications of the described modes and embodiments that are apparent to those skilled in the relevant art are intended to be within the scope of the following claims. For example, U.S. Patent Application Nos. 2012 / 0076831, 2002 / 0045672, 2005 / 0090008, 2006 / 0002978, and 2009 / 0238879 (each of which is incorporated by reference in its entirety herein) and U.S. Patent Nos. 7,846,466; 7,427,602; 7,029,697; 6,890,556; 6,797,738; and 6,281,256 (each of which is incorporated by reference in its entirety herein) provide details, modifications, and variations that are useful in various embodiments described herein.

[0241]

[0255] All publications and patents mentioned in this application and / or listed below are hereby incorporated by reference in their entirety. EXAMPLES

[0242]

[0256] The following examples are provided to further demonstrate the advantages and features of the present invention and are not intended to limit the scope of the disclosure.

[0243] Materials and Methods Microscopy and image acquisition

[0257] Images were acquired on an Olympus BX-51 microscope (Olympus Corporation, Japan) using a DP-70 camera and DP manager 2.2.1 software (Olympus Corporation).

[0244] Isolation of leukocytes from brain and liver

[0258] Leukocytes were obtained from PBS-perfused mouse brains by digesting the brains in PBS containing deoxyribonuclease (0.005 g / ml; Sigma Aldrich) and collagenase IV (0.05 g / ml; Sigma Aldrich) for 60 min at 37°C as previously described (Getts et al., J Exp Med. 29: 2319, 2007). Digestion was stopped with 10% FCS and the homogenate was passed through a 70 μm nylon cell strainer (Becton Dickinson, NJ, USA). The pellet obtained after centrifugation at 340×g for 10 min was resuspended in 30% Percoll (Amersham, Norway) and overlaid on 80% Percoll. Leukocytes were collected from the 30% / 80% interface after centrifugation at 1140×g for 25 min at room temperature. The same protocol is also used to derive leukocytes from the liver and weigh the tissue prior to processing.

[0245] Isolation of leukocytes from spleen, blood and bone marrow

[0259] For flow cytometry analysis, the right femur was dissected and bone marrow cells were flushed out using a syringe filled with PBS. For the isolation of bone marrow progenitor cells, femurs and tibiae from at least four mice were used. The cell suspension achieved after flushing was filtered through a 70 μm cell strainer and centrifuged at 340 g for 5 min. Red blood cells in the resulting pellet were lysed in an NH4Cl-based red blood cell lysis buffer (BD Pharm Lyse™; BD Pharmingen) and then centrifuged at 340 g for 5 min. For peripheral blood, blood was collected by cardiac puncture and immediately transferred into citrate buffer (mMol, Sigma Aldrich). The resulting suspension was loaded onto 70% Percoll and centrifuged at 1140 x g for 20 min at room temperature with the brake off. The interface was collected and the cells were washed once in PBS and centrifuged at 340 x g. For isolation of splenic leukocytes, spleens were passed through a 70-70 μm cell strainer and centrifuged at 340 g for 5 min. Red blood cells in the resulting pellet were lysed in NH4Cl-based red blood cell lysis buffer (BD Pharm Lyse™; BD Pharmingen) and then centrifuged at 340×g for 5 min.

[0246] Flow cytometry

[0260] Cells harvested from brain, liver, blood, and bone marrow (as above) were washed in PBS and blocked with anti-CD16 / CD32 antibody (Biolegend). Viable cells were counted using trypan blue exclusion and routinely demonstrated cell viability of >95%.

[0247]

[0261] Cell surface molecule expression was measured and cell sorting was performed on a FACS ARIA (Becton Dickinson) equipped with Argon ion and HeNe lasers. Live cell populations were gated by forward and side scatter, followed by identification of fluorescent populations determined by forward gating. Sorting was performed using specific fluorescence and scatter parameters that identified the population of interest. Sorting strategies were set to purity achieving >98% purity for the myeloid population.

[0248]

[0262] Acquired FACS data files were analyzed using the flow cytometry program Flow Jo (FlowJo, Ashland, OR, USA). The amount of the cell population of interest was calculated based on the flow cytometry percentages analyzed and absolute cell numbers derived from each organ.

[0249] Induction and evaluation of experimental autoimmune encephalitis (EAE)

[0263] Mice were injected subcutaneously with an emulsion containing 0.1 mg of MOG peptide (MEVGWYRSPFSRVVHLYRNGK (SEQ ID NO: 1); Auspep, Parkville, Victoria, Australia; greater than 95% HPLC purified) and 2 mg / mL of Mycobacterium tuberculosis (Sigma Aldrich) in complete Freund's adjuvant. Two days later, mice were administered ip with 500 μl of pertussis toxin (Sigma Aldrich). Mice were monitored for disease progression and graded on the following scale: 1, floppy tail and / or weakness of one hind limb; 2, weakness of more than one limb, lameness; 3, paralysis of one limb; 4, paralysis of more than one limb, incontinent; 5, moribund.

[0250] Statistics

[0264] Graphs were generated and computer-assisted statistical analyses were performed in GraphPad Prism and InStat (both programs from GraphPad software, San Diego, CA, USA), respectively. Depending on the data, unpaired, two-tailed Student's t-test or one-way ANOVA with Tukey-Kramer post-test was performed, and P<0.05 was considered significant.

[0251]

[0265] For correlation analysis between parameters such as weight loss, infiltration, and viral titer, a quadratic polynomial (Y = A + B * X + C * X^2), nonlinear regression (curve fitting) was used.

[0252] Example 1 Synthesis and characterization of PLG-peptide conjugates and nanoparticle formation

[0266] Poly(lactide-co-glycolic acid) (PLG) was covalently linked to either the Cy5.5 fluorescent dye or the antigen using the coupling reagents 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) / N-hydroxysuccinimide (NHS). The antigen was a proteolipid protein (PLP). 139 ~ 151 ) or ovalbumin (OVA) 323 ~ 339 ) (Figure 1).

[0253]

[0267] Particles of various sizes were prepared by double emulsion and nanoprecipitation methods. The size and zeta potential of the nanoparticle formulations were determined and are provided in Table 1 above.

[0254]

[0268] The coupling efficiency of antigen to PLG was 1 The 1H-NMR analyses were performed. Figure 2 shows the results of (i) PLG, (ii) OVA, measured in DMSO-d6 (calibrated at 2.5 ppm). 323 ~ 339 and (iii) PLG-OVA. 323 ~ 339 of 1 H-NMR spectrum of OVA. 323 ~ 339 The coupling efficiency of OVA to PLG was 323 ~ 339 Calculated by comparing the integrated values ​​of overlapping methyl proton peaks of leucine and isoleucine at 1.4 ppm in (d,d') with the methylene proton peak at 5.3 ppm in PLG (b). A schematic diagram of the polymer-conjugated nanoparticles is provided in Figure 2C.

[0255]

[0269] By varying the chemistry, the coupling efficiency of PLP to PLG can be increased to approximately 20%.

[0256]

[0270] The PLG-Ag conjugates were combined with unconjugated PLG in a defined mixing ratio to precisely control the loading (μg of antigen (Ag) per mg of PLG) (see Table 1).

[0257] Example 2 Size- and time-dependent cellular interactions of PLG nanoparticles

[0271] 80 nm and 400 nm PLG nanoparticles were fluorescently labeled with 1 wt% PLG-Cy5.5 conjugate and incubated with bone marrow derived dendritic cells (BMDCs) or bone marrow derived macrophages (BMMOs) for up to 4 h at 37° C. (FIG. 3). Blue fluorescence indicates DAPI staining of nuclei and red fluorescence indicates PLG-Cy5.5 nanoparticles.

[0258] Example 3 Characterization of BMDC surface markers after treatment with PLG-OVA particles with various antigen loadings

[0272] BMDCs were treated with 300 μg / mL of 400 nm and 80 nm PLG-OVA nanoparticles with various antigen loadings for 3 hours. Non-internalized PLG-OVA nanoparticles were subsequently washed from the cell surface. After 4 days of incubation, cell surface markers MHCII, CD80 and CD86 were assayed using flow cytometry. Figures 4A and 4D show MHCII marker expression after treatment with 400 nm and 80 nm particles, respectively. Figures 4B and 4E show CD80 marker expression after treatment with 400 nm and 80 nm particles, respectively. Figures 4C and 4F show CD86 marker expression after treatment with 400 nm and 80 nm particles, respectively. Treatment of cells with PLG-OVA nanoparticles resulted in significantly downregulated MHCII and CD80 expression, regardless of antigen content.

[0259] Example 4 Antigen-specific induction of regulatory T cells by PLG-OVA particles delivered to antigen-presenting cells (APCs)

[0273] BMDCs or BMMOs were treated with 300 μg / mL of a 400 nm PLG-OVA nanoparticle formulation with a PLG antigen loading of 8 μg / mg for 3 hours. Non-internalized PLG-OVA nanoparticles were then washed from the cell surface before addition of OT-II T cells and 2 ng / mL TGF-β1. Cells were co-cultured for 4 days before using flow cytometry to measure CD25 activation and foxp3 expression in T cells as an indication of regulatory T cell induction. The difference in induction in BMDCs versus BMMOs was significant at p<0.0001 (Figure 5).

[0260] Example 5 Size- and antigen-loading-dependent CD25 activation and induction of regulatory T cells by PLG-OVA particles

[0274] Bone marrow-derived dendritic cells (BMDCs) were treated with 300 μg / mL of 400 nm and 80 nm PLG-OVA nanoparticle formulations for 3 h. Subsequently, non-internalized PLG-OVA nanoparticles were washed from the cell surface before adding OT-II T cells and 2 ng / mL TGF-β1. The cells were co-cultured for 4 days before using flow cytometry to measure CD25 activation and foxp3 expression in T cells. Although both nanoparticle formulations were able to increase CD25 activation similarly, only 400 nm PLG-OVA nanoparticles were able to successfully induce regulatory T cells (Figure 6).

[0261] Example 6 CD25 activation and induction of regulatory T cells as a function of PLG-OVA particle dose

[0275] Regulatory T cell induction is nanoparticle dose dependent. Bone marrow derived dendritic cells (BMDCs) were treated with various concentrations of 400 nm PLG-OVA nanoparticle (8 μg / mg loading) formulations for 3 h. Subsequently, non-internalized PLG-OVA nanoparticles were washed from the cell surface before adding OT-II T cells and 2 ng / mL TGF-β1. The cells were co-cultured for 4 days before using flow cytometry to measure CD25 activation (Figure 7A) and foxp3 expression (Figure 7B) of T cells. CD25 activation reached a maximum at 50 μg / mL, whereas foxp3 expression appeared to plateau at 300 mg / mL.

[0262] Example 7 Size- and concentration-dependent biodistribution of PLG particles

[0276] Mice were injected intravenously (IV) or subcutaneously (SC) with 1.25 mg of 400 nm or 80 nm PLG-Cy5.5 nanoparticle formulations. Cells from liver, kidney, heart, lung, spleen and inguinal lymph nodes were isolated. Data were analyzed by flow cytometry 24 hours after injection. The liver is the primary site of particle accumulation (Figure 8A).

[0263]

[0277] The ratio of cells that were CD45+ to CD45- was determined for liver, spleen and lung (Figure 8B).

[0264]

[0278] Mice were intravenously injected with 1.25 mg of PLG-Cy5.5 nanoparticle formulations of various particle sizes. Data were analyzed by flow cytometry 24 hours after injection. The percentage of Cy5.5+ cells found in the liver, spleen, and lungs was determined for a given particle size (Figure 8C). The majority of 400 nm and 200 nm PLG-Cy5.5 nanoparticles were found in the liver. Approximately 50% of CD45+ cells contained 80 nm and 200 nm PLG-Cy5.5 nanoparticles, respectively, while only about 5% to about 10% of CD45- cells contained 80 nm and 200 nm PLG-Cy5.5 nanoparticles. In contrast, about 75-80% of both CD45+ and CD45- cells contained 400 nm PLG-Cy5.5 nanoparticles (Figure 8D). Injection of 0.625 mg or 1.25 mg of 400 nm PLG-Cy5.5 nanoparticles results in approximately 100% accumulation of the particles in both CD45+ and CD45- cells (Figure 8E).

[0265] Example 8 PLG particles bind to neutrophils and monocytes in the blood.

[0279] Healthy mice (n=3) were intravenously injected with 1.25 mg of 400 nm or 80 nm PLG-Cy5.5 nanoparticle formulations. Two hours after injection, blood was collected and analyzed by flow cytometry. Expression of CD11b, CD11c, Gr-1, and Ly6c markers was used to identify the type of leukocytes. Cy5.5 fluorescence was used to determine which cells had 80 nm and 400 nm PLG-Cy5.5 nanoparticles. PLG-Cy5.5 particles bind to neutrophils and monocytes in the blood (Figure 9).

[0266] Example 9 PLG particles induce regulatory T cells ex vivo and induce tolerance in experimental autoimmune encephalitis (EAE)

[0280] BMDCs, splenic dendritic cells, or liver dendritic cells were treated with 300 μg / mL OVA alone or a 400 nm PLG-OVA nanoparticle formulation (8 μg / mg PLG antigen loading) for 3 h. Non-internalized PLG-OVA nanoparticles were washed from the cell surface before addition of OT-II T cells and 2 ng / mL TGF-β1. Cells were co-cultured for 4 days before using flow cytometry to measure CD25 activation and foxp3 expression in T cells as an indication of regulatory T cell induction.

[0267]

[0281] Liver and splenic dendritic cells were activated by OVA alone, whereas activation of BMDCs did not differ significantly between treatment with OVA and PLG-OVA (FIG. 10A).

[0268]

[0282] Mice were intravenously injected with 1.25 mg of the PLG-Cy5.5 nanoparticle formulation. Data were analyzed by flow cytometry 24 hours after injection. Cells in the spleen showing Cy5.5 fluorescence had the highest levels of CD25 activation and foxp3 expression, indicative of regulatory T cell induction (Figure 10B).

[0269]

[0283] PLG nanoparticles are synthesized by the immunodominant proteolipid protein PLP 139 ~ 151 Epitope (PLG-PLP 139 ~ 151 ) was used to investigate the induction of tolerance for the prevention of relapsing experimental autoimmune encephalitis (R-EAE). R-EAE mice were generated as described above.

[0270]

[0284] The peptides administered to the animals were covalently coupled to the particles. Mice were immunized with PLP on day -7 relative to the time of immunization (day 0). 139 ~ 151 Mice were treated with PLP (N=3-7) or PBS buffer. Disease peak was typically observed at approximately days 12-14, and mice were scored for clinical disease. PBS buffer alone did not prevent disease induction. However, PLP 139 ~ 151PLG particles covalently coupled with resulted in a clinical score of 0 (no disease) at all times except for low clinical scores below 1 shown between days 20 and 30 (Figure 10C). The cumulative disease scores measured from days 0 to 30 post-immunization clearly show that treatment of mice with the nanoparticle formulation resulted in significantly abrogated clinical disease scores compared to controls (Figure 10D).

[0271] Example 10 Controlled delivery of single or multiple antigens in tolerogenic nanoparticles using peptide-polymer bioconjugates Synthesis of antigen-polymer bioconjugates and particle preparation

[0285] Encephalitogenic proteolipid peptide (PLP) 139 ~ 151 or PLP 178 ~ 191 ) and ovalbumin peptide (OVA 323 ~ 339 ) was conjugated to the terminal carboxylic acid groups of PLG (4200 g / mol; 0.17 dL / g) using carbodiimide chemistry (Figures 11A, 19, and 20). The coupling efficiency was 1 The efficiencies of the acPLG-Ag particles (antigen-conjugated PLG-Ag particles) were 73.6%, 74.1%, and 66.9%, respectively, as determined by H-NMR characterization (Figure 11B). Two sizes (400 nm and 80 nm) of acPLG-Ag particles (antigen-conjugated PLG-Ag particles) were prepared using solvent evaporation emulsion (SE) and nanoprecipitation methods, respectively. The Ag loading was controlled by mixing Ag-PLG bioconjugates with unmodified PLG in various ratios (Figure 11C). Given these coupling efficiencies, maximum Ag loading (μg of Ag per mg of particles) of 211 μg / mg (theoretical 266 μg / mg), 218 μg / mg (theoretical 274 μg / mg), and 220 μg / mg (theoretical 297 μg / mg) were obtained for acPLG-PLG, respectively. 139 ~ 151 , acPLG-PLP 178 ~ 191 , and acPLG-OVA 323 ~ 339The size of acPLG-Ag particles prepared by the SE method was minimally affected by varying the Ag loading to 25 μg / mg, but increased slightly for antigen loadings of 50 μg / mg and higher (Table 4). However, surface coupling of Ag to the PLG particles resulted in significantly increased size and polydispersity. The size of particles prepared by nanoprecipitation tended upwards with Ag loading, with a maximum loading of only 2 μg / mg being achievable. The zeta potential was not affected by Ag loading and was highly negative (between -30 and -56 mV) for all acPLG particles. These experiments confirmed that acPLG particles could be prepared with controllable Ag loading by systematic combination of PLG-Ag bioconjugates with unmodified PLG, with well-controlled physicochemical properties.

[0272]

[0286] Fluorescently tagged OVA 323 ~ 339 Using acPLG-IgG1, acPLG particles were compared to Ag-conjugated PLG particles (PLG-Ag) and PLG particles with encapsulated Ag (PLG(Ag)) for Ag-specific antibody binding on the surface. Encapsulation of Ag in the particles (PLG(Ag)) was shown to reduce the ability of antibodies to bind to the particles that could result in immune activation in vivo. Conjugation to the surface of the three particle variants resulted in PLG-OVA 323 ~ 339 acPLG-OVA was more effective than particles (7.5 μg / mg). 323 ~ 339 (8 μg / mg) showed significantly less binding of IgG1 to PLG (OVA) (Figure 1D). 323 ~ 339 ) bound the least amount of IgG1, however a maximum antigen loading of only 3 μg / mg was achievable. The reduction in IgG1 binding was suspected to be the result of significantly lower Ag loading and burst release of Ag, which was observed for other PLG particles as well. Importantly, acPLG particles did not show significant burst release of Ag compared to PLG(Ag) particles (Figure 11E).

[0273] Regulatory T cell induction by acPLG-Ag particles is size- and Ag-loading-dependent

[0287] The acPLG-Ag particles then promote antigen presentation by dendritic cells, followed by naive CD4 + CD25 - The ability to affect T cell activation and induce the formation of regulatory T cells (Tregs) was investigated in vitro as a function of particle size and Ag loading. Since acPLG particles have been shown to mediate immune tolerance in vivo, Treg induction was used to determine the tolerogenic effect of acPLG particles. Both 80 nm and 400 nm acPLG-OVA 323 ~ 339 Delivery of the particles to bone marrow-derived dendritic cells (BMDCs) followed by Ag-specific naive OTII CD4 in the presence of TGFβ. + CD25 - Co-culture with T cells resulted in upregulation of CD25 on T cells, even under the lowest Ag-loading conditions tested (Figures 12A and 12B). CD25 expression was significantly higher in both acPLG-OVA and OVA-P2 cells. 323 ~ 339 Although particle size increased, it did not correlate with Treg induction as measured by CD25 and Foxp3 expression. 323 ~ 339 Only with the particles was high-level induction and dependent on the Ag loading (Figure 12C). At a NP concentration of 300 μg / mL, maximum Treg induction was observed at an Ag loading of 8 μg / mg, with no significant difference observed by increasing the loading up to 150 μg / mg. acPLG-OVA with a diameter of 80 nm 323 ~ 339 The particles only induced low levels of Tregs, regardless of the Ag loading (Figure 12D). In summary, T cell expression of CD25 was particle size independent, whereas Treg induction was particle size dependent. Importantly, we demonstrated that high concentrations, up to 150 μg / mg loading of acPLG-OVA, significantly increased the Treg induction in mice. 323 ~ 339We found that the particles were not significantly different from particles with a loading of 8 μg / mg for the induction of Tregs in vitro.

[0274] Regulatory T cell induction by acPLG-Ag nanoparticles is particle concentration dependent

[0288] Naive CD4 + CD25 - The concentration dependence of acPLG particles on T cell activation and Treg induction was examined by using SEacPLG-OVA with multiple Ag loadings (2, 8, 25, and 150 μg / mg) and particle concentrations (0, 5, 10, 75, 150, and 300 μg / mL). 323 ~ 339 BMDCs were tested using acPLG particles with a loading of 8 μg / mg Ag (1,200 ng / mL Ag delivered) at a NP concentration of 150 μg / mL. The range of Ag delivered to BMDCs was 10 to 45,000 ng / mL (Table 4). A minimum of 1,200 ng / mL Ag was required to achieve CD25 expression in >40% of CD4 T cells. This level of expression was achieved even with low acPLG concentrations (5-10 μg / mL) with an Ag loading of 150 μg / mg (Figure 13A). Similar CD25 expression was achieved using acPLG particles with an Ag loading of 8 μg / mg (1,200 ng / mL Ag delivered) at a NP concentration of 150 μg / mL. CD25 expression in >60% of CD4 T cells occurred for Ag concentrations of 1,875 ng / mL and above. CD4 + CD25 + Foxp3 expression on T cells required higher amounts of Ag to achieve the highest expression levels (>30%). Treg induction correlated with levels of CD25 expression in >60% of CD4 T cells. acPLG-OVA 323 ~ 339 Treg induction by particles was highly dependent on the total amount of Ag delivered per well. Ag delivered above 1,875 ng / mL did not dramatically affect the percentage of Tregs detected in vitro (Figure 13B). acPLG particles prepared with various Ag loadings allowed the determination of Ag requirements to induce significant levels of Tregs in vitro and present the possibility of using acPLG particles to modulate biological responses in vivo.

[0275] [Table 4]

[0276] acPLG-Ag particles are PLP 139 ~ 151 Suppresses immunization-induced EAE

[0289] The ability of acPLG-Ag particles to induce Ag-specific immune tolerance was tested using the R-EAE disease model of MS. In vitro data support particle internalization, Ag presentation, and Treg induction, but in vivo testing is more challenging because NPs must reach the appropriate cell types to elicit a tolerogenic response. Previous studies have demonstrated that Ag-encapsulated PLG (PLP 139 ~ 151 ) particles were administered with an Ag loading of approximately 2-3 μg / mg at a dose of 2.5 mg. Using a preventative disease model, acPLG-PLP 139 ~ 151 The particles were administered intravenously to SJL / J mice on day -7 relative to R-EAE immunization. Untreated control mice showed severe clinical symptoms, as measured by both the mean clinical score (Figure 14A) and cumulative clinical score (Figure 14B), whereas acPLG-PLP 139 ~ 151 Mice treated with the particles showed significantly reduced disease symptoms. 139 ~ 151 The particles were Ag-encapsulated PLG (PLP) given at a dose of 2.5 mg. 139 ~ 151 ) particles (Figures 14A-14B). These results confirmed that higher Ag loading in acPLG particles can reduce the dose of acPLG particles and have a similar ability to induce tolerance in vivo.

[0277] acPLG particles express encephalitogenic peptide (PLP 139 ~ 151 and P.L.P. 178 ~ 191) cocktail to suppress EAE induced by

[0290] Diversity in the autoreactive T cell repertoire is clearly established in autoimmune diseases such as MS; therefore, tolerogenic NPs are likely to need to deliver multiple epitopes to effectively treat diseases whose pathogenesis may be complex. We have developed multiple myelin peptide-PLG bioconjugates, i.e., PLG-PLP 139 ~ 151 and PLG-PLP 178 ~ 191 We investigated whether it is possible to incorporate Ag into a single acPLG particle with precise Ag loading and whether the PLP 139 ~ 151 / PLP 178 ~ 191 We then tested whether IFN-γ / CFA could be used as an effective treatment for R-EAE induced by immunization with IFN-γ / CFA (FIG. 15A).

[0278]

[0291] acPLG particles were administered intravenously to SJL / J mice on day -7 relative to R-EAE immunization. 323 ~ 339 , acPLG-PLP 139 ~ 151 , or acPLG-PLP 178 ~ 191 Control mice treated with particles showed significantly lower mean clinical scores than acPLG-PLP, as measured by both mean clinical scores (FIG. 15B) and cumulative clinical scores (FIG. 15C). 139 ~ 151,178 ~ 191 Interestingly, acPLG-PLP showed more severe clinical disease symptoms compared to the granulocyte-derived 139 ~ 151 Acute disease in mice treated with particles was observed to be attenuated with severe relapses in mice treated with acPLG-PLP. 178 ~ 191 In contrast to mice treated with acPLG-PLP particles, 139 ~ 151,178 ~ 191Mice treated with acPLG showed significantly reduced acute and recurrent disease scores, resulting in a large reduction in the cumulative score measured. These results demonstrate the ability of acPLG particles to simultaneously tolerize to multiple peptides associated with disease development. The modular design of acPLG particles containing various Ags using a PLG-Ag bioconjugate "mix and match" approach clearly demonstrates the versatility of the acPLG particle platform and design.

[0279]

[0292] Soluble peptides, Ag-binding cells, genetically engineered foods, and particles have been investigated as treatment options for applications including allergies, autoimmune diseases, and cell transplantation. The advantage of the particles of the present invention (acPLG particles) over current nano-based tolerance platforms is that tolerance induction by acPLG particles is achieved without the co-delivery of immunosuppressants, which are associated with many side effects. Differences in the uptake mechanism and context of Ag presentation of acPLG particles may be partially responsible for the tolerance induction of platforms such as soluble Ag arrays, tolerogenic nanoparticles (tNPs), and PEGylated gold nanoparticles, which require the co-delivery of various immunomodulatory agents. The results presented herein demonstrate a novel NP platform that achieves precise control over Ag delivery and tolerogenic responses in vivo. This controllable Ag delivery platform enabled the identification of the relationship between Ag loading, concentration, and size of acPLG particles with respect to T cell activation and Treg induction in vitro.

[0280] Materials and Methods

[0293] Poly(lactide-co-glycolide) (50:50) (PLG) with a single carboxylic acid end group in hexafluoro-2-propanol and an intrinsic viscosity of 0.17 dL / g was purchased from Lactel Absorbable Polymer (Birmingham, AL). Poly(ethylene-alt-maleic anhydride) (PEMA) was purchased from Polyscience, Inc. (Warrington, PA). Amine-terminated ovalbumin peptide (NH2-OVA) was purchased from Polyscience, Inc. (Warrington, PA). 323 ~339 ) and proteolipid peptide (NH2-PLP 139 ~ 151 or NH2-PLP 178 ~ 191 ) were purchased from Genscript (Piscataway, NJ). All other reagents were purchased from Sigma Aldrich (St. Louis, MO) unless otherwise noted.

[0281] PLG-Ag bioconjugation

[0294] PLG (37.8 mg, 0.009 mmol, 4200 g / mol) was dissolved in 2 mL of N,N-dimethylformamide (DMF) in a 20 mL scintillation vial equipped with a stir bar. N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDC) (9.0 mg, 0.047 mmol, 5X relative to PLG) was dissolved in 0.5 mL of DMF and added dropwise to the PLG solution. N-hydroxysuccinimide (NHS) (5.5 mg, 0.047 mmol, 5X relative to PLG) was dissolved in 0.5 mL of DMF and added dropwise to the solution. The reaction was allowed to stir at room temperature for 15 minutes. Antigenic peptide (1.2X relative to PLG) was dissolved in a solution of 1 mL of dimethylsulfoxide (DMSO) and 0.5 mL of DMF and stirred at 400 RPM. Triethylamine (5X relative to peptide) was added to the peptide solution and the mixture was added dropwise to the stirred PLG solution. The reaction was allowed to proceed overnight at room temperature. The resulting polymer was isolated and purified by dialysis using a 3,500 molecular weight cut-off membrane against 4 liters of distilled water for 2 days. The distilled water was changed a total of 6 times. The dialyzed polymer was collected, washed 3 times with MilliQ water, centrifuged at 7000xg, then resuspended in 20 mL of water and lyophilized for 2 days. The coupling efficiency of the peptide to PLG was determined by NMR analysis in DMSO-d6.

[0282] mouse

[0295] Female SJL / J mice (6–8 weeks old) were purchased from Harlan Laboratories (Indianapolis, IN). OT-II mice (B6.Cg-Tg(TcraTcrb)425Cbn / J) were purchased from Jackson Laboratory (Bar Harbor, ME).

[0283] Preparation of nanoparticles

[0296] Nanoparticles (acPLG) of two different sizes (80 and 400 nm) were prepared according to nanoprecipitation or emulsion solvent evaporation methods, respectively. To produce acPLG particles using the emulsion solvent evaporation method, Ag-polymer bioconjugates were combined with unconjugated PLG in various ratios to obtain the calculated Ag loading in the particles listed in Table 4. This method has been described in our previous publication. To prepare smaller acPLG, approximately 80-120 nm, the nanoprecipitation method was used. Briefly, 100 mg of PLG (desired ratio of Ag-polymer bioconjugate and unconjugated PLG) was dissolved in acetonitrile at a concentration of 1 mg / mL and poured into 300 mL of MilliQ water with rapid stirring. The solution was stirred for 24-48 hours to completely remove the residual acetonitrile. The acPLG particles were collected using an ultracentrifugation membrane filter 10 kDa MWCO at 4000xg. Cryoprotectant (4% (w / v) sucrose and 3% (w / v) mannitol) was then added to the particles, which were then freeze-dried.

[0284] Nanoparticle characterization

[0297] The size and zeta potential of the nanoparticles were determined by dynamic light scattering (DLS) by mixing 10 μL of 25 mg / mL particle solution in 990 μL of MilliQ pancreas using a Malvern Zetasizer ZSP (Westborough, MA). 323 ~ 339 ) and acPLG-OVA 323 ~ 339The release of peptide from the particles was measured over a period of 72 hours. Approximately 8 mg of each particle was dispersed in 1 mL of PBS and incubated at 37°C. At the designated time points, the particles were centrifuged at 7000xg for 5 minutes and 0.5 mL of supernatant was collected. The particles were resuspended and 0.5 mL of fresh PBS was added to each sample. All supernatant samples were stored at -20°C until the experiment was completed. After the final time point, the particle pellet was dissolved in DMSO and the total amount of protein remaining was determined. Protein content was determined using a Micro BCA assay (Pierce, Waltham, MA).

[0285] OVA in vitro 323 ~ 339 -IgG1 binding

[0298] OVA 323 ~ 339 The antibody (Innovagen, Sweden) was fluorescently labeled with FITC using the Abcam Easy Link FITC Conjugation Kit (Abcam, Cambridge, MA). 20 μg of acPLG particles were mixed with 1 mg / mL of FITC-labeled OVA. 323 ~ 339 After incubation with antibodies for 20 min at 4° C. and washing, fluorescence was measured using a Beckman Coulter CyAn ADP Analyzer (Indianapolis, IN). Statistical differences between groups were determined by performing one-way ANOVA and Tukey's post-hoc test (p<0.05).

[0286] cell culture

[0299] BMDC medium consisted of RPMI containing L-glutamine (Life Technologies, Carlsbad, CA), supplemented with penicillin (100 units / mL), streptomycin (100 mg / mL), 10% heat-inactivated fetal bovine serum (FBS) (Invitrogen Corporation, Carlsbad, CA), and 50 mM β-mercaptoethanol (Sigma Aldrich). Co-culture medium was the same, but without β-mercaptoethanol, supplemented with 1 mM sodium pyruvate, and 0.1 mM non-essential amino acids (Life Technologies, Carlsbad, CA).

[0287] Antibodies and flow cytometry

[0300] FcR blocking was performed with anti-CD16 / 32 antibody (Biolegend) followed by staining with various combinations of the following antibodies: anti-CD4 antibody (RM4-5), anti-CD25 antibody (PC61) (Biolegend), and anti-Foxp3 antibody (FJK-16s) (eBioscience, San Diego, CA). Viability was assessed using a Fixable Violet Dead Cell Stain Kit (Invitrogen, Carlsbad, CA). Foxp3 staining was performed using the eBioscience staining kit according to the manufacturer's protocol. Cytometry data was collected using a Beckman Coulter CyAn ADP Analyzer. Analysis was performed using FlowJo (FlowJo, Ashland, OR).

[0288] Cell isolation and in vitro Treg induction assay

[0301] Treg induction assays were performed with minor modifications as described. CD4 + CD25 - Foxp3 - T cells were isolated from naive CD4 +T cells were isolated from the spleens of OT-II mice using a T cell isolation kit (Miltenyi Biotec, San Diego, CA). The assay was performed in T cell culture. Bone marrow derived dendritic cells (2x10 4 1000 cells / well) were seeded into 96-well round-bottom cell culture plates and various particle concentrations of acPLG-OVA were added. 323 ~ 339 and Ag-loaded doses for 3 h. After incubation, all wells were washed to remove excess particles that were not internalized by the cells. Cells were cultured at 2x10 4 acPLG-OVA was co-cultured with naive T cells at 100 / well. 323 ~ 339 The group receiving antigen instead of soluble OVA at this time 323 ~ 339 (100 ng / mL). After 4 days of co-culture, T cells were harvested, stained for viability, CD4, CD25, and Foxp3, and analyzed using flow cytometry. Statistical differences between groups were determined by performing one-way ANOVA and Tukey's post-hoc test (p<0.05).

[0289] R-EAE disease induction and measurement

[0302] R-EAE was induced by immunization with encephalitogenic peptides as previously described. 139 ~ 151 or PLP 139 ~ 151 and P.L.P. 178 ~ 191 To induce R-EAE, use both 1 mg / mL PLP, respectively. 139 ~ 151 / Complete Freund's adjuvant (CFA) or 0.25 mg / mL PLP 139 ~ 151 / CFA and 0.5 mg / mL PLP 178 ~ 191Mice were immunized by sc administration of 100 μL of 100 μL / CFA distributed over three spots on the nape and hind flank of SJL / J mice. Disease severity in individual mice was assessed using a 0 to 5 point scale: 0=no disease, 1=floppy tail or hind limb weakness, 2=floppy tail and hind limb weakness, 3=partial hind limb paralysis, 4=complete hind limb paralysis, 5=moribund. Differences between disease courses of different treatment groups were analyzed for statistical significance using the Kruskal-Wallis test.

[0290] [Table 5]

[0291] Example 11 Covalent modification of ovalbumin protein with poly(lactide-co-glycolide), TIMP preparation, and in vitro Treg induction assay

[0303] Covalent modification of polymers with proteins offers several advantages for improving the physicochemical properties of nanoparticle drug delivery systems. Importantly, properties such as protein loading as well as nanoparticle size and zeta potential are easier to control.

[0292]

[0304] Ovalbumin is a marker for some CD4 (OVA 323 ~ 334 ;OVA 265 ~ 280 ), CD8(OVA 257 ~ 264), and B cell epitopes. One of the open questions is whether TIMP-encapsulated whole ovalbumin (TIMP-OVA) can tolerize all antigenic epitopes on CD4, CD8 and B cells. The exact number of these epitopes within the ovalbumin protein is known, and the particles used allow for exquisite control of the amount of protein and polymer used, addressing the amount of molecules of antigen needed to tolerize different T and B cell receptors. As such, the dose for different T cell epitopes within the same protein can be addressed.

[0293] General Experimental Design

[0305] Full-length ovalbumin (OVA) protein was conjugated to high and low molecular weight PLGA. Furthermore, once the conjugation was confirmed, TIMP-OVA particles with various controlled loading amounts of OVA were prepared and characterized.

[0294]

[0306] The experiment proceeded as follows: 1. Synthesis of PLGA-OVA bioconjugates using EDC / NHS chemistry. 2. Solubility testing of the resulting PLGA-OVA conjugates in DCM and DMSO to determine their suitability for use in particle formation; 3. Determination of the coupling efficiency of PLGA-OVA conjugates, thus allowing TIMP-OVA particles to be prepared with various predefined Ag loadings; 4. Formation of TIMP-OVA particles with Ag loading varying from 0 to 150 μg OVA / mg PLGA. 5. Characterization of TIMP-PVA particles by DLS and zeta potential analysis.

[0295] [Table 6]

[0296]

[0307] OVA contains 20 lysine groups available for covalent modification. In addition, 14 aspartic acids and 33 glutamic acids are contained within OVA.

[0297]

[0308] Due to the difference in solubility of PLGA and OVA, it is necessary to determine the appropriate stoichiometric ratio of PLGA to OVA to obtain polymer-Ag conjugates with high solubility in the solvent systems for carrying out the conjugation reaction as well as in organic solvents such as DCM or DMSO that are required for particle production.

[0298]

[0309] To address these issues experimentally, six conjugation reactions were performed with molar ratios of PLGA to OVA varying from 5 to 20. A maximum ratio of 20 PLGA:1 OVA was selected based on the protein structure of OVA, where 20 lysine residues were available for coupling with the terminal carboxylic acid group of PLGA. In addition, two molecular weights of PLGA were tested for conjugation efficiency and solubility studies. The selection of these reaction conditions was determined to have the highest potential for obtaining PLGA-OVA bioconjugates with the required Ag content and solubility requirements. A summary of the reaction conditions is presented in Table 7.

[0299]

[0310] Table 7 shows the conditions for ovalbumin conjugation. Six reaction conditions were evaluated with the goal of completely dissolving OVA and PLGA in the same solvent system during the reaction. Additionally, the stoichiometric ratio of PLGA to OVA was varied to obtain a final product that was soluble in dimethyl sulfoxide (DMSO).

[0300] [Table 7]

[0301]

[0311] Table 8 shows the reaction conditions for ovalbumin conjugation using low (L) and high (H) molecular weight PLGA. PLGA was prepared in DMSO at a concentration of 25 mg / mL. OVA was prepared in MilliQ water at a concentration of 25 mg / mL. Prior to adding OVA to the solution containing PLGA, the concentration of PLGA was adjusted to 5 mg / mL to prevent precipitation of the polymer during the conjugation reaction. Additionally, the solvent ratio was maintained to contain 15-20 Vol / Vol% MilliQ water during the conjugation of PLGA to OVA.

[0302] [Table 8]

[0303] Protocol for PLGA-OVA conjugation using the volumes listed in Table 7

[0312] The following protocol was used: A 60 mL glass scintillation vial containing a magnetic stir bar was prepared. A separate 20 mL glass scintillation vial was also prepared containing the appropriate amount of OVA, additional water, and DIPEA. The appropriate amount of PLGA dissolved in DMSO and the specified additional DMSO was added to the 60 mL scintillation vial. Under stirring (300-600 RPM), the appropriate amount of EDC was added dropwise to the PLGA solution and stirred for 5 minutes. Under stirring (300-600 RPM), the appropriate amount of NHS was added dropwise to the EDC-activated PLGA solution and stirred for an additional 10 minutes. Under stirring (300-600 RPM), the aqueous solution containing OVA and DIPEA was added dropwise to the NHS-activated PLGA solution (note that the solution should be clear when this solution has finished being added to the PLGA). The reaction was allowed to proceed overnight at room temperature. To recover the PLGA-OVA conjugate, the solution containing the product was transferred to a 3500Da MWCO dialysis membrane and dialyzed against 4L MilliQ water for 2 days to remove unreacted EDC / NHS / DIPEA and to remove DMSO (Note: the product may precipitate in the dialysis bag. Change the water in the dialysis beaker at least 6 times over 2 days). To collect the product, the precipitate was transferred from the dialysis bag to a 50mL conical centrifuge tube. The material was centrifuged at 7000xg for 15 minutes at 4°C to precipitate the product. The product was washed by resuspension and centrifugation two more times. The final product was resuspended in 5mL MilliQ water, frozen, and lyophilized for 2 days or until the product was dry.

[0304] Solubility test of PLGA-OVA conjugate

[0313] To assess the solubility of the PLGA-OVA conjugate in the solvent used for particle formulation, approximately 1 mg of the conjugate was placed in 1.5 mL of MCT. The results are presented in Table 9. Conjugates 03-23-L3 and 03-23-H1-3 were identified as soluble in DMSO. This allowed these conjugates to be further characterized.

[0305]

[0314] Table 9 shows the solubility study of PLG-OVA polymer conjugates in DMSO. The precipitation observed after addition of DCM was minimal in all cases, which does not seem to affect particle formation.

[0306] [Table 9]

[0307]

[0315] Due to the insolubility of 03-23-L1 and 03-23-L2 in DMSO, these samples were not evaluated for protein content.

[0308]

[0316] The protein content present per milligram of polymer was determined using the Pierce BCA Protein Kit (catalog number 23225). The results are reported in Table 10.

[0309] [Table 10]

[0310] Protocol for particle production using PLGA-OVA conjugate 03-23-L3

[0311] [Table 11]

[0312]

[0317] PLGA was prepared at a concentration of 200 mg / mL in DCM.

[0313]

[0318] PLG-OVA (03-23-L3) was prepared at a concentration of 25 mg / mL in DMSO.

[0314] [Table 12]

[0315] Procedure for TIMP-OVA formulation

[0319] The following protocol was used. 1.1. Clean the sonicator with acetone, ethanol, then water. 1.2. Pipette the appropriate volume of PLGA, as specified in the table above, into a 20 mL scintillation vial. 1.3. Pipette the appropriate volume of PLGA-OVA as specified in the table above into the same 20 mL scintillation vial from step 1.2. 1.4. Add the appropriate volume of 1% PEMA to the 20 mL scintillation vials containing PLGA and PLG-OVA. 1.5. Sonicate the solution for 30 seconds at 100% amplitude. 1.6. Pour the sonicated mixture into an appropriate volume of 0.5% w / v poly(ethylene-alt-maleic anhydride) dissolved in water while stirring at 300 RPM. 1.7. Stir the particles overnight to allow the dichloromethane to evaporate. 1.8. Prepare a solution of cryoprotectant (sucrose 10 g / 25 mL MilliQ water; mannitol 6 g / 20 mL MilliQ water). The mannitol solution takes longer to dissolve and needs to be heated. Heat at 70 °C for 15-30 min with frequent vortexing. Upon storage, the mannitol will precipitate out of solution and will need to be heated again. The sucrose solution should be soluble at all times. Using a premade solution and reheating the mannitol is acceptable. 1.9. Pass the particle solution through a 40 μm cell strainer. Distribute the solution into 50 mL Falcon tubes. 1.10. Chill the particles on ice for 15 minutes. 1.11. Centrifuge at 7000 x g relative centrifugal force for 15 minutes at 4°C. 1.12. Aspirate the supernatant completely. 1.13. Add 3 mL of 1 M sodium bicarbonate-sodium carbonate buffer to each tube and chill the particles on ice for 15 minutes. 1.14. Using a 1 mL pipette or a pipette aid fitted with a 5 mL serological pipette, resuspend the pellet. 1.15. After the pellet is well dispersed (no visible aggregates), add 1 M sodium bicarbonate-sodium carbonate buffer to each tube until the total volume is 25 mL. 1.16.Centrifuge at 4°C for 15 minutes at a relative centrifugal force of 7000 x g. 1.17. Aspirate the supernatant completely. 1.18. Add 3 mL of 1 M sodium bicarbonate-sodium carbonate buffer to each tube and chill the particles on ice for 15 min. 1.19. Resuspend the pellets. After the pellets are well dispersed, add 1 M sodium bicarbonate-sodium carbonate buffer to each tube until the total volume is 25 mL. 1.2 Centrifuge at 7000xg relative centrifugal force for 15 minutes at 0.4°C. 1.21. Aspirate the supernatant completely. 1.22. Add 3 mL of MilliQ water to the tube and chill the particles on ice for 15 minutes. 1.23. Resuspend the pellet. After the pellet is well dispersed, add additional MilliQ water until the particle concentration is between 4-8 mg / mL. Assume particle recovery is 40%. 1.24. Disperse particles evenly in water. 1.25. Pass the particle solution through a 40 μm cell strainer. 1.26. Prepare sample tubes for lyophilization and 2 mL tubes for particle aliquots. Pre-weigh at least 1-3 of these tubes to determine the amount of particles per tube. 1.27. Pipette 800 μL of particle solution into each tube and save at least 200 μL of particle solution in a 1.5 mL microcentrifuge tube for characterization by DLS / Zeta analysis (only 20 μL of particle sample in MilliQ water needs to be used to perform DLS / Zeta analysis). 1.28. For each sample tube receiving cryoprotectant, mix 100 μL of sucrose and 100 μL of mannitol solution together and add to the particles while mixing with a pipette, for a total volume of 1 mL per tube. The concentration of cryoprotectant is 4% w / v sucrose and 3% w / v mannitol. 1.29. Freeze all samples, including those without cryoprotectant, in a -80°C freezer for at least 5 hours, except for samples used for DLS / Zeta analysis (which will be placed in a 4°C refrigerator for later characterization). 1.30. Freeze-dry the samples for 1-2 days.

[0316] [Table 13]

[0317] Evaluation of the biological activity of TIMP-OVA conjugates using an in vitro Treg induction assay

[0320] The aim of this study was to determine the effect of antigen loading in polymer-conjugated TIMP-OVA on the induction of naive CD4+ T cells (OTII) into regulatory T cells (CD4+CD25+Foxp3+). Experimental Group:

[0318] [Table 14]

[0319]

[0321] The amount of OVA antigen per mL of medium was calculated based on the dose of TIMP-OVA and the amount of OVA protein loaded per mg of TIMP. The bold and italicized cells in Table 14 indicate the particles tested in the Treg experiment. Importantly, the amount of Ag delivered per well encompassed a significant range from 0 ng / mL to 45000 ng / mL.

[0320] [Table 15]

[0321] Bone marrow-derived dendritic cell cultures (following the method of Lutz et al.)

[0322] Preparation of BMDCs was performed as previously described. DCs were prepared by culturing bone marrow cells obtained from C57BL / 6 mice. Bone marrow cells were flushed from the tibia and femur using a syringe equipped with a needle. The collected cells were incubated in ACK lysis buffer to lyse red blood cells. Bone marrow cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum, 100 units / mL penicillin, 100 mg / mL streptomycin, 2 mM L-glutamine, 50 μM 2-mercaptoethanol, and 20 ng / mL granulocyte-macrophage colony-stimulating factor. Culture medium was changed on days 3, 6, and 8. Cells were ready for use on day 10.

[0322] Cell isolation and in vitro Treg induction assay

[0323] CD4+CD25-foxp3- T cells were isolated from the spleens of OT-II mice (B6.Cg-Tg(TcraTcrb)425Cbn / j, Jackson Laboratory, Bar Harbor, ME) using a naive CD4+ T cell isolation kit (Miltenyi Biotec, San Diego, CA). The assay was performed in RPMI medium supplemented with 10% fetal bovine serum, 1% pen / strep, and non-essential amino acids. APCs (2x10 4 100 cells / well) were seeded into a 96-well round-bottom cell culture plate and incubated with soluble OVA. 323 ~ 339 Treated with peptide (100 ng / mL) or particles with various Ag loadings and particle doses, in the presence of 2 ng / mL TGFβ, 2x10 4 The cells were co-cultured with naive T cells at 100 / well. After 4 days of co-culture, T cells were harvested, stained for CD4, CD25, and Foxp3, and analyzed using a Cyan cytometer.

[0323] conclusion

[0324] PLGA-OVA bioconjugates were successfully synthesized using EDC / NHS (carbodiimide) chemistry. BCA assay was used to determine the protein content per mg of PLGA-OVA bioconjugate. The amount of protein per mg was dependent on the molecular weight of the polymer as well as the stoichiometric ratio of PLGA:OVA. The PLGA-OVA conjugate with the highest protein content was 03-23-L3 and the lowest was 03-23-H3.

[0324]

[0325] As a starting point, TIMP-OVA particles were formulated with various Ag loadings from 0 μg / mg to 150 μg / mg using PLGA-OVA conjugate 03-23-L3 due to its high loading capacity. TIMP-OVA particles prepared using 03-23-L3 showed sizes measured by DLS between 300 nm and 850 nm. TIMP-OVA at 150 μg / mg showed an unusually high PDI, higher than 0.7. The zeta potential of TIMP-OVA was between -30 and -60 mV.

[0325]

[0326] Preliminary in vitro studies using a Treg induction assay to characterize the ability of the various TIMP-OVA particles to induce regulatory T cells in the presence of TGFb demonstrated that the protein remained active after conjugation and TIMP formulation. 323 ~ 339 It should be noted that these antibodies are believed to be less effective than the TIMP (OVA) particles.

[0326]

[0327] Although particular embodiments of the present invention have been described and illustrated, such embodiments should be considered merely as examples of the present invention and not as limitations of the present invention as interpreted according to the appended claims.

[0327]

[0328] All patents, patent applications and other references cited herein are incorporated by reference in their entirety.

Claims

1. A composition comprising one or more antigens covalently bound to carrier particles having a negative zeta potential, said one or more antigens being encapsulated within said particles.

2. A composition comprising one or more antigens encapsulated within polymeric carrier particles, said one or more antigens being covalently bound to the polymer that makes up said polymeric carrier particles.

3. The composition of claim 1 or 2, further comprising a non-conjugated carrier polymer.

4. The composition of any one of claims 1 to 3, wherein the particles have a zeta potential of less than about -100 mV.

5. The composition of any one of claims 1 to 3, wherein the particles have a zeta potential of between about -100 mV and about -15 mV.

6. The composition of any one of claims 1 to 5, wherein the particles have a zeta potential of between about -100 mV and about -75 mV.

7. The composition of any one of claims 1 to 5, wherein the particles have a zeta potential of between about -50 mV and about -20 mV.

8. 8. The composition of claim 1, wherein the particles comprise a copolymer having a molar ratio of about 50:50, 80:20 to about 100:

0.

9. 9. The composition of any one of claims 1 to 8, wherein the particles comprise polystyrene particles, carboxylated polystyrene particles, PLURONIC® stabilized polypropylene sulfide particles, or poly(lactic-co-glycolic acid) particles.

10. The composition of any one of claims 1 to 9, wherein the particles comprise poly(lactic-co-glycolic acid).

11. 11. The composition of claim 1, wherein the particles have an average diameter of between about 0.1 μm and about 10 μm.

12. 12. The composition of claim 1, wherein the particles have an average diameter of between about 0.3 μm and about 5 μm.

13. 12. The composition of claim 1, wherein the particles have an average diameter of between about 0.5 μm and about 3 μm.

14. 12. The composition of claim 1, wherein the particles have an average diameter of between about 0.5 μm and about 1 μm.

15. 12. The composition of claim 1, wherein the particles have an average diameter of about 0.5 μm.

16. 16. The composition of any one of claims 1 to 15, wherein the one or more antigens comprise an autoimmune antigen, an antigen expressed on a tissue to be transplanted into a subject, an enzyme for enzyme replacement therapy, or an allergen.

17. The one or more antigens are selected from the group consisting of myelin basic protein, acetylcholine receptor, endogenous antigen, myelin oligodendrocyte glycoprotein, pancreatic beta cell antigen, insulin, glutamic acid decarboxylase (GAD), collagen type 11, human cartilage gp39, fp130-RAPS, proteolipid protein, fibrillarin, small nucleolar protein, thyroid stimulating factor receptor, histone, glycoprotein gp70, pyruvate dehydrogenase dehydrolipoamide acetyltransferase (PCD-E2), hair follicle antigen, A-gliadin, gliaden, insulin, proinsulin, islet specific glucose-6-phosphatase catalytic subunit related protein (IGRP), human tropomyosin isoform 5, bahiagrass pollen (BaGP), peach allergen Pru p3, alpha s1-cane milk allergen, Apig1 cereria allergen, Bere1 Brazil nut allergen, B-lactoglobulin milk allergen, bovine serum albumin, Cor a 1.04 hazelnut allergen, myelin-associated glycoprotein, aquaporin, α3 chain of type IV collagen, ovalbumin egg allergen, Advate, antihemophilic factor, Kogenate, Eloctate, recombinant factor VIII Fc fusion protein, Refacto, Novo 17. The composition of claim 16, comprising at least a portion of a protein selected from the group consisting of Factor VIIa, recombinant Factor VII, eptacog alfa, helixate, monanin, coagulation factor IX, wilate, ceredase, auglucerase, cerezyme, imiglucerase, eleruso, taliglucerase alfa, fabrazyme, agalsidase beta, aldrazyme, -I-iduronidase, myozyme, acid glucosidase, elaprase, iduronate-2-sulfatase, naglazyme arylsulfatase B, or N-acetylgalactosamine-4-sulfatase.

18. The one or more antigens are selected from the group consisting of myelin basic protein, acetylcholine receptor, endogenous antigen, myelin oligodendrocyte glycoprotein, pancreatic beta cell antigen, insulin, proinsulin, IGRP, glutamic acid decarboxylase (GAD), collagen type 11, human cartilage gp39, fp130-RAPS, proteolipid protein, fibrillarin, small nucleolar protein, thyroid stimulating factor receptor, histones, glycoprotein gp70, pyruvate dehydrogenase dehydrolipoamide acetyltransferase (PCD-E2), hair follicle antigen, A-gliadin, gliaden, human tropomyosin isoform 5, bahiagrass pollen (BaGP), peach allergen Pru p3, alpha s1-cane milk allergen, Apig1 celeriac allergen, Bere1 Brazil nut allergen, B-lactoglobulin milk allergen, bovine serum albumin, Cor a 1.04 The composition of claim 16 comprising hazelnut allergen, myelin-associated glycoprotein, aquaporin, alpha 3 chain of type IV collagen, ovalbumin egg allergen, Advate, antihemophilic factor, Kogenate, Eloctate, recombinant Factor VIII Fc fusion protein, Refacto, Novo VIIa, recombinant Factor VII, eptacog alfa, Helixate, Monanin, coagulation factor IX, Wilate, ceredase, alglucerase, cerezyme, imiglucerase, elerso, taliglucerase alfa, fabrazyme, agalsidase beta, aldrazyme, -I-iduronidase, myozyme, acid glucosidase, elaprase, iduronate-2-sulfatase, naglazyme arylsulfatase B, or N-acetylgalactosamine-4-sulfatase.

19. 19. The composition of any one of claims 1 to 18, wherein the one or more antigens comprise one or more epitopes.

20. 20. The composition of claim 19, wherein the one or more epitopes are associated with allergy, an autoimmune disease, an enzyme used in enzyme replacement therapy, a lysosomal storage disease, or an inflammatory disease or disorder.

21. 21. The composition of claim 20, wherein the one or more epitopes are associated with type 1 diabetes mellitus, multiple sclerosis, systemic lupus, neuromyelitis optica, idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura, membranous nephropathy, bullous pemphigoid, pemphigus vulgaris, myasthenia gravis, mucopolysaccharidosis storage disease, gangliosidosis, hypoalkaline phosphatasia, cholesterol ester storage disease, hyperuricemia, growth hormone deficiency, renal anemia, Gaucher disease, Fabry disease, Fuller's disease, Hunter disease, Maroteaux-Lamy disease, hemophilia A, hemophilia B, von Willebrand disease, venous thrombosis, purpura fulminans, mucopolysaccharidosis VI, Pompe disease, celiac disease, or inflammatory bowel disease including Crohn's disease and ulcerative colitis.

22. 21. The composition of claim 20, wherein the one or more epitopes are associated with myozyme, alglucerase, imiglucerase, taliglucerase, agalsidase beta, 1-iduronidase, acid glucosidase, iduronate-2-sulfatase, N-acetylgalactosamine-4-sulfatase, antihemophilic factor, factor VII, eptacog alfa, factor IX, miglustat, lomiplastim, epotetin alfa, protein C, laronidase, lumizyme factor VIII.

23. 23. The composition of any one of claims 1 to 22, wherein the one or more antigens are directly covalently attached to the carrier particles.

24. 24. The composition of any one of claims 1 to 23, wherein the particles are biodegradable.

25. 25. The composition of any one of claims 1 to 24, further comprising a pharma- ceutically acceptable carrier.

26. 1. A method for inducing antigen-specific tolerance in a subject, comprising administering to the subject an effective amount of a composition comprising one or more antigens covalently bound to carrier particles having a negative zeta potential, wherein the one or more antigens are encapsulated in the particles.

27. 27. The method of claim 26, wherein said administering is carried out to treat or prevent a disease or condition.

28. 28. The method of claim 27, wherein the disease or condition is selected from the group consisting of an autoimmune disease, a lysosomal storage disease, an enzyme deficiency, an inflammatory disease, an allergy, a transplant rejection, and a hyperimmune response.

29. 29. The method of claim 28, wherein the disease or condition is selected from the group consisting of multiple sclerosis, type 1 diabetes, asthma, food allergies, environmental allergies, inflammatory bowel diseases including celiac disease, Crohn's disease and ulcerative colitis, mucopolysaccharide storage diseases, gangliosidosis, hypoalkaline phosphatasia, cholesterol ester storage disease, hyperuricemia, growth hormone deficiency, renal anemia, hemophilia, hemophilia A, hemophilia B, von Willebrand disease, Gaucher disease, Fabry disease, Furler disease, Pompe disease, Hunter disease, Maroteaux-Lamy disease and conditions caused by the antigen in the subject to reduce an over-response to the antigen.

30. 30. The method of any one of claims 26 to 29, wherein administration of the composition results in the induction and proliferation of both antigen-specific and non-specific regulatory T cells.

31. 31. The method of any one of claims 26 to 30, wherein the composition further comprises a non-conjugated carrier polymer.

32. 32. The method of any one of claims 26 to 31, wherein the carrier particles comprise polystyrene particles, carboxylated polystyrene particles, PLURONIC® stabilized polypropylene sulfide particles, or poly(lactic-co-glycolic acid) particles.

33. 33. The method of any one of claims 26 to 32, wherein the carrier particles comprise poly(lactic-co-glycolic acid) particles.

34. 34. The method of any one of claims 26 to 33, wherein administration of the composition prevents accumulation of neutrophils and other granulocytes in the subject.

35. 35. The method of any one of claims 26 to 34, wherein the composition is administered intravenously.

36. 36. The method of any one of claims 26 to 35, wherein the composition minimizes or eliminates burst release of the one or more antigens in a subject following administration.

37. 11. A method for inducing regulatory T cells, comprising treating the T cells with an effective amount of the composition of claim 1, wherein the T cells have a particle size greater than 80 nm.

38. 1. A method for the preparation of tolerizing immune modifying particles (TIMPs) having a negative zeta potential, comprising: a) covalently linking one or more carrier polymers to one or more antigens to form carrier polymer-antigen conjugates; and b) contacting the carrier polymer-antigen conjugate with a solution under conditions effective to form a TIMP. wherein the TIMP is formed having a negative zeta potential and the one or more antigens are encapsulated in the TIMP.

39. 39. The method of claim 38, wherein contacting the carrier polymer-antigen conjugate with a solution is performed in the presence of unconjugated carrier polymer at a defined mixing ratio.

40. 40. The method of claim 38 or 39, wherein the particles have a zeta potential of less than about -100 mV.

41. 40. The method of claim 38 or 39, wherein the zeta potential of the particles is between about -100 mV and about -15 mV.

42. 42. The method of any one of claims 38 to 41, wherein the zeta potential of the particles is between about -100 mV and about -75 mV.

43. 42. The method of any one of claims 38 to 41, wherein the zeta potential of the particles is between about -50 mV and about -20 mV.

44. 44. The method of any one of claims 38 to 43, wherein the particles comprise polystyrene particles, carboxylated polystyrene particles, PLURONIC® stabilized polypropylene sulfide particles, or poly(lactic-co-glycolic acid) particles.

45. 45. The method of any one of claims 38 to 44, wherein the particles comprise poly(lactic-co-glycolic acid) particles.

46. 46. ​​The method of any one of claims 38 to 45, wherein the particles have an average diameter of between about 0.1 μm and about 10 μm.

47. 47. The method of any one of claims 38 to 46, wherein the particles have an average diameter of between about 0.3 μm and about 5 μm.

48. 47. The method of any one of claims 38 to 46, wherein the particles have an average diameter of between about 0.5 μm and about 3 μm.

49. 47. The method of any one of claims 38 to 46, wherein the particles have an average diameter of between about 0.5 μm and about 1 μm.

50. 47. The method of any one of claims 38 to 46, wherein the particles have an average diameter of about 0.5 μm.

51. 51. The method of any one of claims 38 to 50, wherein the carrier polymer is formed by copolymerization.

52. 52. The method of any one of claims 38 to 51, wherein the solution has a basic pH.

53. 53. The method of any one of claims 38 to 52, wherein the solution comprises sodium bicarbonate, potassium bicarbonate, lithium bicarbonate, potassium dihydrogen phosphate, sodium dihydrogen phosphate, or lithium dihydrogen phosphate.

54. 54. The method of any one of claims 38 to 53, wherein the one or more antigens comprise an autoimmune antigen, an antigen expressed on a tissue to be transplanted into the subject, an enzyme for enzyme replacement therapy, or an allergen.

55. The one or more antigens are selected from the group consisting of myelin basic protein, acetylcholine receptor, endogenous antigen, myelin oligodendrocyte glycoprotein, pancreatic beta cell antigen, insulin, glutamic acid decarboxylase (GAD), collagen type 11, human cartilage gp39, fp130-RAPS, proteolipid protein, fibrillarin, small nucleolar protein, thyroid stimulating factor receptor, histone, glycoprotein gp70, pyruvate dehydrogenase dehydrolipoamide acetyltransferase (PCD-E2), hair follicle antigen, A-gliadin, gliaden, insulin, proinsulin, islet specific glucose-6-phosphatase catalytic subunit related protein (IGRP), human tropomyosin isoform 5, bahiagrass pollen (BaGP), peach allergen Pru p3, alpha s1-cane milk allergen, Apig1 cereria allergen, Bere1 Brazil nut allergen, B-lactoglobulin milk allergen, bovine serum albumin, Cor a 1.04 hazelnut allergen, myelin-associated glycoprotein, aquaporin, α3 chain of type IV collagen, ovalbumin egg allergen, Advate, antihemophilic factor, Kogenate, Eloctate, recombinant factor VIII Fc fusion protein, Refacto, Novo 55. The method of claim 54, comprising at least a portion of a protein selected from the group consisting of Factor VIIa, recombinant Factor VII, eptacog alfa, helixate, monanin, coagulation factor IX, wilate, ceredase, alglucerase, cerezyme, imiglucerase, eleruso, taliglucerase alfa, fabrazyme, agalsidase beta, aldrazyme, -I-iduronidase, myozyme, acid glucosidase, elaprase, iduronate-2-sulfatase, naglazyme arylsulfatase B, or N-acetylgalactosamine-4-sulfatase.

56. The one or more antigens are selected from the group consisting of myelin basic protein, acetylcholine receptor, endogenous antigen, myelin oligodendrocyte glycoprotein, pancreatic beta cell antigen, insulin, proinsulin, IGRP, glutamic acid decarboxylase (GAD), collagen type 11, human cartilage gp39, fp130-RAPS, proteolipid protein, fibrillarin, small nucleolar protein, thyroid stimulating factor receptor, histones, glycoprotein gp70, pyruvate dehydrogenase dehydrolipoamide acetyltransferase (PCD-E2), hair follicle antigen, A-gliadin, gliaden, human tropomyosin isoform 5, bahiagrass pollen (BaGP), peach allergen Pru p3, alpha s1-cane milk allergen, Apig1 celeriac allergen, Bere1 Brazil nut allergen, B-lactoglobulin milk allergen, bovine serum albumin, Cor a 1.04 The method of claim 54, comprising hazelnut allergen, myelin-associated glycoprotein, aquaporin, alpha 3 chain of collagen type IV, ovalbumin egg allergen, Advate, antihemophilic factor, Kogenate, Eloctate, recombinant Factor VIII Fc fusion protein, Refacto, Novo VIIa, recombinant Factor VII, eptacog alfa, Helixate, Monanin, coagulation factor IX, Wilate, ceredase, alglucerase, cerezyme, imiglucerase, elerso, taliglucerase alfa, fabrazyme, agalsidase beta, aldrazyme, -I-iduronidase, myozyme, acid glucosidase, elaprase, iduronate-2-sulfatase, naglazyme arylsulfatase B, or N-acetylgalactosamine-4-sulfatase.

57. 57. The method of any one of claims 38 to 56, wherein the one or more antigens comprise one or more epitopes.

58. 58. The method of claim 57, wherein the one or more epitopes are associated with allergy, an autoimmune disease, an enzyme used in enzyme replacement therapy, a lysosomal storage disease, or an inflammatory disease or disorder.

59. 59. The method of claim 58, wherein the one or more epitopes are associated with type 1 diabetes, multiple sclerosis, systemic lupus, neuromyelitis optica, idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura, membranous nephropathy, bullous pemphigoid, pemphigus vulgaris, myasthenia gravis, mucopolysaccharidosis storage disease, gangliosidosis, hypoalkaline phosphatasia, cholesterol ester storage disease, hyperuricemia, growth hormone deficiency, renal anemia, Gaucher disease, Fabry disease, Fuller's disease, Hunter disease, Maroteaux-Lamy disease, hemophilia A, hemophilia B, von Willebrand disease, venous thrombosis, purpura fulminans, mucopolysaccharidosis VI, Pompe disease, celiac disease, or inflammatory bowel disease including Crohn's disease and ulcerative colitis.

60. 59. The method of claim 58, wherein the one or more epitopes are associated with myozyme, alglucerase, imiglucerase, taliglucerase, agalsidase beta, 1-iduronidase, acid glucosidase, iduronate-2-sulfatase, N-acetylgalactosamine-4-sulfatase, antihemophilic factor, factor VII, eptacog alfa, factor IX, miglustat, lomiplastim, epotetin alfa, protein C, laronidase, lumizyme factor VIII.

61. 61. The method of any one of claims 38 to 60, wherein the one or more antigens are directly covalently attached to the carrier polymer.

62. 62. The method of any one of claims 38 to 61, wherein the particles are biodegradable.

63. 63. The method of any one of claims 38-62, further comprising formulating the TIMP in a pharma- ceutically acceptable carrier.

Images